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The studies described in this thesis were designed to investigate inhibin and inhibin-
related peptides throughout human pregnancy. The first approach was to characterize
antibodies raised against the intact inhibin molecule or different peptide fragments of
inhibin subunits in order to obtain suitable antibodies for radioimmunoassay and
Western blot analysis. The results showed that two sheep antibodies, Y29 and Y33,
which were raised against synthetic human inhibin a-(l-23)-NH2, were specific to
inhibin-like molecules in placental extracts and amniotic fluids. An antibody (Monash
antibody) raised in a rabbit against 32 kDa inhibin was the most sensitive antibody for
measuring inhibin in plasma and placental extracts. The development of the Western
blot analysis for inhibin was successful with Y29 and R187 antibodies and another
monoclonal antibody raised against human (3A-(87-l 14)-NH2- These three antibodies
showed specificity to purified 32 kDa bovine inhibin and the antibodies to PA-subunit
fragments also showed specificity to recombinant human activin A.
Inhibin levels were measured during pregnancy. There was an increase in inhibin
levels in the luteal phase after the luteinizing hormone (LH) surge which reached a
peak during the first two weeks of pregnancy. The levels of inhibin declined after this
first peak and then rose again, reaching a second peak during 7-8 weeks of pregnancy.
A second fall was observed until 30 weeks of gestation followed by a dramatic
increase at approximately 36 weeks which was sustained until delivery. These results
suggest that before the formation of the placenta, the corpus luteum is a potential
source of inhibin. Human chorionic gonadotrophin (hCG), oestradiol (E2) and
progesterone (P4) were also measured in order to investigate any interactions between
inhibin and these hormones in vivo. The results showed that oestradiol and
progesterone increased throughout pregnancy as did inhibin. hCG increased during
early pregnancy and declined after 12 weeks and remained at this level until delivery.
Immunoactive inhibin levels in placental extracts from various stages of pregnancy
were measured. The results showed that inhibin levels were very high at 7 weeks and
decreased towards term. Placental hCG content was also shown to reach maximal
concentrations at 7 weeks and was less in mid-term and term. These results suggest a
possible transient relationship between inhibin and hCG, E2 and P4 during
pregnancy.
Inhibin bioactivity in placental extracts was measured using a sheep pituitary cell
bioassay. The results showed that the bioactivity of inhibin in placental extracts did not
change throughout pregnancy whereas the immunoactivity decreased from early
pregnancy towards term. Placental inhibin bioactivity was immunoneutralized in sheep
pituitary cell cultures using inhibin a- and (3-subunit antibodies. The results showed
that only the inhibin a-subunit antibody could neutralize inhibin bioactivity in the
placenta and the same antibody could be used to neutralize inhibin bioactivity in
amniotic fluid.
Immunoactivity and bioactivity of inhibin was investigated in amniotic fluids during
early, mid-term and term pregnancy. The results showed that inhibin levels measured
by radioimmunoassay (RIA) with Y29 and R187 antibodies decreased towards term,
whereas the inhibin level measured by the Monash antibody increased towards term.
The level of bioactivity was different from immunoactivity; the lowest activity was
observed in mid-term whereas the same level was found in early and term pregnancy.
These results provide evidence for the presence of dimeric inhibin in amniotic fluid
and may also suggest that different species of inhibin-related peptides exist in amniotic
fluid at various stages of pregnancy.
The cellular localization of inhibin a- and PA-subunits was examined using
antibodies raised against these two subunits. Syncytiotrophoblast and cytotrophoblast
cells showed positive staining throughout pregnancy. The intensity of staining
corresponding to each inhibin subunit varied at different stages of pregnancy with
maximum a-immunoactivity during early pregnancy and maximum (3A-
immunoactivity at term.
To examine the expression of inhibin genes in placental tissue during pregnancy,
Northern blot analysis using inhibin a-subunit cDNA and (3B-subunit riboprobes was
carried out. The results from this study showed expression of inhibin a- and {3B-
mRNAs by placental tissue throughout pregnancy. The a-mRNA showed greater
expression in 7 weeks placentae when compared to mid-term and term placentae,
whereas the pB-mRNA was abundant throughout pregnancy and its degree of
expression increased in the later stages of pregnancy.
To investigate whether trophoblast cells actually produce inhibin subunits, the in situ
hybidrization technique was employed to demonstrate inhibin gene expression. Using
35s-labelled inhibin subunit riboprobes, it was demonstrated that all three inhibin
subunit mRNAs were expressed in both syncytiotrophoblast and cytotrophoblast cells.
Inhibin oc-mRNA was expressed throughout pregnancy and the degree of expression
in early placenta was higher than in term. Inhibin PA-mRNA was also expressed in







In 1923, the existence of inhibin was first suspected from the results of an experiment
in which it was demonstrated that after damage of the germinal epithelium of the testis
by radiation in the rat the anterior pituitary hypertrophied with the appearance of typical
"castration cells" (Mottram & Cramer, 1923). This phenomenon led to the postulate
that the radiation caused the disappearance of an internal secretion from seminal
epithelium which might be responsible for the morphological changes in pituitary
glands. Martins and Rocha (1931) demonstrated that an injection of bull or goat
testicular extracts completely prevented these castration effects in male rats. In 1932,
McCullagh reported that the administration of aqueous extracts of bull testes to
castrated male rats resulted in the disappearance of castration cells in pituitary glands
without increasing the weight of the accessory sex organs. In the same experiments,
the solvent extracts were also shown to have effects on the accessory sex organs but
not on castration cells. The water soluble factor was termed 'inhibin' and the solvent
factor 'androtin' which was later elucidated as testosterone. However, there followed a
long period of controversy on the existence of inhibin due to the lack of sensitive
assays to monitor its activity. In the late 1960s, the development of an FSH
radioimmunoassay allowed many studies to accumulate direct evidence for the
existence of inhibin. FSH-suppressing activity characteristic of inhibin was detected in
semen of various species, bovine seminal plasma, urine and spermatic venous blood
(Fachini et al, 1963; Fachini & Ciaccolini, 1966; Lugaro et al, 1969; 1973). Moreover,
rete testis fluid showed marked FSH-suppressing activity when tested using the
suppression of uterine weight in hCG-injected mice as an end point (Setchell &
Wallace, 1972; Setchell & Sirinathsinghji, 1972). In the same year, human seminal
plasma was shown to suppress FSH levels in the blood of castrated male rats
(Franchimont et al, 1972). Setchell & Jacks (1974) also demonstrated the same FSH-
suppressing activity in ovine rete testis fluid. Evidence for the independent regulation
of FSH and LH secretions was observed in testicular feminization patients with high
LH levels but normal FSH levels (Judd et al, 1972) and in connection with congenital
absence of Leydig cells (Berthezene et al, 1976). This phenomenon was also
confirmed by normal levels of LH and high levels of FSH in patients with impaired
sperm production (Setchell et al, 1977). In the cow, de Jong & Sharpe (1976)
demonstrated an inhibitory effect of steroid-free bovine ovarian follicular fluid (FF) on
FSH, but not LH, secretion following castration. This direct evidence of inhibin in
follicular fluid was supported by the observation of an increase in FSH but not LH
levels at the menopausal transition (Sherman & Korenman, 1975) and the elevation of
FSH in the woman with normal LH and oestradiol who had no follicular development
(Boyar et al, 1977).
There has been a tremendous amount of information on many aspects of inhibin in the
last decade e.g. sources, detection, estimation, isolation, purification, structural
analysis, biosynthesis, secretion, distribution and physiological role. These aspects
will be reviewed as follows:
1. Assays of inhibin
1.1 Bioassays
Bioassays of inhibin have been developed based on the ability of inhibin to suppress
FSH secretion. The original in vivo bioassay was the reversed Steelman-Pohley assay
using the suppression of inhibin on the synergistic effect of FSH to hCG in
augmentation of ovarian weight of immature rats (Steelman & Pohley, 1953; Setchell
& Wallace, 1972). Similar types of assay, using uterine or ovarian weight in mice or
rats as the end points, were developed to measure inhibin activity (Setchell &
Sirinathsinghji, 1972; Chari et al, 1976; Ramasharma et al, 1979). Another bioassay
relied on the suppressive effect of inhibin on increasing ovarian weight in unilaterally
ovariectomized mice (Sato et al, 1978). However, results from these bioassays were
difficult to interpret because of the presence of FSH-binding inhibitors in gonadal
fluids which made the assay non-specific (Sluss & Reichert, 1984). Thus, in
combination with low precision and sensitivity, these types of assay had many
limitations. Since the radioimmunoassay of FSH was developed (Midgley, 1967) an in
vivo bioassay based on the suppression of FSH concentrations in blood as an end
point of the injection of inhibin preparations has been extensively used to measure
inhibin bioactivity. Several assays with the same principle were developed using both
sexes of rats and mice under different conditions i.e intact, castrated and
ovariectomized to detect inhibin activity in bovine, porcine, mare and human ovarian
follicular fluids (de Jong and Sharpe, 1976; Welschen et al, 1977; Miller et al, 1979;
Daume et al, 1978) and in rat, bovine and ovine testes extracts (Davies et al, 1978;
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Keogh et al, 1976; Nandini et al, 1976; Sheath et al, 1979) and in ovine rete testis fluid
(Setchell & Jacks, 1974).
The assay for the hypothalamic releasing factors using dispersed pituitary cells (Vale et
al, 1972) was developed and adapted for monitoring inhibin bioactivity. At present in
vitro bioassays using the monolayer culture of rat or sheep pituitary cells are
extensively used with the FSH content of the cells (Scott et al, 1980; 1982), the FSH
and LH released into the culture medium (Steinberger & Steinburger, 1976; DePaolo,
et al, 1979; Tsonis et al, 1986) or the FSFl and LH secreted in response to (luteinizing
hormone releasing hormone (LHRH) stimulation (de Jong et al, 1979; Eddie et al,
1979) measured to monitor inhibin bioactivity. Although these bioassay systems are
more specific and sensitive than the in vivo bioassays mentioned above, there are still
some limitations to overcome. The rat monolayer culture systems are not sensitive
enough to detect inhibin in circulating blood and also show specificity to follistatin
(Robertson et al, 1990a) which is another type of FSH-suppressing protein. The
highly sensitive ovine pituitary cell culture system developed by Tsonis et al (1986)
enables the measurement of circulating inhibin. However, sheep pituitary cells are very
sensitive to oestradiol and progesterone (Miller & Huang, 1985; Batra & Miller, 1986)
and also testosterone (Eddie et al, 1979). Thus, it is necessary to ensure removal of all
steroids from the sample by treatment with charcoal and/or immunoneutralization prior
to measurement in this system (Tsonis et al, 1986). Furthermore, inhibin preparations
containing some growth factors can stimulate pituitary cell differentiation and
multiplication (Tsonis et al, 1987b; Tsonis et al, 1988b; Dorrington et al, 1988). These
complications make the interpretation of results more complex. Nevertheless, at
present the ovine monolayer pituitary cell culture is still the most sensitive assay
system to determine the biological activity of inhibin-containing preparations .
1.2 Immunological measurements
Antibodies raised against intact inhibin molecules and different fragments of inhibin a-
and P-subunits have been extensively used for immunoassay, immunoneutralization





Immunoassays of inhibin have been developed using different principles. The most
sensitive and widely used is radioimmunoassay which has two categories according to
the type of antibody. The first type is the RIA using a polyclonal antibody against
purified bovine 58 kDa or 32 kDa inhibin (McLachlan et al, 1986a; McLachlan et al,
1987a; Robertson et al, 1988a; 1988b) and purified porcine or bovine intact inhibin
(Hasegawa et al, 1987; 1988). These assays have been shown to have negligible
cross-reaction with other proteins in the inhibin family such as activin, transforming
growth factor-p (TGF-{3), and Mullerian inhibiting substance (MIS) (McLachlan et al,
1986a). Interestingly, another immunoactive inhibin species, pro-aC, which has been
found in bovine and porcine follicular fluids, has been shown to cross-react more than
200% in this assay (Robertson et al, 1989; Sugino et al, 1989). In addition,
preparations containing recombinant a-inhibin-immunoreactive proteins have also
shown the same displacement in the assay as the standard which was pooled serum
from female patients undergoing exogenous gonadotrophin therapy (Schneyer et al,
1990). However, this type of assay has been widely used to measure serum inhibin in
many species under different physiological and pharmacological conditions.
Another type of assay has been developed using antibodies raised to a range of
synthetic peptides representing the amino terminal region of the 20 kDa mature a-
subunit of porcine 1-25 or 1-26 inhibin (Rivier et al, 1986; McNeilly et al, 1989;
Schanbacher, 1988; Sharpe et al, 1988) and human 1-23, 6-30 or 1-32 inhibin
(McNeilly et al, unpublished data; Sinosich et al, 1991; Groome et al, 1990; Saito et
al, 1989; Mersol-Barg et al, 1990). This type of assay has been used to measure
inhibin in serum, gonadal extracts and culture medium of gonadal cells or tissues from
many species. Although this assay does not cross-react with other inhibin-related
proteins (activin, TGF-P, MIS), it detects immunoactive a-subunits as well as dimeric
inhibin. Thus, the levels of a-subunit in inhibin-containing preparations must be taken
into consideration.
Enzyme-linked immunosorbant assay (ELISA)
More recently, an enzyme-linked immunosorbant assay of inhibin has been developed
by a Belgian group using two antibodies directed against different a-subunit
fragments (Eliard et al, 1990). This is a direct assay for the immunoactive a-subunit
but is not an ideal assay for dimeric inhibin. It has been demonstrated to be comparable
with the above heterologous RIAs in sensitivity and reproducibility. Since this method
is less time-consuming and labour-saving, it has been widely used in clinical research
to detect inhibin levels in males, females, children and fetuses (see Proceedings of
Inhibin Symposium, Ginical Investigations, Medgenix Diagnostics, 1990).
Immunoradiometric assay (IRMA)
The last quantitative immunoassay is the immunoradiometric assay using two
antibodies raised against inhibin a-subunit and P-subunit fragments. This assay is
theoretically highly specific for dimeric inhibin and does not cross-react with the a-
subunit (Knight et al, 1991). However, at present, this assay is not sensitive enough
to measure inhibin levels in human serum.
1.2.2 Immunolocalization
In the past five years, advances in immunology in combination with advanced
histochemical techniques, have enabled antibodies to inhibin a-and P-subunit
fragments to be used to demonstrate the localization of inhibin subunits in various
tissues. The inhibin subunits are localized in different cell types of the ovary. Human
and rat granulosa cells contain the inhibin a-subunit (Smith et al, 1991; Cuevas et al,
1987; Merchenthaler et al, 1987; Meunier et al, 1988a) and inhibin PA- and PB-
subunits (Meunier et al, 1988a). Meunier and colleagues (1988a) also demonstrated
the inhibin a-subunit in rat theca and interstitial cells. Luteal cells are also show
positive staining with the inhibin a-subunit antibody (Smith et al, 1991; Cuevas et al,
1987; Merchenthaler et al, 1987; Meunier et al, 1988a). Immunolocalization of inhibin
Subunits in rat testicular tissue has also been investigated. Rat Sertoli cells have shown
positive staining with an antibody raised against the inhibin a-subunit (Cuevas et al,
1987; Merchenthaler et al, 1987; Rivier et al, 1988; Saito et al, 1989; Shaha et al,
1989). In addition, the last two groups have also shown the localization of inhibin P-
subunits in rat Sertoli cells. However, only one group has been able to detect inhibin
subunits in Leydig cells (Shaha et al, 1989). The control mechanism of inhibin and
FSH remains unclear but there is indirect evidence demonstrating a feedback loop
between the gonads and the pituitary gland (de Jong, 1987). This study has been
further confirmed by the localization of inhibin subunits in pituitary gonadotrophs
(Roberts et al, 1989) and the PA-subunit has also been localized in central neural
pathways of rat brain (Sawchenko ct al, 1988). Inhibin a-subunit immunoactivity has
also been localized in human cytotrophoblast cells (Petraglia et al, 1987a;
Merchenthaler et al, 1987) and decidua (Petraglia et al, 1990).
1.2.3 Immunoneutralization
Polyclonal antisera raised against the amino terminal of the inhibin a-subunits of
bovine, porcine and human have been shown to neutralize inhibin bioactivity in vivo
and in vitro (Forage et al, 1987; Findlay et al, 1989; Rivier & Vale, 1989; Saito et al,
1989; van Dijk et al, 1986; Mann et al, 1989). These antibodies have been exploited as
an indirect method to monitor inhibin bioactivity in vivo and in vitro.
2. Isolation and characterization of inhibin and related
peptides
Although inhibin has been shown to exist for more than half a century (Mottram &
Cramer, 1923) it is only within the last decade that investigators have succeeded in its
isolation and characterization after being hampered, in the intervening years, by the
hydrophobic nature of the protein and the lack of specific assays with high sensitivity.
The first successful isolation of inhibin from bovine follicular fluid (bFF)
demonstrated a 58 kDa glycoprotein consisting of a 43 kDa subunit linked to a 15 kDa
subunit by disulphide bonds (Robertson et al, 1985). Proteolytic cleavage of the 43
kDa subunit caused by the low pH conditions of the purification process gave rise to a
31 kDa peptide consisting of 20 kDa and 11 kDa subunits (Robertson et al, 1986).
Similar molecular masses of inhibin in bFF were also confirmed by other investigators
(Fukuda et al, 1986; Miyamoto et al, 1986; Knight et al, 1989). Moreover, a range of
high molecular weight species, 65 kDa, 88 kDa, 108 kDa and 120 kDa, were
Identified by Miyamoto et al (1986) using monoclonal antibodies to 32 kDa bovine
inhibin. Miyamoto et al (1986) also reported the presence of a 32 kDa glycoprotein in
porcine follicular fluid (pFF), which consisted of 20 kDa and 13 kDa subunits. This
confirmed the findings of Rivier et al (1985) and Ling et al (1985). These two subunits
have been termed a- and {3-subunits. Furthermore, Ling et al (1986a; 1986b)
identified two forms of inhibin in pFF: the so called inhibin A and inhibin B. The
difference between these two proteins was found to be the amino acid sequences of the
smaller subunits which are termed (3A and (3B.
Leversha et al (1987) isolated a 30 kDa species consisting of 20 kDa and 16 kDa
subunits from sheep follicular fluid and the same molecular size of inhibin was also
reported in ovine rete testis fluid by Bardin et al (1987). In human follicular fluid
(hFF), based on immunoactivity and in vitro bioactivity studies, a number of
molecular sizes of inhibin, 30 kDa, 36 kDa, 59 kDa and 66 kDa, were identified by
Robertson et al, (1990b). The 59-66 kDa was the predominant species as previously
reported in bFF (Robertson et al, 1985).
Recently, two immunoactive forms of inhibin with no bioactivity have been identified
from bFF. First, a 27 kDa peptide termed pro-aC and secondly, a 25 kDa termed aN-
subunit (see Section 1.3). These are presumably the products of proteolysis and
rebinding of inhibin a-subunit precursors (Knight et al, 1989; Sugino et al, 1989;
Robertson et al, 1989). These immunoactive forms can cross-react with the antibodies
against dimeric inhibin as mentioned in Section 1.2.1. At present, the amount of these
two biologically inactive forms secreted into the circulation is unknown. Moreover,
changes in the immunoactive to bioactive ratio of inhibin over the menstrual cycle have
been observed (Robertson et al, 1988a). This has led to a great controversy as to the
significance of serum inhibin immunoactivity in different physiological conditions.
The isolation of activins, dimers of the (3-subunits of inhibin, is connected to that of
inhibin. Ling et al (1985) reported that a fraction obtained during the purification of
inhibin from pFF stimulated rather than inhibited FSH secretion from rat pituitary
cells. This protein was further purified and proved to be a disulphide-linked
homodimer of inhibin PA-subunits (Activin A) or a heterodimer of inhibin j3A- and
PB-subunits (Activin AB) (Ling et al, 1986b; Vale et al, 1986). The purified protein
showed a single band of 24 kDa in molecular size on sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) under non-reducing conditions
which upon reduction was found to consist of 2 subunits (Ling et al, 1986a; 1986b;
Vale et al, 1986). These proteins have opposite actions to that of inhibin. Activin B
(PBpB) has never been isolated as a native protein from biological fluids but has been
biologically produced using transfection of mammalian tissue culture cells and has
similar biological activities and potencies to the other two native activins (Mason et al,
1989). Surprisingly, activin A has been reported to have an identical structure to
erythroid differentiating factor (EDF) (Eto et al,1987; Kitaoka et al, 1987).
3. Inhibin structural analysis and homologies
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Recently, success in cloning inhibin genes from porcine (Mason et al, 1985; Mayo et
al, 1986), bovine (Forage et al, 1986), ovine (Bardin et al, 1987), rat (Esch et al,
1987; Woodruff et al, 1987) and human sources (Mason et al, 1986; Mayo et al, 1986;
Stewart et al, 1986) has revealed complete structures of inhibin and activin subunit
precursors that were initially deduced from the complementary DNAs (cDNAs). These
subunits are separately encoded by different genes. Using Southern blot analysis of
somatic cell hybrid DNAs and in situ hybridization, it was demonstrated that the
human inhibin a and {3B genes were assigned to different regions of chromosome 2
whereas the inhibin PA gene was located on chromosome 7 (Barton et al, 1989). The
exon-intron structure of the genes coding for individual inhibin subunits are very
similar between species. The gene for the human inhibin a-subunit contains an intron
of 2.1 kb which splits the coding region while that for the bovine inhibin a-subunit
also has a single 1.7 kb intron. An intron of 10 kb has been demonstrated in the PA
gene of human and bovine species (Stewart et al, 1986) whereas the full length
sequence of the human PB gene contains an intron of 2.5 kb (Mason et al, 1989). This
conservation of genomic structure is also supported by a stong structural homology of
protein sequences, suggesting that they are derived from one ancestral gene as a result
of duplications.
Significant homology exists between the structures of the a- and p-subunits within
and between a number of species (Mason et al, 1985; Forage et al, 1986; Woodruff et
al, 1987; Leversha et al, 1987). The precursors of porcine, human and bovine inhibin
subunits and their cDNAs have been demonstrated (Mason et al, 1985; 1986; Mayo et
al, 1986; Forage et al, 1986). The amino acid sequence of the a-subunit precursor
shows 85% homology between humans, pigs and cattle (Mason et al, 1986). The PA
and PB protein precursors show 70% homology within and between species (Mason
et al, 1985; 1986). These subunit precursors are subsequently processed at sites of
paired arginine residues to yield the 43 kDa a-subunit and the 15 kDa P-subunit
(Figure 1.1) which are the C-terminal region of its precursor protein. The 43 kDa a-
subunit is further processed to a 20 kDa peptide which is the a-subunit of the 32 kDa
dimeric inhibin. Whether the cleavage of these proteins occurs before or after
dimerization is not known. Flowever, the fact that 58 kDa inhibin is converted to 31
kDa inhibin when in contact with serum suggests that a-subunit cleavage can occur
after dimerization (McLachlan et al, 1986a). The porcine and human mature a-






















Figure 1.1 Structures of inhibin and activin
amino acids for human, 364 amino acids for porcine). The PA mature subunits in
both species are identical, 116 amino acids in length and derived from the C-terminal
of their precursors which are 424 amino acids in length. The pB mature subunit is 115
amino acids in length and is derived from the C-terminal of a 407 amino acid protein
precursor. In addition, human pA- and PB-subunit show a difference of only one
amino acid. There are at least three amino acids which differ between the human,
porcine and bovine.
It is reported that inhibin is a glycoprotein due to its binding ability to lentil-lectin and
concanavalin A (Jansen et al, 1981; de Jong et al, 1982; Godbout & Labrie, 1984).
The amino acid sequence of the human a-subunit precursor predicts three possible
glycosylation sites, one at the pro-region and the other two within the mature region,
whereas in porcine and bovine only two glycosylation sites are predicted, one located
in the pro-region and the other in the mature region. However, only one possible
glycosylation site occurs in the pro-region of both p-subunits and no glycosylation site
is present in the mature region (Mason et al, 1985; Mayo et al, 1986; Forage et al,
1986). Glycosylation of the mature a-subunit accounts for the difference between
molecular weights determined by SDS-PAGE and that based on amino acid weights.
The mature inhibin a- and p-subunits which contain seven and nine cysteine residues
respectively show a similar distribution of these residues and also some sequence
homology around them, further suggesting a common ancestral gene. Interestingly,
there is a structural similarity between inhibin p-subunits and other growth factor-
related peptides, such as TGF-P (Derynck et al, 1985), MIS (Cate et al, 1986), the
decapentaplegic gene complex in Drosophila (Padgett et al, 1987) and the VG1 gene in
Xenopus (Weeks and Melton, 1987). The homology is evidently in the domains
surrounding the highly-conserved cysteine residues.
4. FSH-suppressing protein (FSP or follistatin)
FSH-suppressing protein (FSP), a glycosylated single chain polypeptide has been
isolated during the purification of inhibin from bFF (Robertson et al, 1987) and pFF
(Ueno et al, 1987), and as a product of stellate cells derived from bovine pituitary
glands (Gospodarowicz & Lau, 1989). These proteins have inhibin-like bioactivity
(5-30% as potent as bovine and porcine 31-32 kDa inhibin) in vitro. FSP proteins are
different from inhibin, based on their primary and secondary structures and
immunoactivity. Bovine FSP consists of three molecular weight proteins of 31 kDa,
35 kDa and 39 kDa whereas 32 kDa and 35 kDa proteins are found in pFF. All forms
have identical amino-terminal amino acid sequences (Robertson et al, 1987; Ueno et al,
1987). The FSP proteins were found to be products of one gene which has arisen
through alternative gene splicing (Shimasaki et al, 1988a). This gene has been
characterized and sequenced from cDNA libraries of porcine ovaries (Esch et al,
1987), rat ovaries (Shimasaki et al, 1989) and human testes (Shimasaki et al, 1988b).
The deduced amino acid sequence of porcine FSP demonstrated homology to a human
pancreatic trypsin inhibitor (Esch et al, 1987). Using in situ hybridization, the
expression of FSP mRNA has been demonstrated in rat ovary, kidney and brain
(Shimasaki et al, 1989). The same group have also shown by Northern blot analysis
that the expression of mRNA in the ovary can be stimulated by pregnant mare's serum
gonadotrophin (PMSG) treatment.
FSP is synthesized locally within the rat follicle to granulosa cells (Findlay et al,
1990). Bovine granulosa cells in culture secrete FSP and its secretion can be
stimulated by bovine FSH and cAMP, but not by LH, suggesting that FSP may act as
a local regulator of ovarian function (Klein et al, 1991). FSP has effects on
differentiation of granulosa cells and delays the process of luteinization (Xiao et al,
1990). However, FSP has also been reported to be an activin-binding protein
(Nakamura et al, 1990). Thus, the physiological role of this protein requires further
investigation.
5. Sources and physiological significance of inhibin and
related peptides in the female
There is strong evidence that inhibin, as measured in peripheral blood during the
ovarian cycle, is produced by the ovary. In 1976, inhibin activity was demonstrated in
bovine follicular fluid (de Jong & Sharpe, 1976) and later in the follicular fluid of
other species (Schwartz & Channing, 1977; Welschen et al, 1977; Channing et al,
1981; Fujii et al, 1983) including human (Chari et al, 1979). Granulosa cells from
various species such as rat (Erickson & Hsueh, 1978; Hermans et al, 1982; Croze &
Franchimont, 1984; Sander et al, 1984), cow (Henderson & Franchimont, 1981), pig
(Channing et al, 1982a) and human (Channing et al, 1984) have been shown to
produce inhibin in vitro. Furthermore, the production of inhibin from large follicles
was greater than from small follicles (Channing et al, 1982b) and also the inhibin
content in large follicles was greater than that in small follicles (Tsonis et al, 1983).
The localization of inhibin subunits in rat granulosa cells (Cuevas et al, 1987;
Merchenthaler et al, 1987; Meunier et al, 1988a) and the expression of inhibin subunit
mRNAs (Meunier et al, 1988a; Rivier et al, 1989; Torney et al, 1989; Woodruff et al,
1988; 1989; Schwall et al, 1990) provide further evidence that follicles are a source of
peripheral inhibin during the follicular phase.
In the primate including man the corpus luteum has also been suggested as a major
source of ovarian inhibin production. The concentration of immuno- and bioactive
inhibin in luteal tissue is very high (Davis et al, 1987) and immunoactive inhibin is
produced by human luteal cells in culture (Smith et al, 1992). Using antibodies
directed against epitopes on either the a- or (3-subunit, inhibin has been localized to
the granulosa-lutein cells of the human corpus luteum (Smith et al, 1991). mRNA for
the inhibin a-subunit is strongly expressed in human luteal tissue as shown by
Northern blot analysis (Davis et al, 1987, Reddi et al, 1990b) and in luteal tissue from
the marmoset monkey (Hillier et al, 1989). Recently very convincing evidence for the
localization of mRNA for both a-and (3A- subunits in the granulosa-lutein cells of the
corpus luteum of monkey was obtained using in situ hybridisation with cDNA probes
(Schwall et al, 1990).
In addition, studies involving luteectomy in the monkey (Basseti et al, 1990) and
ovariectomy in women (Illingworth et al, 1991) resulted in a marked fall in circulating
inhibin levels; further indicating that the ovary is the main if not the only source of
inhibin. More direct evidence for the source of secretion of inhibin by the ovary is
available from a study in which its concentration was measured in ovarian venous
blood (Illingworth et al, 1991). At all stages of the cycle the concentration of inhibin in
ovarian venous plasma is higher than that in peripheral blood, confirming its secretion
by the ovary. However, in the follicular phase, the concentration of inhibin in ovarian
venous blood draining each ovary is similar. In contrast the concentration of oestradiol
in blood draining the ovary containing the dominant follicle is much higher than in that
draining the contralateral ovary. These findings indicate that all antral follicles in the
ovary make a significant contribution to the secretion of inhibin rather than solely the
dominant follicle as is the case with oestradiol. In the luteal phase, the concentration
of inhibin is significantly higher in venous blood draining the ovary containing the
corpus luteum than in that from the contralateral ovary. Moreover, when the corpus
luteum is enucleated or luteotrophic support withdrawn by the administration of an
antagonist of GnRH, there is a marked fall in the concentration of inhibin in peripheral
plasma (Fraser et al, 1989; McLachlan et al, 1989; Smith & Fraser, 1991). These
findings strongly suggest that the corpus luteum secretes inhibin.
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5.1 Endocrine role of inhibin
The inhibin hypothesis postulates that inhibin selectively suppresses FSH secretion
and this action have been previously shown in many experiments in various species.
However, little is known about the role of inhibin in the human female and it is
necessary to refer to studies in other species to deduce information from the hormonal
profiles of normal or experimental cycles.
In the follicular phase of the menstrual cycle the concentration of FSH falls while that
of LH rises slightly (McLachlan et al, 1987a; Reddi et al, 1990a; McLachlan et al,
1990). It might have been expected, therefore, that the secretion of inhibin, which by
definition suppresses the secretion of FSH selectively, would increase at this time.
Although it was claimed initially (McLachlan et al, 1987a) that there was a progressive
rise in inhibin concentration during the follicular phase, further more detailed studies
have demonstrated that during the mid-follicular phase of the cycle, when the
concentration of FSH is suppressed, there is no change in the concentration of inhibin
which remains constant until 2 or 3 days before ovulation. In contrast, the
concentration of oestradiol rises progressively throughout the follicular phase from the
time that the ovulatory follicles become dominant (about Day 6). In the 48 hours prior
to the LH peak the concentration of inhibin rises, falls slightly at around the time of
ovulation and then rises again to reach a peak in the mid-luteal phase of the cycle. In
the few days prior to the onset of menstruation, the concentration of inhibin falls
coincidental with the fall in the concentration of progesterone and oestradiol (Roseff et
al, 1989). At the same time the concentration of FSH rises, strongly suggesting that
inhibin is secreted by the corpus luteum together with oestradiol and progesterone, and
suppresses the secretion of FSH during the luteal phase. The pattern of inhibin
secretion is very similar in the non-human primate (Fraser et al, 1989; Basseti et al,
1990; Smith et al, 1990; Webley et al, 1991). Inhibin levels are low during the
follicular phase and increase following the LH surge to reach a maximum during the
luteal phase.
It is likely that, as in the sheep and the rat, inhibin complements oestradiol in
regulating the secretion of FSH (Rivier & Vale, 1989; Baird et al, 1990). As there is
little change in the concentration of inhibin in the follicular phase, it is unlikely to be
responsible for the decline in the concentration of FSH at this time which is due to the
increased secretion of oestradiol by the dominant follicle. Rather, inhibin contributes
to the overall level of negative feedback, the amount reflecting the total number of
antral follicles in the ovaries. Thus, the rise in FSH concentration which occurs
premenopausally is associated with reduced levels of inhibin (MacNaughton et al,
1990). In the luteal phase the combined secretion of inhibin and oestradiol suppresses
the secretion of FSH to a level below the threshold necessary to activate and sustain
the growth of large antral follicles. Thus all follicles > 5mm in diameter found during
the luteal phase of the menstrual cycle are atretic.
5.2 Paracrine and autocrine role of inhibin and activin
Activin (and TGF-(3) enhances the ability of FSH to induce aromatase activity by
immature rat granulosa cells, an effect which is partially reversed by adding inhibin
(Ying et al, 1986; Ying, 1988). Similar results were observed in rat granulosa cells by
Hutchinson et al (1987) who also noted a suppression in progesterone production.
The effect of porcine inhibin on reversing the enhancement of FSH-induced aromatase
activity by activin, could not be confirmed using bovine inhibin (Hutchinson et al,
1987). Experiments involving the effects of inhibin on granulosa cells are confounded
by the production of endogenous inhibin by the granulosa cells. Thus, in contrast to
the well characterised effect of activin on granulosa cells, the role of inhibin is
uncertain.
However, inhibin appears to have well-defined actions on theca cells. In rat theca cell
preparations inhibin enhanced LH-induced androgen production, an effect which was
attenuated by activin (Hsueh et al, 1987). Similar findings were observed in human
theca cells cultured in serum-free medium (Hillier et al, 1991a; 1991b). Recombinant
human inhibin, in concentrations which are within the range found within the follicle,
markedly enhanced the action of LH and insulin-like growth factor (IGF) in
stimulating the production of androstenedione and dehydroepiandrosterone, but not
progesterone, when added to theca cells in culture (Hillier et al, 1991a). In the absence
of LH or IGF, inhibin alone had very little action. In contrast, activin suppressed the
basal production of androgens in this system and inhibited the stimulatory effect of
inhibin (Hillier et al, 1991b). These findings suggest a mechanism by which the
granulosa cells could influence thecal cell function. Furthermore, theca cells of the
follicle also probably influence the growth and differentiation of granulosa cells. TGF-
P, which is structurally related to activin, causes a dose-dependent increase in
aromatase activity and inhibin production, an effect which is additive to that of FSH
(Zhiwen et al, 1988). Although rat and bovine thecal tissue cultured in vitro produce
TGF-p (Skinner et al, 1987) it is not yet known whether activin is produced by theca
cells as well as granulosa cells.
5.3 Control of inhibin production
While there is strong evidence to suggest that FSH can stimulate inhibin production by
the ovary, the exact mechanism is not entirely understood. Injection of PMSG or FSH
into rats, sheep or women results in a large increase in the concentration of immuno-
and bioactive inhibin in the ovaries and in serum (Lee et al, 1981; McLachlan et al,
1986a; Buckler et al 1989; Tsonis et al, 1988a). In the study by Tsonis et al (1988a),
the concentration of bioactive inhibin was very closely correlated with the rise in the
concentration of oestradiol and with the number of large antral follicles. However, in
the short term the concentration of FSH appears to have little influence on the secretion
of inhibin by the ovary. In the sheep, inhibin secretion is unaffected for up to 12 hours
after injecting FSH in amounts which double the basal concentration (Campbell et al,
1991). Inhibin is secreted by the sheep ovary in pulses but each pulse is unrelated to
pulses of FSH or LH (McNeilly & Baird, 1989; Campbell et al, 1989). In women
there are episodic fluctuations in the concentration of inhibin in peripheral blood
during the luteal phase (Nakajima et al, 1990). However, the magnitude of these
pulses is modest (<20%) and they are unrelated to episodic pulses of LH or
progesterone. Whether these fluctuations in peripheral plasma concentrations of
inhibin reflect pulsatile ovarian secretion is difficult to determine due to the long half-
life ofinhibin.
There is abundant evidence in vitro that inhibin production by granulosa cell cultures is
dependent on FSH. FSH and testosterone enhance the induction of inhibin production
by bovine (Henderson & Franchimont, 1981) and immature human (Hillier et al,
1991c) granulosa cells. The production of inhibin by granulosa cells recovered from
large follicles is responsive to LH as well as FSH, while luteinized granulosa cells are
only stimulated by LH (Tsonis et al, 1987a). In this latter study it was shown that LH
stimulated the production of oestradiol and progesterone as well as inhibin. cAMP and
prostaglandin E (which stimulates the production of intracellular cAMP) both mimic
the effect of LH and FSH on granulosa cells suggesting strongly that gonadotropins
exert their effect on inhibin production via the adenyl cyclase system linked to specific
receptors (Bicsak et al, 1987).
There is evidence both in vivo and in vitro that a similar mechanism operates within
luteal tissue. Injection of hCG in vivo prolongs the life span of the corpus luteum and
stimulates inhibin secretion (Illingworth et al, 1990). Production of inhibin (and
oestradiol and progesterone) by dispersed human luteal cells in culture is stimulated by
hCG in a dose-dependent manner (Smith et al, 1992). Whether the same paracrine
factors which modulate the responsiveness of the granulosa cells of the follicle to
gonadotrophins operate in the corpus luteum is not yet clear.
6. Inhibin and its related peptides in pregnancy
There is an increase in peripheral inhibin concentrations in the luteal phase of the
normal menstrual cycle. Many direct and indirect studies have shown that the corpus
luteum is a potential source of inhibin (McLachlan et al, 1987c; Tsonis et al, 1988;
Illingworth et al, 1991; Smith et al, 1991). The concentration of circulating
immunoactive inhibin during pregnancy has been reported in primates. Smith and
colleagues (1990) have demonstrated an increase in inhibin levels throughout
pregnancy in the common marmoset monkey and this finding has also been observed
in the Japanese monkey (Nozaki et al, 1990). In human pregnancy, many studies
have revealed an elevation in peripheral bioactive (Qu et al, 1991) and also
immunoactive inhibin (McLachlan et al, 1987b; Abe et al,1990; Kettel et al, 1991;
Tabei et al, 1991; Smitz et al, 1990; Rombauts et al, 1990). Although the human
corpus luteum is likely to be a source of circulating inhibin in the normal cycle
(McLachlan et al, 1989; Smith et al, 1991), it is not the only potential source in
pregnancy (McLachlan et al, 1987b). Studies have shown inhibin bioactivity in the
rabbit (Hochberg et al, 1981) and human placenta (Bandivdekar et al, 1981). The
finding in human placenta was confirmed by the presence of bioactive and
immunoactive inhibin in term placental extracts (McLachlan et al, 1986b). Inhibin
secretion from primary cultures of human trophoblasts was reported by Petraglia et al
(1987a) and these authors also demonstrated the presence of inhibin a-subunit
immunoactivity in cytotrophoblast cells of the human placenta. This localization was
confirmed by Merchenthaler and colleagues in the same year (Merchenthaler et al,
1987).
In human pregnancy, inhibin a-subunit cDNA was isolated from a placental cDNA
library (Mayo et al, 1986). Davis and colleagues (1987) have shown the expression of
inhibin a- and only PA-subunit mRNAs in term placenta while Reddi and colleagues
(1990b) have demonstrated a- and {5B-subunit gene expression in term placenta by
Northern blot analysis.
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The regulation of inhibin secretion and its effect on the function of other hormones
have also been examined. Human chorionic gonadotropin (hCG) stimulated inhibin
secretion from cultured placental cells and this effect could be mimicked by 8-bromo-
cyclic AMP, forskolin and cholera toxin (Petraglia et al, 1987a). Inhibin also
suppressed the stimulatory effects of GnRH on hCG secretion of trophoblast cells
(Petraglia et al, 1987a). However, in tissue culture of placental explants inhibin only
suppressed hCG secretion by term placenta, not by first trimester placenta (Mersol-
Barg et al, 1990). Furthermore, in human placental cell cultures activin stimulates the
production of progesterone, not hCG, but it enhances the stimulation of GnRH on
hCG release and the latter effect can be reversed by inhibin (Petraglia et al, 1990).
There is evidence for the presence of inhibin in mid-term amniotic fluid (Sinosich et al,
1991) and activin A in amniotic fluid (Abe et al, 1989) which suggests that the fetus
plays a role in the production of inhibin. However, circulating inhibin levels in
umbilical cord have been shown to be lower than in maternal blood vessels and there is
no difference between umbilical vein and artery levels (McLachlan et al, 1986b; Tabei
et al 1991; Kettelet al, 1991).
Apart from human trophoblast, decidual tissue has been reported to be another
possible source of inhibin. Petraglia and colleagues (1990) have shown the localization
of inhibin-subunits and the expression of the mRNAs for inhibin-subunits in decidual
tissue throughout pregnancy.
However, the role of inhibin in pregnancy remains unknown. The significant
homology observed between inhibin and the decapentaplegic gene complex in
Drosophila (Padgett et al, 1987) and the VG1 gene in Xenopus (Weeks & Melton,
1987) which are involved in early embryogenesis suggests a possible role for inhibin
in embryonic differentiation. Furthermore, inhibin |3-subunits have a striking
homology with TGF-|3 which has recently been shown to have an important role in
different embryonic events (Heine et al, 1987).
7. Structure of the human placenta
After fertilization, the mature ovum undergoes segmentation or cleavage into
blastomeres. During the division of blastomeres the gradual accumulation of fluid
results in formation of the blastocyst or fertilized ovum. At this stage the outer cells
which are destined to produce the trophoblast can be distinguished from the inner cell
mass which are destined to produce the embryo. The blastocyst becomes polarized as
it is embedded in the endometrium. The outermost pole, developing towards the
endometrium cavity, becomes the chorion laeve, and the innermost pole becomes the
chorion frondulosome or the villous and extravillous components of the placenta.
As the blastocyst contacts the endometrium, proliferating trophoblasts invade. Some
trophoblasts invade maternal blood vessels, replacing the vascular smooth muscle and
endothelium cells resulting in the formation of trophoblast-lined vascular channels.
Other trophoblasts are orderly formed into discrete chorionic villous structures. These
villous structures (Figure 1.2) consist of an outer layer of syncytiotrophoblasts which
are derived from the fusion of mononuclear cytotrophoblasts, cells in the inner layer
lying beneath the syncytiotrophoblast layer. These two subdivisions of trophoblasts
are distinguishable; the cytotrophoblast consists of individual cells with relatively pale-
staining cytoplasm, and in the syncytiotrophoblast, dark-staining nuclei are distributed
irregularly within a common basophilic cytoplasm. The cytotrophoblasts are joined to
each other and the syncytiotrophoblasts by desmosomes. The trophoblasts lie on a
basement membrane surrounding a central core of mesenchymal cells, macrophages
and capillary endothelium.
The chorionic villi begin as small buds and grow from a stem into a complex
branching structure. As the placenta matures, the short, thick, early stem villi branch
repeatedly, forming progressively finer subdivisions and greater numbers of
increasingly smaller villi. Each of the main stem villi and its branches constitute a
placental cotyledon. The villi in a cotyledon are classified according to their positions
in the tree, the type of fetal blood vessels and the connective tissue structure. The stem
villous has centrally-located fetal arteries and veins and a rich connective tissue
stroma. Intermediate villi branch from the stem villi containing arterioles and venules,
and branch into terminal villi. These terminal or tertiary villi have fetal capillaries and a
minimal fetal diffusion distance (see Boyd & Hamilton, 1970).
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During the first trimester, the growth of the placenta is rapidly driven by the
multiplication of the cytotrophoblasts. These proliferation cells extend through the tips
of the villi, which anchor the placenta to the uterus, as cytotrophoblast columns which
then spread out to form the cytotrophoblast shell. This shell is interposed between the
villi and uterine decidua. As cytotrophoblast cells mature, they lose mitotic activity and
then fuse to form syncytiotrophoblast.
Placental growth slows down during the second and third trimesters, and the relative
ratio of syncytiotrophoblast to cytotrophoblast increases dramatically. It has been
suggested that the differentiation of cytotrophoblasts to syncytiotrophoblasts
encompasses an intermediate state (Kurman et al, 1984a; 1984b). The trophoblasts in
this state (so called 'intermediate trophoblasts') are the cells characterized as round, or
polyhedral mononuclear cells with larger and hyperchromatic nuclei compared to those
of normal villous cytotrophoblasts. The intermediate trophoblast has abundant
cytoplasm which is less eosinophilic than that of syncytiotrophoblast. Mononuclear
trophoblasts with these characteristics are found in villi and extravillous sites.
The villous trophoblasts are the potential sites of hormone production, but the
hormonal expression of these morphologically distinct trophoblasts are different. The
cytotophoblast synthesizes the hypothalamic releasing factors secreted by the placenta
such as GnRH, CRF and somatostatin (Khodr & Siler-Khodr, 1980; Petraglia et al,
1987b, c; 1989; Robinson et al, 1988; Watkins & Yen, 1980). The
syncytiotrophoblast synthesizes chorionic gonadotrophin (CG), chorionic
somatomammotrophin (CS) and different forms of growth hormone (Hoshima et al,
1982; Beck et al, 1986; Liebhaber et al, 1989). It is also the most active steroidogenic
placental cell type; the aromatiziation of C19 steroids from fetal and maternal origin
into CI8 phenolic oestrogens takes place in syncytiotrophoblast cells (Fournet-
Dulguerov et al, 1987). Both syncytiotrophoblasts and cytotrophoblasts are the site of
inhibin-like peptide production (Petraglia et al, 1987a; 1990; Merchenthaler et al,
1987; Tovanabutra et al, 1991).
Extravillous cytotrophoblasts and syncytiotrophoblasts (giant wandering cells) and
cytotrophoblasts of the chorion laeve also produces hormones, but the profile of
synthesized hormones of these extravillous trophoblasts are different from the villous
trophoblasts. The extravillous trophoblastic cells do not react with antibodies to CS,
and CG in the same manner as those of villous trophoblasts (Sasagawa et al, 1987).
The unique phenotype of extravillous trophoblast revealed by immunocytochemical
studies most likely reflects the impact of their milieu rather than intrinsic differences in
the differentiation of villous and extravillous cells. Although it is likely that
paracrine/autocrine control is involved in these processes, the factors responsible for
the morphological and functional differentiation of the trophoblasts are still unknown.
The placenta is an organ which has dynamic changes in growth rate, structure and
cellular composition. Moreover, the function of each cell type may vary during
pregnancy (e.g CG is produced by cytotrophoblasts of the blastocyst during
implantation). At the beginning of first trimester, the villous cytotrophoblasts do not
produce CG but syncytiotrophoblasts secrete vast amounts and the production falls
substantially when the pregnancy progresses to term. Studies on the placenta must be
viewed carefully and the results must be interpreted with caution.
8. Aims of thesis
In this thesis I shall describe studies aimed at identifying the nature of inhibin and
related peptides in human pregnancy.
In Chapter 2, in order to obtain a suitable antibody for monitoring inhibin
immunoactivity produced by the placenta in different studies (e.g. the molecular
species of inhibin in placental extracts and immunohistochemistry), RIA and Western
immunoblot analysis were exploited to test the specific cross-reaction of the available
inhibin antibodies to inhibin.
Aiming to investigate inhibin interaction with other hormones and the potential source
of peripheral inhibin during pregnancy, the studies in Chapter 3 were designed to
measure the concentration of inhibin, hCG, oestradiol and progesterone in plasma of
pregnant women from conception through implantation until delivery.
In Chapter 4 the experiments were designed, first to exploit the available in vitro sheep
pituitary cell bioassay for measuring and characterizing bioactive inhibin in placental
extracts from different stages of pregnancy, secondly to observe inhibin immuno¬
activity in placental extracts and changes in the immunoactivity to bioactivity ratio
during pregnancy and lastly to observe the relationship between placental immuno-
active inhibin and hCG content in placental extracts during pregnancy.
To obtain information on inhibin in amniotic fluid during pregnancy the studies in
Chapter 5 were performed, first to use three available antibodies which recognise
different parts of the inhibin molecule, secondly to examine the in vitro bioactivity of
amniotic fluid inhibin and lastly to verify the dimeric inhibin bioactivity by
immunoneutralization of the bioactivity using an antibody raised against the human
synthetic inhibin a-subunit.
The cellular localization of inhibin a- and P-subunits in human placenta was
investigated throughout pregnancy by the studies in Chapter 6 using immuno-
histochemical techniques.
The studies in Chapter 7 were aimed to investigate inhibin gene subunit expression in
the human placenta and also to examine the different expression of these subunit
mRNAs at various stages of pregnancy. Finally, to further our understanding on the
site of inhibin subunit protein production and gene expression, the study in Chapter 8
was carried out to investigate the cellular localization of inhibin gene expression using
the in situ hybridization technique.
CHAPTER 2
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Characterization of antibodies used for
radioimmunoassay and immunocytochemistry by
Western blot analysis of inhibin and related
peptides
2.1 Introduction
At present there are two types of antibodies to inhibin available. The first type is an
antibody against purified bovine 58 or 32 kDa inhibin (McLachlan et al, 1986a; 1987a;
Robertson et al, 1988a; 1988b) and partially-purified porcine or bovine inhibin
(Hasegawa et al, 1987; 1988). The radioimmunoassays (RIAs) developed using these
antibodies are very sensitive, thus allowing the measurement of low levels of inhibin
in the circulation of human and other species.
The second type of antibody is raised to a range of synthetic peptides representing the
amino terminal region of the mature a-subunit of porcine 1-25 or 1-26 inhibin (Rivier
et al, 1986; McNeilly et al, 1989; Schanbacher et al, 1988; Sharpe et al, 1988) and
human 1-23, 6-30 or 1-32 inhibin (McNeilly et al, unpublished data; Groome et al,
1990; Saito et al, 1989; Sinosich et al, 1991; Mersol-Barg et al, 1990). The RIA with
this a-subunit antibody has been widely used to measure inhibin in different
preparations such as gonadal extracts, culture media of gonadal cells or tissues and
also in serum of some species.
RIAs using either of these antibodies do not cross-react with other proteins in the
inhibin family (activin, TGF-P and MIS) but have strong cross-reactivity with another
immunoactive inhibin species, pro-aC, which has been found in bovine and porcine
follicular fluids (Robertson et al, 1989; Sugino et al, 1989; Schneyer et al, 1990).
Apart from their advantages for RIA, these antibodies are also useful in identifying
and characterizing inhibin in preparations separated by electrophoretic procedures in
particular Western immunoblot analysis. This technique has been exploited to
demonstrate the molecular species of inhibin in bovine follicular fluid (Miyamoto et al,
1986; Knight et al, 1989), human serum (Schneyer et al, 1990) and culture media
from gonadal cells (Grootenhuis et al, 1990 ).
The experiments in this chapter were designed to use RIA and Western blot analysis to
test the specificity of the available inhibin antibodies with inhibin immunoactivity in
placental extracts from various stages of pregnancy and to compare this with ovarian
follicular fluid inhibin. It had been hoped to use these antibodies to characterize
inhibin-like peptides in placental extracts. In the event it was not possible to obtain
sufficient quantities of purified protein. However, the antibody and methods obtained
were useful for immunohistochemistry.
2.2 Characterization of antibodies by radioimmunoassay
2.2.1 Materials & Methods
Placental extracts
Placental tissue was obtained from pregnancy terminations at 7 weeks and 16 weeks,
and from full term pregnancy. The placental cotyledons were cut off and washed
extensively with phosphate-buffered saline (PBS; see Appendix 1) to remove blood.
The tissues were homogenized in two volumes of PBS with a Polytron homogenizer.
The homogenate was then centrifuged at 1,000 g for 15 min at 4°C and the supernatant
collected and recentrifuged at 100,000 g for lh at 4°C. The supernatant was stored at
-70° C until the assays were performed.
Human follicular fluid (hFF)
hFF was obtained from patients undergoing ovarian stimulation for in vitro
fertilization during oocyte retrieval.
Antibodies
Antibodies to different fragments of inhibin a- and pA-subunits were purchased or
kindly provided from different sources (as summarized in Table 2.1 with
accompanying details). The assays using these antibodies were developed with advice
from Dr. Alan McNeilly and help from Ms. Wendy Crow.
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1) Y29 is the antibody raised in sheep against human inhibin a-(l-23)-NH2
(Peninsula Laboratories, San Carlos, CA) conjugated with rabbit gammaglobulin by
the carbodi-imide method and produced by Dr. Alan McNeilly (McNeilly et al, 1989).
2) 6DF5 is the antibody raised in sheep against human inhibin a-(l-23)-NH2 fragment
(kindly prepared by Dr. Rodney Kelly) conjugated with rabbit gammaglobulin by Dr.
Alan McNeilly.
3) S55 is the antibody raised in sheep against porcine inhibin a-(l-26)-NH2 (kindly
provided by Dr. Jean Rivier) conjugated with ovalbumin .
4) R187 is the antibody raised in rabbit against human inhibin (3-(97-l 12)-NH2
conjugated with Ultrasyl-D resin by Dr. Rodney Kelly.
5) Monash antibody (no. 1989) is the antibody raised in rabbit against 31kDa bovine
inhibin using the method described by McLachlan et al (1986a).
Radioimmunoassays
1) Inhibin assay using the Y29 antibody
Reagents:
Assay buffer: 0.075 M phosphate buffer, pH 7.3, containing 0.15 M NaCl, 1%
bovine serum albumin (RIA grade, Sigma) and 0.01% thiomersal (BDH).
Standards: Human inhibin a-subunit (l-23)-NH2 (Peninsula Laboratories) was
diluted in assay buffer to obtain the working range from 3.9 to 2000 pg/100(il.
Antiserum: Y29 was diluted with assay buffer at the dilution of 1 in 60,000.
Tracer: The 125I-human inhibin a-(l-23)-NH2 was prepared by a modification of the
chloramine-T method (McNeilly et al, 1989). The iodination was performed as
follows:
A peptide aliquot (l|ig/50|il in 0.1M phosphate buffer, pH 7.5) and 5|il of Na125I (10
mCi/100p.l, Amersham) were pipetted into a 1.5ml Eppendorf tube. 10 jil of
chloramine-T (lmg/ml in 0.5 M phosphate buffer, pH 7.5) was added and the reaction
solution mixed and left to stand for 60 seconds. The reaction was stopped by the
addition of 10 (il of sodium metabisulphite (lmg/ml in 0.05M phosphate buffer, pH
7.5) and 430 (il 0.05M phosphate buffer containing 0.05% 3-((3-cholamidopropyl)
dimethylammonio)-l-propanesulfonate (CHAPS, Sigma). The mixture was
chromatographed to separate 125I-peptides from free 125I using a 30x1 cm Sephadex
G-25 column which has been previously equilibrated with 0.05M phosphate buffer
containing 0.05% CHAPS (eluent buffer). 0.8 ml fractions were collected and the
elution profile is shown in Figure 2.1. The two fractions at the top of the peptide
peaks were kept as the stock tracer.
Assay procedure:
The assay was performed by incubating 100 p.1 sample, 100 |il of the diluted antibody
(1:60,000) in assay buffer and 100 (il of 125j. labelled antigen (15,000 cpm/100(il in
assay buffer) with 200 |il assay buffer at 4°C for 24 h. The antigen-antibody
complexes were precipitated by adding 100 p.1 of diluted normal sheep serum (1:500)
and 100 |il of diluted donkey anti-sheep/goat globulin (1:10) which were both kindly
donated by the Scottish Antibody Production Unit (SAPU), Lanarkshire, Scotland.
After 18 h further incubation at 4°C, 1 ml of 0.9% NaCl was added and the assay
tubes centrifuged at l,600g for 20 min at 4°C. The supernatant was discarded and the
precipitate counted in a gamma counter (Pharmacia-Wallac 1261 multigamma manual
gamma counter). The data were analysed using the 'Assay Zap Universal Assay
Calculator' written by Dr. P.L. Taylor for Elsevier, Biosoft, U.K. The sensitivity of
the assay was 15 pg/100(il and the coefficients of variation of intra-assay and inter-
assay were 3.9% and 11.2% respectively.
2) Inhibin assay using the 6DF5 antibody
Assay buffer, standards, tracer and assay protocol were as described in the assay with
the Y29 antibody.
Antiserum: 6DF5 was diluted with assay buffer to 1 in 10,000.
3) Inhibin assay using the S55 antibody
Assay buffer, standards and assay procedure were as described in the assay with the
Y29 antibody.
Antiserum: S55 antibody was diluted with assay buffer at the dilution of 1 in 40,000.
Tracer: The 125I-porcine inhibin a-(l-23)-NH2 was prepared by the modified
chloramine-T method (McNeilly et al, 1989). The iodination was performed as
described above. The iodination profile is shown in Figure 2.2.
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Fraction numbar
Figure 2.1 Representative elution profile of human inhibin a-(l-23)-NH2 iodination.
Labelled hormone Free 125-1
Fraction numbar
Figure 2.2 Representative elution profile of porcine inhibin a-(l-26)-NH2 iodination.
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The assay protocol is the same as for the inhibin assay with the Y29 antibody.
4) Inhibin assay using the R187 antibody
Reagents:
Assay buffer: 0.075 M phosphate buffer, pH 7.3, containing 0.15 M NaCl, 1%
bovine serum albumin (RIA grade, Sigma) and 0.01% thiomersal (BDH).
Standards: Human inhibin pA-subunit (97-112)-NH2 was diluted in assay buffer to
obtain a working range from 20 to 5,000 pg/lOOpl
Antiserum: R187 antibody was diluted with assay buffer to 1 in 1,000.
Tracer: The 125I-human inhibin PA-(97-112)-NH2 was prepared as described for
human (1-23) a-inhibin. The iodination profile is shown in Figure 2.3.
Assay procedure:
The RIA was performed by incubating 100 jil of sample or standard with 100 jil of
diluted first antibody (1:1000) and the incubation volume adjusted to 400 p.1 with 200
pi assay buffer. The assay tubes were incubated at 4°C for 24 h, and 100 pi of labelled
antigen (15,000 cpm) was added. The incubation proceeded for a further 24 h at 4°C.
100 pi of diluted normal rabbit serum (1:500) and 100 pi of diluted donkey anti-rabbit
immunoglobulins (1:40) provided by SAPU were added to separate the antigen-
antibody complexes. After incubation for a further 18 h at 4°C, the assay tubes were
centrifuged and the precipitates counted. The data were calculated using the same
computer programme described above.
5) Inhibin assay with the Monash antibody
Reagents:
Assay buffer: lOmM phosphate buffer, pH 7.3, containing 0.15 M NaCl, 0.5%
bovine serum albumin (RIA grade, Sigma) and 0.1% sodium azide (BDH).
Human recombinant inhibin A: was purchased from NEH (NEH rhINH-R-90/1).
Standards: A partially-purified human follicular fluid was prepared using the method
described elsewhere (Reddi et al, 1990a). The activity of this inhibin-containing
preparation was 23.0 ± 1.2 U/l (mean ± SEM) which was assayed against ovine rete
testis fluid standard using the in vitro sheep pituitary cell bioassay (Tsonis et al,
1988). The range of standards was from 3.6 to 230 mU/lOOpl. An arbitrary unit of
this standard was different from the partially purified human follicular fluid used by
the Monash group (Robertson et al, 1988b) because they were standardized against the
same ovine rete testis fluid standard in different bioassay systems. The rat pituitary cell
bioassay was not as sensitve as the sheep pituitary cell bioassay as mentioned




Figure 2.3 Representative elution profile of human inhibin pA-(97-l 12)-NH2
iodination.
cells to human inhibin made an arbitrary unit of these two standards incomparable.
However this in-house standard was standardized against human recombinant inhibin
A (NIH rhINH-R-90/1) in radioimmunoassay and one milliunit of this standard was
equal to 3.5 pg recombinant inhibin A (Smith et al, unpublished data).
Antiserum (no. 1989): The antiserum was purchased from Monash University,
Melbourne, Australia and diluted to 1 in 3,000 with assay buffer containing normal
rabbit serum (SAPU) at a dilution of 1 in 600.
Tracer: Bovine 31 kDa inhibin (purchased from Monash University) was iodinated
using the chloramine-T method and further purified by the method described by
McLachlan et al (1986a) with slight modifications. The iodination procedure was
carried out as follows:
20 |il (1-2 |ig) of 31 kDa bovine inhibin, 20 (il of 0.5 M phosphate buffer (pH 7.5)
and 10 |il of Na125I (10 mCi/100 jil, Amersham) were pipetted into a 1.5ml
Eppendorf tube. 80pl of chloramine-T in 0.5 M phosphate buffer (400 qg/ml) was
added and the reaction was left to proceed for 60 seconds. 40 (il of sodium
metabisulphite (3mg/ml in distilled water) and 800 ^1 of 0.02M phosphate buffer
containing 0.1% BSA were added to terminate the reaction. The mixture was then
subsequently purified by applying it to a PD10 column (Sephadex G-25, Pharmacia)
which was pre-equilibrated with 30ml of 0.02M phosphate buffer, pH 6.0, containing
0.1% BSA (eluent buffer A). Fractions of 0.5 ml were collected and the elution profile
is shown in Figure 2.4.
The protein peak fractions were pooled and made up to 20 ml with eluent buffer A,
then applied to a column containing 400 |il pre-equilibrated Red Sepharose
(Pharmacia) which was prewashed with 10 ml eluent buffer A. The effluent was
collected and reapplied to the column. After the effluent had run through, the column
was washed with 3x1ml of eluent buffer A. The iodinated inhibin was eluted with
2x1ml of eluent buffer A containing 1M KC1 (BDH) and 4 M Urea (BDH). In order to
remove the KCl/Urea, the collected fractions were applied to PD10 columns which
were previously equilibrated with 30 ml of 10 mM phosphate buffer, pH 7.3,
containing 0.15 M NaCl, 1% BSA and 0.1% Triton X-100 (eluent buffer B).
Following the sample, 1.5 ml of eluent buffer B was run through the column and the
effluent was discarded. A further 3 ml of the eluent buffer B was applied and the
eluate containing iodinated bovine inhibin from each PD10 column was collected and








The assay was set up by incubating 100 p.1 of sample or standard, 100 pi of diluted
antibody and 200 pi of assay buffer for 24 h at room temperature. 100 pi of 125I-
bovine inhibin (15,000 cpm/lOOpl in assay buffer containing 0.1% Triton X-100) was
added and the reaction mixture was incubated for a further 24 h at room temperature.
After adding 100 pi of diluted donkey anti-rabbit immunoglobulin (1:64 in assay
buffer) provided by SAPU, the incubation was continued for a further 16-18 h at 4°C.
I.5 ml of 0.9% NaCl containing 4% polyethyleneglycol 6000 (BDH) and 0.1% Triton
X-100 was added and the assay tubes centrifuged at 2,500g for 45 min at 4°C. The
supernatant was aspirated and the precipitate counted. The sensitivity of the assay
(ED20, ED50 and EDgo) was 7.6, 22.1 and 50.4 mU/lOOpl (n=20) respectively and




This antibody demonstrated the inhibin immunoactivity of placental extracts. Parallel
dilution curves of human inhibin a-(l-23)-NH2 standard and placental extracts from 7
weeks, 16 weeks and delivery were obtained (Figure 2.5a). The same parallelism was
also obtained from human follicular fluid (Figure 2.5b).
6DF5 antibody
The RIA using 6DF5 antibody which was raised against human inhibin a-(l-23)-NH2
demonstrated parallelism in the dose-response lines between placental extracts from
different stages of pregnancy, but not the standard (Figure 2.6).
S55 antibody
The dose-response lines of human inhibin a-(l-23)-NH2 and hFF were parallel in the
RIA with the S55 antibody, raised against porcine a-(l-26)-NH2), (Figure 2.7a) but
this parallelism was not observed with placental extracts. However, the dilution curves
of placental extracts from 7 weeks and 16 weeks of pregnancy, and delivery were
parallel (Figure 2.7b)
R187 antibody
This antibody, which is raised against the inhibin PA-subunit fragment, demonstrated
specific cross-reactivity to recombinant activin A at high concentrations from 100 ng
upwards (Figure 2.8a). Human follicular fluid and placental extracts from various
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Figure 2.5 (a) Dose-response lines of synthetic human inhibin a-(l-26)-NH2 (O)
and placental extracts from 7 weeks ( # ), 16 weeks ( A ) and delivery ( □ )
demonstrating parallelism in RIA using Y29 antibody, (b) Parallelism between the
dilution curves of human inhibin a-(l-26)-NH2 ( O) and human follicular fluid (• ).
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Figure 2.6 Dose-response curves of human inhibin a-(l-26)-NH2 ( O ) and placental
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Figure 2.7 (a) Dose-response curves of synthetic human inhibin a-(l-26)-NH2 ( O )
and human follicular fluid ( • ). (b) Dose-response curves of placental extracts from 7
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Figure 2.8 (a) Dose-response curves of human inhibin (3A-(97-l 12)-NH2 ( • ) and
recombinant activin A ( 0 ) demonstrating parallelism, (b) Dose-response curves of
human inhibin (3A-(97-l 12)-NH2 ( O ), h-FF ( A ) and placental extracts from 7 weeks
( • ), 16 weeks ( A ) and delivery ( □ ) demonstrating low immunoactivity in RIA
with R 187 antibody. Placental extracts from different stages of gestation showed
similar potency in displacing the tracer and the curves are superimposed one and
another.
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Monash antibody (no. 1989)
The RIA with this antibody showed about 10-fold greater sensitivity to placental
extracts than the Y29 antibody. The partially-purified hFF standard curves and the
dilution curves of placental extracts are parallel and this parallelism was also observed
with human recombinant inhibin A (Figures 2.9a and 2.9b)
2.2.3 Discussion
The results in this section show that the antibody against 31kD inhibin is the most
sensitive in measuring inhibin in placental extracts. This antibody has been reported to
specifically cross-react with inhibin in numerous biological fluids including term
placental extracts (see review by Robertson, 1990). Little is known of placental
function during pregnancy and the species of inhibin secreted by the placenta is
unidentified. Thus, the results demonstrating parallelism of placental extract dilution
curves from different stages of pregnancy and partially-purified hFF standard show
the specificity of the Monash antibody and the similarity of inhibin species produced
during gestation.
The present data also show parallelism between the displacement of placental extracts
from different stages of gestation and hFF in RIAs using the Y29 antibody. The
displacement curves are similar to those obtained using the Monash antibody. This
suggests specificity of both antibodies which is not seen in RIAs with the 6DF5, S55
and R187 antibodies. The Monash antibody, which is raised against intact bovine
dimeric inhibin, has been shown to cross-react with free a-subunit or pro-aC
(Robertson et al, 1989; Sugino et al, 1989) suggesting that this antibody recognizes
the a-subunit. Y29 antibody is directed against the inhibin a-subunit. Thus, these
antibodies detect intact inhibin and also the a-subunit or pro-aC. Nevertheless,
recombinant inhibin A shows parallel displacement with hFF standards and placental
extracts in the RIA using the Monash antibody. This suggests that the same species of
immunoactive inhibin as recombinant inhibin A is present in hFF and placental
extracts.
The antibody R187, raised against human inhibin (3A(97-112)-NH2, also has
immunogenic activity. The sensitivity of the assay with the inhibin PA-peptide
fragment standard is 170 pg/tube and with recombinant activin A is 100 ng/tube.
Recombinant activin A dilutes in parallel with the inhibin PA-peptide fragment
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Figure 2.9 (a) Dose-response curves of partially-purified human follicular fluid inhibin
standard ( O ) and placental extracts from 7 weeks ( • ), 16 weeks ( A ) and delivery
( ■ ) demonstrating parallelism, (b) Dilution curves of partially-purified human
follicular fluid inhibin standard ( O ) and human recombinant inhibin A ( ▲).
fluid. This antibody reveals more immunoactivity of inhibin (3A-subunit in placental
extracts from various stages of pregnancy than in hFF. These results are difficult to
interpret because both inhibin and activin have the same (3-subunit structure. It would
have been interesting to determine the displacement of recombinant inhibin in the R187
assay system but unfortunately the sensitivity of this system is fairly poor in detecting
hFF standards and it was not possible to obtained sufficient recombinant inhibin A for
the assay. However, it has already been demonstrated that hFF contains mostly intact
inhibin and no activin could be identified (Robertson et al, 1990b). Thus, it is likely
that the displacement curves shown by placental extracts in this system represent intact
dimeric inhibin.
The immunogenic activity of R187 antibody is not helpful for the RIA of either activin
or inhibin but it may have an application for further study of these proteins by
immunoblotting analysis and immunocytochemistry. In addition, this type of p-
antibody has proved useful in immunocytochemistry (Tovanabutra et al, 1991),
immunoblotting analysis of partially-purified proteins (Groome & Lawrence, 1991)
and developing a specific immunoassay for inhibin such as the two-site
immunoradiometric assay (Knight et al, 1991).
2.3 Characterization of antibodies for Western immuno¬
blotting analysis
2.3.1 Materials & Methods
Antibodies & Proteins
From the data obtained from the experiments in Section 2.2, Y29, R187 and the
monoclonal antibody raised against synthetic human inhibin pA-(84-112)-NH2 (MAb
PA) kindly provided by Dr. Nigel Groome (see the details of this antibody in Section
6.3.1.2, Chapter 6) were used to develop a method of Western immunoblotting
analysis. 32 kDa inhibin was supplied with the inhibin kit purchased from Monash
University. Recombinant inhibin A was kindly donated by Dr. Anthony J. Mason,
Genetech Inc., California, USA.
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and
Western immunoblotting analysis.
Samples were electrophoresed on precast 5 to 15% sodium dodecyl sulphate (SDS)
polyacrylamide slab gels (15 mm thick) under reducing or non-reducing conditions
(Laemmli, 1970). Under non-reducing conditions, sample aliquots were heated at
90°C for 5 min with the same volume of sample buffer containing 4% SDS (Bio-Rad
Laboratories, Richmond, CA), 20% sucrose (BDH), 0.1% bromophenol blue (Bio-
Rad) and 0.375 M Tris-HCl, pH 6.8. For reducing conditions, sample buffer
contained 10% 2-mercaptoethanol (BDH) apart from what is mentioned above.
Electrode running buffer, pH 8.3 contained 0.025 M Tris base, 0.192 M glycine
(BDH) and 0.1% SDS. The samples were electrophoresed at 25 mA and 200 V for 4
h. In order to calibrate molecular weights of proteins, the prestained SDS-PAGE
standards, low range (15-110 kDa) were electrophoresed along with the proteins (Bio-
Rad). The proteins were electroblotted (semi-dry transferred) on to a nitrocellulose
membrane (0.4 micron: Bio-Rad) by using Multiphore II Nova blot electrophoretic
transfer unit (Pharmacia LKB). The transfer buffer contained 39 mM glycine, 48 mM
Tris base, 0.0375% SDS and 20% methanol. The nitrocellulose membranes were
blocked with 5% dried skimmed milk (Marvel) in TBS-0.1% Tween (TBS, Tris-
buffered saline, pH 7.4 containing 0.01M Tris-HCl and 0.15M NaCl) for 90 min at
room temperature with gentle shaking. The membrane was washed three times, 5 min
each, in TBS containing 0.1% Tween and then incubated with primary antibody.
Inhibin a- immunoblotting
The membrane was incubated with Y29 antibody (1:100) in TBS containing 0.1%
Tween for 90 min at room temperature with gentle shaking. The membrane was
washed with TBS-0.1% Tween three times, 5 min each and then incubated with rabbit
anti-sheep immunoglobulin (Dako Ltd, High Wycombe, Bucks) 1:50 in TBS-0.1%
Tween for 2 h at room temperature with gentle shaking. The membrane was washed
three times with TBS for 5 min each. The membrane was further incubated with
sheep-PAP (Dako, Ltd.) 1:100 in TBS for 30 min and washed in TBS 3x 5 min. The
membrane was developed in 0.05 M Tris-HCl, pH 7.6 containing 0.05%
diaminobenzidine tetrahydrochloride (DAB) and 0.01% H2O2 until the bands
appeared. The membrane was rinsed with distilled water to stop the reaction and dried
at room temperature. The specificity of antibody was checked by replacing the primary
antibody with non-immune sheep serum (Vector Laboratories).
Inhibin {5-immunoblotting
The membrane was incubated with R187 (1:100) or MAb(5A (1:200) antibodies in
TBS containing 0.1% Tween for 90 min at room temperture. The membrane was
washed with TBS-0.1%Tween 3x 5 min and then incubated with rabbit anti-mouse
immunoglobulin (Dako Ltd) 1:50 in TBS-0.1% Tween for 2 h at room temperature
with gentle shaking. The membrane was washed again with TBS for 3x 5 min. The
membrane was further incubated with Mouse-PAP (Dako Ltd.) 1:100 in TBS for 30
min and washed 3x 5 min in TBS. The membrane was developed as described for
inhibin a-immunoblotting. The specificity of the antibody was checked by replacing
the primary antibody with non-immune rabbit serum (Dako Ltd).
2.3.2 Results
In Figure 2.10a, the immunoblotting of 0.25 fig bovine inhibin standard with antibody
(Y29) directed against human a (1-23) inhibin revealed the 31 kDa band, whereas no
band was shown with non-immune sheep serum. Figure 2.10b shows the
immunoblotting of recombinant activin A at different concentrations (0.5, 1, 2 and 4
fig), revealing two bands of 28 kDa and 14 kDa with R187 antibody. These bands
were not seen with non-immune rabbit serum.
Figure 2.11a shows immunoblotting of 31 kDa bovine inhibin standard (0.25 fig)
with Y29 antibody. One band of 31 kDa was demonstrated under non-reducing
conditions and one band of 18 kDa under reducing conditions.
Immunoblotting of bovine inhibin standard and recombinant activin A under non-
reducing and reducing conditions with MAb(3A are shown in Figure 2.11b. For
bovine inhibin (0.25 fig), the non-reducing conditions reveal one band at 31 kDa
corresponding to intact inhibin while the band at slightly under 16 kDa was shown
under reducing conditions. 1 (lg of recombinant activin A showed two bands at 28














Figure 2.10 (a) Immunoblotting of 31kDa bovine inhibin standard with Y29 antibody
and non-immune sheep serum (NSS) under non-reducing conditions, (b)
Immunoblotting of recombinant activin A at different concentrations with R187








Inhibin (0.25 itg) Activin (1 ^ig)





Figure 2.11 (a) Immunoblotting of 31kDa bovine inhibin standard under non-
reducing (N) and reducing (R) conditions with Y29 antibody, (b) Immunoblotting of
31kDa bovine inhibin standard and recombinant activin A under non-reducing and
reducing conditions with MAbpA antibody.
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2.3.3 Discussion
The results from immunoblotting of 31kDa bovine inhibin standard and recombinant
activin A using Y29, R187 and MAbpA antibodies demonstrated the specificity of
these antibodies to each inhibin subunit. Figure 2.10a shows that, under non-reducing
conditions, the Y29 antibody which is directed against the inhibin a-subunit peptide
detects intact bovine 31 kDa inhibin. When the intact molecule is broken down into 14
kDa P- and 18 kDa a-subunits under reducing conditions, the Y29 antibody reacts
with only the a-subunit suggesting that the specificity of this antibody is limited to the
a-subunit only.
The MAbpA monoclonal antibody directed against the inhibin PA-(84-l 12)-NH2-
subunit detects intact bovine 31 kDa inhibin and 28 kDa activin under non-reducing
conditions. This antibody also detects 14 kDa p-subunits which are derived from
intact inhibin 31 kDa and activin under reducing conditions. The antibody is specific to
the P-subunit only and has proved useful for immunohistochemistry as shown in
Chapter 6. The R187 polyclonal antibody which is raised against the inhibin PA-(97-
112)-NH2-subunit also shows specificity for activin under non-reducing conditions
and the activin P-subunit under reducing conditions. Surprisingly, immunoblotting of
activin with MAbPA and R187 antibodies shows two bands of proteins under non-
reducing conditions and one band under reducing conditions. This must be due to the
degradation or breaking down of the intact activin molecule into its subunits during
storage in acetic acid. This degradation must be taken into consideration for any
bioassay experiments examining effects of this activin preparations. However, Y 29
antibody is specific to the inhibin a-subunit, whereas R187 and MAbpA are specific
to the inhibin P-subunit. The results from this section and the previous one will be




Relationship between peripheral immunoactive
inhibin, human chorionic gonadotrophin,
oestradiol and progesterone during human
pregnancy
3.1 Introduction
In late human pregnancy, there is an elevation in the peripheral concentration of
immunoactive inhibin (McLachlan et al, 1987b; 1987c; Abe et al, 1990; Kettel et al,
1991; Tabei et al, 1991; Smitz et al, 1990; Rombauts et al, 1990) and also bioactive
inhibin (Qu et al, 1991). However, reports of the timing and nature of the changes in
circulating inhibin vary, particularly in the very early days of pregnancy where the
only available data have been obtained following infertility treatment with ovarian
superovulation regimes (McLachlan et al, 1987c).
In addition, the source of the circulating inhibin remains uncertain. During the human
menstrual cycle, the corpus luteum is the principal source of circulating inhibin
(Illingworth et al, 1991) and pharmacologic stimulation of the corpus luteum with
hCG at concentrations similar to those seen in early pregnancy cause a marked increase
in the circulating inhibin concentration. However, increased inhibin concentrations
have also been described during pregnancy in agonadal women who conceived as a
result of in vitro fertilisation with donor oocytes, thus demonstrating that the corpus
luteum cannot be the only source of circulating inhibin at this time. Indeed, the
detection of inhibin bioactivity and immunoactivity in placental extracts (McLachlan et
al, 1986b; Tovanabutra et al, 1990) including the localization of inhibin subunits
(Petraglia et al, 1987a; Merchenthaler et al, 1987; Tovanabutra et al, 1991) and the
expression of its mRNA in term placentae (Davis et al, 1987; Reddi et al, 1990b) show
that the human placenta is likely to be an important source of inhibin in pregnancy.
In order to investigate the patterns of inhibin secretion in pregnancy and its interaction
with other hormones, two studies were performed to obtain serial measurements of the
concentration of inhibin, hCG, oestradiol and progesterone in plasma from volunteers
1) prior to the LH surge until day 65 of pregnancy and 2) from 12 weeks of pregnancy
until term.
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3.2 Materials and Methods
3.2.1 Study design & plasma samples
1) In order to investigate changes in the inhibin concentration around implantation,
peripheral blood samples were obtained from four healthy volunteers recruited prior to
conception. All subjects were healthy (age range 28-33) with no past history of
infertility or endocrine disorders and all conceived within six months of joining the
study. Samples were obtained from each subject, three times a week, starting in the
late follicular phase (Day 8-10 of the cycle) and continuing either until menstruation or,
if conception took place, until 11 weeks after the last menstrual period. In addition,
each subject collected daily urine samples throughout the study period and the date of
ovulation was taken as the day after the peak urinary LH value as measured by rapid
LH immunoassay (Djahanbakhch et al, 1981). One of the subjects conceived during
the first study cycle. In the other three subjects, the cycle prior to the conception cycle
was taken as the "non-conception" cycle for comparison with the "conception cycle".
2) In order to investigate the changes in inhibin concentration in later pregnancy,
peripheral blood samples were obtained from 9 women attending the antenatal clinic at
the Simpson Memorial Maternity Pavilion. All subjects were healthy (age range 26-35)
with no past history of endocrine disorders. Samples were collected at four-weekly
intervals from 12 weeks since the last menstrual period until delivery. In all subjects,
the gestation based on the last menstrual period was confirmed by early pregnancy
sonography.
Plasma was separated by centrifugation and stored at -20°C for later assay of inhibin,
progesterone, oestradiol and hCG.
3.2.2 Radioimmunoassays
1) Inhibin assay
A heterologous radioimmunoassay with antibody to 31kDa bovine (antibody 1989)
inhibin and iodinated 31 kDa bovine inhibin as a tracer was used to measure inhibin
(Robertson et al, 1988b). A partially-purified human follicular fluid (Reddi et al,
1990a) was used as the standard. Details of the reagents are described in Section 2.2
of Chapter 2.
The assay procedure was also as described in Section 2.2 of Chapter 2, except the
sample volume varied from 50 to 200 (il according to the age of pregnancy but the total
volume was kept at 200 pi by the addition of pooled inhibin-free postmenopausal
plasma (PPS). 200 pi PPS was also added to the standard curve, non-specific binding
(NSB) and maximum binding (Bo) tubes to correct for non-specific plasma effects.
2) Progesterone assay
Plasma progesterone was measured using the double antibody RIA developed by
Chatteijee, Sweeting, Hillier & Baird (unpublished data).
Reagents:
Assay buffer. 0.25 M citrate buffer, pH 4.0, containing 0.1% gelatin.
Standard: Preg-4-ene 3, 20-dione (Sigma) was prepared in progesterone-free
postmenopausal plasma to obtain a working range between 1-127.2 nmol/1.
Antibody: The antibody, raised in a rabbit against progesterone-lla-hemisuccinate
conjugated to BSA, was donated by Dr. J. E. T. Corrie, MRC Collaborative Centre,
Mill Hill.
Tracer: 125I-progesterone-l la-glucuronide-tyramine was prepared by Mr. Ian
Swanston using the chloramine-T technique.
Assay procedure:
50 pi of plasma sample or standard was incubated with 100 pi of antibody (1 in 4,000
in assay buffer), 100 pi of tracer (25,000 cpm/100 pi assay buffer containing 0.036 g
% of 8-anilino naphthalene sulphonic acid) for 3 h at room temperature (the non¬
specific plasma effect was corrected for by adding 50 pi of postmenopausal plasma
into the NSB and Bo tubes). 100 pi of diluted normal rabbit serum (1:640) and 100 pi
of diluted donkey anti-rabbit serum (1:20) were added and the assay tubes were
incubated overnight at 4°C. After adding 1 ml of 0.9% saline, the assay tubes were
centrifuged at 2,500 rpm for 30 min at 4°C. The supernatant was discarded and the
precipitate counted. The data was analysed using the Assay Zap programme. The
sensitivity of the assay was 3.5 nmol/1 whereas the intra- and inter-assay coefficients
of variation were 6.2% and 9.1% respectively.
3) Oestradiol assay
Plasma oestradiol was radioimmunoassayed using the ether extraction method
described by Glasier et al (1989).
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Reagents:
Assay buffer: 0.05 M phosphate buffer, pH 7.2, containing 0.15 M NaCl, 0.1%
gelatin and 0.01% thiomersal.
Standard: 17(3-oestradiol (Sigma) was prepared in assay buffer to obtain the working
range of 30 to 10,000 pmol/1.
Antibody: A sheep anti-oestradiol antibody was provided by Dr. R. Webb, IAPGR,
Roslin, Midlothian.
Tracer: 125 I-oestradiol-3-carboxymethyl ether iodohistamine was prepared by Ms
Martha Urquhart using a chloramine-T method.
Assay procedure:
100 |il of sample or standard was pipetted into a 12x75mm borosilicate tube
(Sarstedt). The sample was extracted by vortexing with 1 ml diethyl ether (BDH).
After freezing the plasma layer in a dry ice/methanol mixture, the ether layer was
decanted into a borosilicate tube and dried down under a stream of nitrogen in a
heating block. 100 fil of antibody diluted with assay buffer (1:2,000,000) and 200 jil
of tracer (12,000 cpm/200 p.1 assay buffer) were added and the assay tubes incubated
at 4°C overnight. The assay tubes were incubated on ice for 15 min and then the
antigen-antibody complex was separated from free hormone by adding 500 p.1 dextran-
coated charcoal solution containing 1.25% charcoal (BDH) and 0.125% dextran
(BDH). The incubation was continued on ice for a further 15 min. The charcoal was
precipitated by centrifugation at l,500g for 15 min at 4°C. The supernatant was
transferred to a polypropylene tube and then counted. The data was analysed as for the
progesterone assay. The sensitivity of the assay was 25 pmol/1 whereas the intra- and
inter-assay coefficients of variation were 8% and 15% respectively.
4) Human chorionic gonadotrophin assay
hCG was assayed using the hCG MAIAclone Monopack purchased from Serono.
This assay was developed by combining an immunoradiometric system with a
magnetic solid phase. The assay was performed as described in the supplier's
instructions.
Reagents:
1251 Anti-hCG reagent: Two iodinated mouse monoclonal antibodies to hCG in Tris-
buffer containing normal sheep serum, BSA, inert dye (red) and 0.2% sodium azide.
Standards: Standard hCG (1st IRP/3rd IS 75/357) was prepared in horse serum at 5,
10, 25, 100, 250 and 500 mlU/ml.
Assay diluent: Horse serum containing 0.2% sodium azide.
Separation agent: Tris-buffer containing BSA, 0.1% sodium azide and sheep
antiserum to fluorescein covalently bound to magnetic particles.
Wash buffer: Tris-buffer containing 0.1% sodium azide.
Assay procedure:
50 p.1 of sample or standard and 500 pi of1251 anti-hCG were incubated at 37°C for 15
min. 200 pi of separating agent was added to the reaction mixture and the assay tubes
were placed on a rack in a magnetic separator for 2 min. The supernatant was carefully
decanted and the sediment complex washed with 500 pi of wash buffer to reduce non¬
specific binding by repeating the separation step in the magnetic separator. The assay
tubes were counted and the data processed using the computer programme supplied by
Nuclear Enterprises Technology Ltd. The sensitivity of the assay was 5 mlU/ml
whereas the intra- and inter-assay coefficients of variation were 3% and 6.5%
respectively.
3.2.3 Statistical Analysis
In the calculation of results a log-normal distribution was assumed. Results are,
therefore, presented throughout as geometric means with 67% confidence intervals
(CI) and all subsequent statistical analysis is carried out on logarithmically-transformed
data. The circulating hormone levels in the "conception" and "non-conception" cycles
were compared by two-way analysis of variance (ANOVA) using a commercial
statistics software package (CLR Anova, Clear Lake Research), taking type of cycle
and time since ovulation as within-subject variables.
3.2 Results
Comparison of "conception" and "non-conception" cycles
Figure 3.1 shows the concentrations of inhibin, progesterone, oestradiol and hCG in
the first fourteen days of the "conception cycle" and in the preceding "non-conception"
cycle. In both cycles, the inhibin concentration (Figure 3.1a) rose after ovulation. In
the "non-conception" cycles a peak value was observed on day 8 after the LH peak
(geometric mean 239.8 U/l: CI 207.2-277.5 U/l) before the concentrations fell again
as luteolysis occurred, reaching 78.8 U/l (CI 53.0-117.1 U/l) on day 14 after the LH
peak. In contrast, during the "conception" cycles, the inhibin concentration continued
to rise after the mid-luteal phase concentration of 199.9 U/l (CI 173.2-230.6 U/l) to
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Figure 3.1 Geometric mean (67% confidence intervals) plasma concentrations of
inhibin, progesterone, oestradiol and hCG for the three subjects from whom samples
were collected during the conception cycle (-•-) and during the previous non-
conception cycle (-O-). The data are normalised around the mid-cycle LH peak .
( Conception cycle v. Non-conception cycle; *= p <0.Q5)
inhibin concentrations in the two cycles were compared using two-way ANOVA, no
significant difference was found between the inhibin concentrations in the two cycles.
When the inhibin concentrations after the appearance of hCG were compared (days 13-
15, Student's paired t test), the inhibin concentrations were found to be significantly
(p<0.05) greater during the conception cycle. No difference was found in the
concentration of either oestradiol or progesterone between the conception cycles and
the non-conception cycles before the appearance of hCG (Figures 3.1b and 3.1c).
Serial hormone concentrations throughout pregnancy
The pattern of inhibin secretion in early pregnancy from 4 volunteers is shown in
Figure 3.2.
The mean plasma concentrations of inhibin, progesterone, oestradiol and hCG in 4
volunteers from 5 days before the LH peak through conception and implantation until
day 65 after the LH peak are shown in Figure 3.3a. The mean plasma concentrations
of the same hormones for 9 volunteers between week 12 after the LMP and week 40
after the LMP are shown in Figure 3.3b.
The mean inhibin concentration rose steadily after the LH surge and reached the first
peak of 351.9 U/l (CI 275.7-449.0 U/l) around day 16. The level of inhibin declined
after the first peak and then rose to reach a second peak (513.0 U/l: CI 442.1-595.3
U/l) around day 47 after the LH surge. The inhibin concentration subsequently fell to
a nadir at 16 weeks (227.4 U/l: CI 200.9-257.5 U/l), before rising steadily to a third
peak of 614.2 U/l (CI 544.3-693.0 U/l) at term.
The mean plasma concentrations of progesterone, oestradiol and hCG are also shown
in Figure 3.3a. Following ovulation, the progesterone concentration rose to reach a
first peak between days 13 and 20 (maximum value 126.9 nmol/1: CI 114.5-140.7
nmol/1). A second peak (156.0 nmol/1: CI 130.1-187.2 nmol/1) was then observed at
around day 47 of pregnancy, before the progesterone concentration gradually
increased from 12 weeks (104.9 nmol/1: CI 96.5-114.2 nmol/1) through term. In
contrast to the pattern seen for inhibin and progesterone, the peripheral concentration
of oestradiol exhibited a steady rise from the first luteal phase sample (233.2 pmol/1:
CI 196.0- 274.4) until term (95,177 pmol/1: CI 85,431-106,034 pmol/1). hCG was
first measured above the detection limit of the assay on day 10-11 after the LH surge.
The concentration then increased rapidly to reach a peak at day 47 of pregnancy
(196,318 IU/L: CI 163,170-236,200 IU/1) before falling to a level of 28,600 IU/1
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Figure 3.2 Plasma concentrations of inhibin during early pregnancy in 4 volunteers
(a, b, c and d). Data is centred around the day of the LH peak.
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Figure 3.3 Geometric mean (67% confidence intervals) plasma concentrations of
inhibin, progesterone, oestradiol and hCG for (a) the four subjects from whom thrice
weekly samples were obtained before and after conception and (b) the nine subjects
from whom samples were obtained at four-week intervals starting at twelve weeks
after the last menstrual period.
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(CI 20,400-40,200 IU/1) at 20 weeks. Thereafter, the hCG concentration showed little
change for the remainder of the pregnancy.
Correlation between inhibin and hCG, oestradiol and progesterone
It appears from Figures 3.3a and 3.3b that the peaks in mean inhibin concentration
coincide with those for progesterone, while the mean concentrations of oestradiol and
hCG follow a different pattern. This is reflected in the close correlation between
inhibin and progesterone concentrations in both early (r=0.584; p<0.001) and late
pregnancy (r=0.553; p<0.001). There is also, however, a close correlation between
inhibin and oestradiol concentrations in both early (r=0.602; p<0.001) and late
pregnancy (r=0.361; p<0.01). The correlation between inhibin and hCG was also
significant in early pregnancy (r=0.373; p<0.01) although not in late pregnancy (r=
0.063; NS). It is notable, however, that the peak concentration of hCG coincided with
that for inhibin at day 47 after the LH peak.
3.3 Discussion
This is the first study to report serial measurements of inhibin concentrations in the
early days of spontaneously-occurring pregnancy in healthy volunteers. Previous
studies of inhibin secretion in pregnancy have commenced later in pregnancy, have not
included serial measurements, and have not been well characterised with regard to the
timing of conception. The best characterised data previously available is based on
inhibin concentrations in pregnancy cycles following superovulation for assisted
conception and may not be reflective of the true situation.
It is notable that there are three peaks of inhibin secretion during pregnancy. The first
peak is very similar both in magnitude and duration to that previously reported
(Illingworth et al, 1990) in non-pregnant volunteers who had received hCG in
concentrations similar to those seen in normal human pregnancy. This first peak of
inhibin therefore probably reflects corpus luteum activity. The early fall-off in inhibin
concentration after the first peak is interesting and raises the possibility that the rescued
corpus luteum may exhibit maximum activity at day 16 after ovulation before
subsequently reducing its hormone output.
No difference was seen between "conception" and "non-conception" cycles before the
appearance of hCG. This finding contrasts with that recently reported in marmosets by
Webley et al (1991). It may be that the small number of subjects involved in this study
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means that subtle differences between the two cycles have been missed. There is,
however, no evidence of differences with the magnitude seen in marmosets.
Do these measurements of immunoactive inhibin reflect increased inhibin bioactivity in
terms of an increased inhibitory effect on FSH secretion? It is now clear that the
antibody used in this assay binds entirely to epitopes on the inhibin a-subunit and
exhibits a marked cross-reaction with either free a-subunit or the pro-aC precursor
(Robertson et al, 1989). However, both the putative tissues of origin for inhibin in
pregnancy, the corpus luteum and the placenta, have been demonstrated to have
positive immunostaining for the inhibin f}-subunit (Smith et al, 1992; Tovanabutra et
al, 1991). In addition, the presence of either free a-subunit or a-subunit precursors
has not yet been established in women. Support for the possibility that this is dimeric
inhibin comes from the findings of Qu et al (1991) who reported enhanced inhibin
bioactivity in respect of FSH suppression during pregnancy. However, given the
methodologic difficulties in adequately removing the high concentrations of sex
steroids in pregnancy, the inhibin in vitro bioassay may not be specific for non¬
steroidal FSH suppression under these circumstances.
The physiological function of inhibin in pregnancy remains uncertain. The low
concentration of immunoactive FSH during pregnancy may suggest a combined
suppressive effect of inhibin and oestradiol on the secretion of pituitary FSH.
However, the high concentrations of circulating sex steroids, particularly in late
pregnancy, make the significance of the FSH suppressant properties of inhibin
uncertain at this time.
A paracrine role has been suggested for inhibin and activin within the placenta. In
placental cell cultures, inhibin can reverse the effect of activin on augmenting the
stimulation by GnRH of hCG release as well as stimulate progesterone secretion
(Petraglia et al, 1989). Inhibin also suppresses the stimulatory effects of GnRH on
hCG secretion (Petraglia et al, 1987a). Interestingly, in cultured placental explants,
inhibin suppresses hCG secretion by term placenta but not by first trimester placenta
(Mersol-Barg et al, 1990). The correlation between peripheral inhibin and hCG which
is positive and significant in early pregnancy but not significant in later pregnancy may
thus reflect changing paracrine functions of inhibin/activin during pregnancy.
A further possible role for inhibin/activin is in embryogenesis as suggested by the
finding of Roberts et al (1991) on the expression of inhibin/activin subunit mRNAs
during rat embryogenesis. Activin is a member of the TGF-J3 group of growth factors
and is a potent mesoderm induction factor (van den Eijnden-Van Raaij et al, 1990)
which may be particularly important in promoting axial development in notochord and
muscles (Thomsen et al, 1990). Activin is also capable of inhibiting the proliferation of
ovarian precursor cell lines as well as the growth of a testicular precursor cell line
while inhibin has been found to promote proliferation of ovarian precursor cell lines
(Gonzalez-Manchon & Vale, 1990). What is the relationship between the embryogenic
functions of predominantly activin and the changes in circulating inhibin concentration
seen during pregnancy? This is uncertain as the circulating hormone concentrations are
unlikely to be representative of local growth factor activity and further, the activin
concentrations in the circulation are unknown.
CHAPTER 4
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Placental inhibin immunoactivity and bioactivity
during pregnancy and its relation to placental
human chorionic gonadotrophin
4.1 Introduction
Placental inhibin bioactivity was first reported in rabbit by Hochberg et al (1981) and
in human by Bandivdekar et al (1981). Recently, using the heterologous RIA and the
in vitro rat pituitary cell bioassay, human term placental extracts were shown to
possess inhibin bioactivity and immunoactivity (McLachlan et al, 1986b). Many
authors including ourselves (see Chapter 3) have demonstrated an increase in
peripheral immunoactive (McLachlan et al, 1987a; Abe et al, 1990; Kettel et al, 1991;
Tabei et al, 1991; Smitz et al, 1990; Rombauts et al, 1990) and bioactive inhibin (Qu et
al, 1991) during human pregnancy. At present, much more information is required in
order to clarify the physiological role of inhibin in pregnancy which still remains
unknown.
Furthermore, in recent years an increasing number of proteins have been shown to be
secreted by the human placenta. Among these proteins are some known and some
unknown growth factors. These factors have effects on cell growth and differentiation
(See review by Hill et al, 1987). The differentiation and multiplication of cells were
reported to have an effect on their specialized functions e.g hormone production.
During the attempt to bioassay inhibin in placental extracts, ovine pituitary cell
multiplication caused by unknown growth factors was observed. Term placental
extracts had the greatest effect compared to placental extracts from mid-term and 7
weeks of pregnancy (Tovanabutra et al, unpublished data).
The experiments in this chapter were designed: 1) to observe the overall effects of the
growth factors in term placental extracts on the FSH secretion of the ovine monolayer
pituitary cell cultures in order to exploit the available in vitro sheep pituitary cell
bioassay to measure inhibin bioactivity in placental extracts. 2) to examine the
bioactivity and use in vitro immunoneutralization techniques to characterize the
bioactive placental inhibin. 3) to observe inhibin immunoactivity in placental extracts
and changes in the immunoactivity to bioactivity ratio during pregnancy and 4) to
observe the relationship between placental immunoactive inhibin and hCG content in
placental extracts during pregnancy.
4.2 Materials and Methods
Placental extracts
Placental tissue was obtained from pregnancy terminations at 7 weeks, 16 weeks and
at full term pregnancy. The placenta was extracted as described in Section 2.2 in
Chapter 2. The supernatant was kept at -70° C until the assays were performed.
Inhibin in vitro bioassav
Pituitary cell cultures
A sensitive in vitro bioassay using sheep pituitary cells was performed as previously
described (Tsonis et al, 1986). Briefly, 4-6 mature female sheep pituitary glands were
removed and placed in Dulbecco's phosphate-buffered saline (DPBS, Flow
Laboratories) containing 7.5 mM glucose. Pituitaries were weighed, chopped into
small cubes (3-4 mm), and washed thoroughly in DPBS containing 7.5 mM glucose
and 0.1% BSA (Sigma). The chopped tissue was placed in a 25 ml spinner flask with
0.5% trypsin (Type III-S, Sigma) in 12.5 ml DPBS containing 7.5 mM glucose and
0.1% BSA for 30 min at 37°C with gentle stirring. The enzyme solution was replaced
with 12.5 ml supplemented Dulbecco's modified Eagle's medium (DMEM; Row
Laboratories, Rickmansworth, Herts, U.K.), containing 10% (v/v) lamb serum (Row
Laboratories), 2.5% (v/v) fetal bovine serum (Flow Laboratories), 10 mM NaHCC>3,
2 mM glutamine (Sigma), penicillin 50 mU/ml and streptomycin 50 mg/ml (Row
Laboratories). The trypsinized tissue was gently stirred for a further 30 min at 37°C.
The medium was replaced with 12.5 ml of Ca2+ and Mg2+ free DPBS (DPBS"; Row
Laboratories) containing 2 mM EDTA and 0.1% BSA and stirred gently for 10 min at
4°C. The tissue fragments were washed 3-4 times with DPBS" and dispersed using a
series of three sterile, siliconized, flame-treated Pasteur pipettes of progressively
decreasing bore diameter (5-2 mm). The dispersed cells were transferred into
supplemented DMEM, collected by centrifugation at 500 g for 10 min at room
temperature and washed twice with supplemented DMEM. The debris and undispersed
tissue fragments were removed during the washing step. The cells were resuspended
in 20 ml supplemented DMEM and counted using a haemocytometer. Viability,
assessed by the trypan blue exclusion test, was accepted from 90% upwards.
Aliquots of 2x10s cells/50 fil were plated in multiple-well plates (Corning Glassware,
Corning, NY, U.S.A.). The incubation volume was made up to 600 |il with
supplemented DMEM. The plates were incubated in a water-saturated atmosphere of
95% air and 5% CO2, to maintain the pH of the medium at 7.2-7.4, for 48 h. The
medium was then aspirated. The test materials, 100 jll of anti-oestradiol diluted 1:50 in
supplemented DMEM and 100 |il of RU486 (a progesterone antagonist) in
supplemented DMEM (2ng/100 ^il) were added to the wells and then the final
incubation volume was made up to 600 jll with supplemented DMEM. The cells were
cultured for a further 48 h and the spent media collected and assayed for FSH activity
by radioimmunoassay.
Assay procedure
Placental extracts from different stages of pregnancy were charcoal-stripped to remove
steroids (McLachlan et al, 1986b) prior to the assay. Five doses of placental extracts
were assayed in quadruplicate ranging from 0.05-0.8 ^1.
The inhibin reference standard used was a preparation of ovine rete testis fluid (oRTF)
with an arbitrary potency of 1 U/mg (Eddie et al, 1979). A charcoal-Sep-Pak-treated
ovine follicular fluid (CGT-1083-oFF) was used as the quality control. They were
assayed in quadruplicate at five doses ranging between 12.5-200 mU/well for standard
and 0.823-66.67 nl/well for quality control. The FSH dose-response curves of
standard and samples were expressed as a percent inhibition of control wells with no
exposure to inhibin. Regression analysis was calculated using a computer programme
(Scott et al, 1980). The slope, precision index and significance of regression (Finney's
G) were calculated (Finney, 1964). The relative potencies of samples showing
parallellism and linearity to the reference standard (p>0.05: Borth, 1976) were
calculated by comparison with the reference standard. The sensitivity of the assay was
0.05-0.1 U/ml, the index of precision 5.2% and the significance of regression
(G)<0.02. The inter-assay coefficient of variation was 14.9%.
Neutralization of inhibin bioactivity
Different doses of charcoal-stripped placental extracts, human follicular fluid (hFF)
and ovine follicular fluid were assayed to produce an FSH dose-inhibition curve and
doses producing about 50% inhibition were chosen to study the in vitro neutralization
effect of the Y29 polyclonal antibody. The test materials at selected doses were
incubated with the antibody at different concentrations at room temperature for 2 h
before being added to the preincubated pituitary cell cultures in triplicate. After making
up the final incubation volume to 600 pi with supplemented DMEM, the culture plates
were incubated for a further 48 h and the spent media were collected and assayed for
FSH.
Radioimmunoassays
1) Ovine FSH assay
FSH in culture media was measured using a specific double-antibody
radioimmunoassay as previously described (McNeilly et al, 1976).
Reagents:
Assay buffer: 0.075 M phosphate buffer, pH 7.4, containing 0.15 M NaCl, 1%
bovine serum albumin (RIA grade, Sigma) and 0.01% thiomersal (BDH).
Standards: Ovine FSH (NIH-oFSH-S9) was diluted in assay buffer to obtain the
working range from 15.6 to 1000 ng/ml.
Antiserum: Anti-human FSH sera, M91/1 (Lynch & Shirley, 1975) was diluted to 1 in
5,000 with 0.075 M phosphate buffer (pH 7.4) containing 0.15 M NaCl, 0.05 M
EDTA and 0.6% normal rabbit serum (SAPU)
Tracer: The 125I-NLAMDD-oFSH-l was prepared using the lactoperoxidase method
as previously described (McNeilly et al, 1986).
Assay procedure:
The assay was performed by incubating 100 pi standards or 50 pi of samples, 100 pi
of the diluted antibody and 300 or 350 pi of assay buffer at 4°C overnight. 100 pi of
125j_ labelled antigen (15,000 cpm/lOOpl in assay buffer) was added and the
incubation continued at 4°C for a further 24 h. The antigen-antibody complexes were
precipitated by adding 100 pi of donkey anti-rabbit serum (SAPU) diluted to 1 in 20
with 0.075 M phosphate buffer, pH 7.4, containing 4% dextran (BDH). After 18 h
incubation at 4°C, 0.75 ml of 5% PEG in 0.075 phosphate buffer containing 0.015 M
NaCl was added and the assay tubes centrifuged at 1,600g for 20 min at 4°C. The
supernatant was aspirated and the precipitate counted in a gamma counter (Pharmacia-
Wallac 1261 multigamma manual gamma counter). The data were analysed using the
'Assay Zap Universal Assay Calculator'. The sensitivity of the assay was 16 ng/ml
and the coefficients of variation of inter-assay and intra-assay were 6.6% and 9.9%
respectively.
2) Ovine LH assay
Culture media LH was assayed using a double-antibody RIA as previously described
(McNeilly et al, 1986).
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Reagents:
Assay buffer. 0.075 M phosphate buffer, pH 7.4, containing 0.15 M NaCl, 1%
bovine serum albumin (RIA grade, Sigma) and 0.01% thiomersal (BDH).
Standards: Ovine LH (NEH-0LH-SI8) was diluted in assay buffer to obtain the
working range from 0.1 to 20 ng/ml.
Antiserum: Anti-ovine LH sera, R29, was diluted to 1 in 120,000 with 0.075 M
phosphate buffer (pH 7.4) containing 0.15 M NaCl.
Tracer: LH preparation (LHM4 )was iodinated using a lactoperoxidase method by Mrs
Gwen Cowen.
Assay procedure:
The assay was performed by incubating 100 |il standards or samples, 100 p.1 of the
diluted antibody and 200 p.1 of assay buffer at 4°C overnight. 100 (il of 125j_ labelled
antigen (15,000 cpm/lOOfil in assay buffer) was added and the incubation continued at
4°C for a further 24 h. The antigen-antibody complexes were precipitated by adding
100 p.1 of donkey anti-rabbit serum (SAPU) diluted to 1 in 32 with assay buffer and
100 p.1 of normal rabbit serum diluted 1:800 with assay buffer. The incubation was
continued for a further 18 h at 4°C and 1ml of 0.9% NaCl was added. The assay tubes
were centrifuged at l,600g for 20 min at 4°C. The supernatant was decanted and the
precipitate counted in a gamma counter. The data were analysed using the 'Assay Zap
Universal Assay Calculator'. The sensitivity of the assay was 0.2 ng/ml and the
coefficients of variation of intra-assay and inter-assay were 4.9% and 14%
respectively.
3) Ovine Prolactin (PRL) assay
Ovine prolactin was assayed using a double-antibody RIA as previously described
(McNeilly & Andrews, 1974).
Reagents:
Assay buffer: 0.075 M phosphate buffer, pH 7.4, containing 0.15 M NaCl, 1%
bovine serum albumin (RIA grade, Sigma) and 0.01% thiomersal (BDH).
Standards: Ovine PRL (NIH-oPRL-S15) was diluted in assay buffer to obtain the
working range from 0.8 to 200 ng/ml.
Antiserum: Anti-ovine PRL sera, R2532, was diluted to 1 in 128,000 with 0.075 M
phosphate buffer (pH 7.4) containing 0.15 M NaCl.
Tracer: The 125I-NIAMDD-oPRL-17 was prepared using a lactoperoxidase method as
previously described (McNeilly et al, 1986)
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Assay procedure:
The assay was performed by incubating 30 (il standards or samples, 100 (il of the
diluted antibody, 100 jil of 125j_ labelled antigen (15,000 cpm/100|il in assay buffer)
and 100 (il of assay buffer at 4°C for 24 h. The antigen-antibody complexes were
precipitated by adding 100 |il of donkey anti-rabbit serum (SAPU) diluted 1 in 32 with
assay buffer and 100 (J.1 of normal rabbit serum diluted 1:400 with assay buffer. The
incubation was continued for a further 24 h at 4°C and 1ml of 0.9% saline was added.
The assay tubes were centrifuged at 1,600g for 25 min at 4°C. The supernatant was
decanted and the precipitate counted in a gamma counter. The data were analysed using
the 'Assay Zap Universal Assay Calculator'. The sensitivity of the assay was 0.8
ng/ml and the coefficients of variation of intra-assay and inter-assay were 7% and 9%
respectively.
4) Inhibin assay
Inhibin immunoactivity in placental extracts was measured using the heterologous RIA
with the Monash antibody as described in Section 2.2 in Chapter 2.
5) Human chorionic gonadotropin assay
hCG was assayed using the hCG MAIA clone Monopack purchased from Serono. The
assay was performed as described in Section 3.2 in Chapter 3.
Cell counting
Pituitary cells were removed from the culture wells by trypsinization (modified method
from Sigma Chemical Co. Catalogue). Briefly, after the conditioned medium was
collected, the cells were washed with 400 (il of DPBS" and then incubated with 200 fil
of 0.2% trypsin in DPBS- containing 0.08% EDTA for 20 min at 37°C. The trypsin
activity was neutralized by adding 600 |il of supplemented DMEM before the solution
was transferred into a sterile conical tube. The cells were collected by spinning at 500g
for 10 min at 20°C and then resuspended in 400 |il of supplemented DMEM. Cells
were counted using a haemocytometer.
Statistical analysis
For any comparison the data were subjected to one-way analysis of variance and
subsequently examined using Newman-Keul's test (ANOVA; Clear Lake Research,
Houston, Texas, U.S.A.).
4.3 Results
4.3.1 Characterization of sheep pituitary cells inhibin bioassay
Mitogenic activity in term placental extracts was observed in sheep pituitary cell
cultures during the inhibin bioassay. As shown in Figure 4.1, after the incubation with
different doses of term placental extract for 48 h the number of pituitary cells increased
from 2.00 ± 0.22 x 105 (control; supplemented DMEM) to 3.01 ± 0.03 x 105 (0.1 p.1
placental extract) ; p<0.01. The cell number did not significantly change at the doses
between 0.1 to 1 jj.1 of placental extract. At the higher doses of placental extract the
number of cells increased from 2.00 ± 0.22 x 105 (control) to 3.84 ± 0.12 x 105 (lp.1
placental extract); p<0.01 and 6.58 ± 0.19 x 105 (50 |il placental extract); p<0.01.
Conditioned medium was assayed for ovine FSH, LH and PRL. The release of ovine
LH and PRL was not different in the presence or absence (control) of different doses
of placental extract as shown in Figures 4.2 and 4.3. In Figure 4.4, on the contrary,
FSH release was suppressed in a dose-dependent manner by placental extract (0.20-
1.56 p.1) despite an unchanged cell number as shown in Figure 4.1.
4.3.2 Inhibin bioactivity in placental extracts from different stages of
pregnancy
FSH dose-response curves of placental extracts from 7 weeks, 16 weeks and term
pregnancy are parallel to the inhibin reference standard (oRTF) as shown in Figure
4.5. The bioactivity of inhibin in charcoal-stripped placental extracts from various
stages of pregnancy was measured. The level remained unchanged from 7 weeks
(73.68 ± 15.90 U/g, n=5) through 16 weeks (87.67 ± 5.96 U/g, n=5 ) until term
(91.7 ± 7.58 U/g, n=5) as shown in Figure 4.6.
4.3.3 Immunoneutralization of placental inhibin using Y29 and MAb(3A
antibodies and the effect of activin on FSH secretion in sheep pituitary
cell cultures
Inhibin activity in placental extracts from different stages of pregnancy and hFF
generated FSH inhibition-curves in a dose-related manner, as shown in Figure 4.7a.
The dose of each inhibin preparation (6.25 (il of hFF and 3.125 (il of placental extracts
from different stages of pregnancy) producing suppression of FSH release at around
50% of control was chosen for in vitro immunoneutralization by the Y29 antibody. In
Figure 4.7b an increase in volume of the antibody from 12.5 p.1 could neutralize the
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Figure 4.1 Effect of term placental extract on the proliferation of sheep pituitary cell
cultures for 48h, after an initial 48 h preincubation with no treatment. Values represent




























Figure 4.2 Effect of term placental extract on the release of LH from sheep pituitary
cell cultures for 48h, after an initial 48 h preincubation with no treatment. Values
represent the mean ± SEM of quadruplicate wells/dose.
Placental extract (pi)
Figure 4.3 Effect of term placental extract on the release of prolactin from sheep
pituitary cell cultures for 48h, after an initial 48 h preincubation with no treatment.
Values represent the mean ± SEM of quadruplicate wells/dose.
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Figure 4.4 Effect of term placental extract on the release of FSH from pituitary cell
cultured for 48h, after an initial 48 h preincubation with no treatments. Values represent














I I II iff]
1000
Figure 4.5 The FSH dose-response curves of oRTF [inhibin reference standard] ( O )
and placental extracts at 7 weeks (A ), 16 weeks (□) and term ( ■ ) demonstrating

















Figure 4.6 Bioactive inhibin levels in placental extracts from 7 weeks, 16 weeks and
term pregnancy.Values represent the mean ± SEM.
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inhibin bioactivity resulting in an increase in oFSH release. The inhibin activity in each
preparation was completely neutralized when the volume of the antibody was increased
to 100 pi. Non-immune sheep serum had no neutralization effect in control wells.
For mid-term and term placental extracts a stimulatory effect on FSH release was
observed after neutralization by the antibody as shown in Figure 4.8a. This stimulatory
effect in mid-term and term placental extracts could increase FSH release to 165.35 ±
31.57% and 144.72 ± 25.55% respectively of the control level. A stimulatory effect
of recombinant activin A was also observed in sheep pituitary cell cultures. The pattern
of stimulation was dose-dependent; FSH release was increased up to 140 ± 5.45% of
control at 1 |ig of activin/well (Figure 4.8b).
Figure 4.9 demonstrates immunoneutralization of hFF and placental extracts from 7
weeks, 16 weeks and term pregnancy by the MAb(3A antibody. The suppression of
FSH release (% of control) by the inhibin in each preparation (6.25 pi of hFF and
3.125 pi of placental extracts from different stages of pregnancy) did not change
statistically, even at the highest concentration (10 pg of immunoglobulin).
4.3.4 Inhibin immunoactivity in placental extracts from different stages
of pregnancy
The levels of immunoactive inhibin in placental extracts from 7 weeks, 16 weeks and
term are shown in Figure 4.10. The activity decreased from 84.90 ± 7.15 U/g at 7
weeks through 19.87 ± 4.49 U/g at 16 weeks (p<0.01) to 5.94 ± 0.55 U/g at term
(p<0.01).
4.3.5 hCG immunoactivity in placental extracts from different stages of
pregnancy
The levels of immunoactive hCG in placental extracts from 7 weeks, 16 weeks and
term are shown in Figure 4.11. The hormone content decreased from 5559.24 ±
1887.88 IU/g at 7 weeks through 181.12 ± 57.28 U/g at 16 weeks (p<0.01) to 15.68
± 3.99 U/g at term (p<0.01).
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Figure 4.8 (a) The reverse effect of inhibin bioactivity, by immunoneutralization using
Y29 antibody, in hFF ( • ) and placental extracts from 7 weeks (A ), 16 weeks (□ )
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Figure 4.8 (b) Effect of recombinant activin A on FSH release from sheep pituitary cell
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Figure 4.9 Effect ofMAb^A antibody on the suppressing activity of bioactive inhibin
in hFF ( O ) and placental extracts from 7 weeks ( ■ ), 16 weeks ( ▲ ) and term
pregnancy ( □ ) on the FSH secretion from sheep pituitary cell cultures.
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Figure 4.10 Immunoactive inhibin levels in placental extracts from 7 weeks, 16 weeks
and term pregnancy. Values represent the mean ± SEM.
7 6
Weeks of pregnancy
Figure 4.11 Immunoactive hCG levels in placental extracts from 7 weeks, 16 weeks
and term pregnancy. Values represent the mean ± SEM.
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4.4 Discussion
The bioactivity of inhibin in placental extracts from different stages of pregnancy was
examined using the sheep pituitary cell culture bioassay. Since there is direct and
indirect evidence for the existence of different growth factors in the human placenta
(Hill et al, 1987), the mitogenic activity of human placental extracts was anticipated
during the bioassay. This anticipation was confirmed by the finding from our
preliminary study that 7 weeks, 16 weeks and term placental extracts caused sheep
pituitary cell multiplication in vitro and the mitogenic activity was highest in term
placental extracts. The present data show that term placental extract possessed high
mitogenic activity which caused cell numbers to increase several fold (Figure 4.1). The
production of hormones and other specialized functions are influenced by the degree of
cellular differentiation. In contrast, the results from this chapter demonstrate that the
release of ovine LH and PRL during pituitary cell multiplication caused by placental
mitogenic factors was not altered (Figures 4.2 and 4.3). The suppression of ovine
FSH release by bioactive inhibin in placental extracts has the same dose-dependent
pattern as other inhibin preparations (Figure 4.5). This finding is similar to that
reported by Tsonis et al (1988b) who found that pituitary cell division and
multiplication had no effect on the bioassay of inhibin in conditioned medium from
human granulosa cells using sheep pituitary cell cultures. The mitogenic activity of
placental extracts does not interfere with the measurement of bioactive inhibin in
placental extracts. A possible explanation of the unchanged hormone production could
be that most pituitary cells are not gonadotrophs, some of them are lactotrophs or
fibroblasts and the cell type that increases in number has not been identified whether
they are gonadotrophs or not. The identity and physiological mechanism of this
placental mitogenic factor needs further investigation. However, the placental
mitogenic factor could be a combination of different growth factors which are abundant
in placentae. These unknown growth factors are more likely to be proteins, due to the
removal of steroids from placental extracts by charcoal-stripping prior to the assay.
The FSH-suppressing activity in placental extracts appears to be mostly due to inhibin
because of the complete abolition of the inhibitory effect after immunoneutralization.
In addition, the bioactivity of inhibin which can be immunoneutralized in vitro by Y29
antibody (anti 1-23 a-subunit) but not by MAbpA antibody (anti P-subunit) showed
that the blocking of the N-terminal fragment of the a-subunit has an effect on the
function of the bioactive site of the inhibin molecule. This is supported by previous
studies which have shown that anti-pl-26 a-inhibin can immunoneutralize sheep
ovarian inhibin bioactivity in vitro and in vivo (Mann et al, 1989); anti-human 1-32 a-
inhibin can immunoneutralize inhibin bioactivity in vivo (Mersol-Barg et al, 1990) and
anti-human 6-30 a inhibin can immunoneutralize human ovarian inhibin bioactivity in
rat pituitary cell cultures (Sinosich et al, 1991).
The stimulatory effect of mid-term and term placental extracts on FSH secretion
(Figure 4.8a) which is similar to the stimulatory effect of activin on FSH secretion
(Figure 4.8b), suggests the production of activin by the human placenta in later stages
of pregnancy. Furthermore, the bioactivity of inhibin at later stages of pregnancy might
be the combined effects of inhibin and activin.
Inhibin bioactivity in placental extracts does not change throughout pregnancy (Figure
4.6) whereas inhibin immunoactivity decreases towards term (Figure 4.10). Taken
together, the indirect evidence of the presence of an activin-like effect in placental
extracts and the fact that the heterologous radioimmunoassay using the Monash
antibody has been shown to measure various immunoactive forms of inhibin, some of
which, such as pro-aC, have no bioactivity, suggest that at various stages of
pregnancy the placenta produces different amounts and molecular species of inhibin or
activin.
hCG immunoactivity in placental extracts decreases towards term (Figure 4.11) in the
same manner as inhibin immunoactivity. This suggests a relationship between hCG
and inhibin which are both synthesized by syncytiotrophoblast cells. This is supported
by the paracrine function of inhibin in the regulation of hCG secretion in placental cell
cultures (Petraglia et al, 1987a) and the suppressive effect of inhibin on hCG secretion
in placental explant cultures (Mersol-Barg et al, 1990).
CHAPTER 5
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Inhibin immunoactivity and bioactivity in
amniotic fluid during pregnancy
5.1 Introduction
Inhibin bioactivity and immunoactivity have been demonstrated in human placental
extracts (McLachlan et al, 1986b) and these activities change throughout pregnancy
(Tovanabutra et al, 1990). Decidual tissue is likely to be another source of inhibin in
pregnancy (Petraglia et al, 1990). Fetal cord blood contains immunoreactive inhibin
(McLachlan et al, 1986b), but there is no difference between the levels of inhibin in
umbilical artery and umbilical vein and the concentration is only half of the maternal
blood value which suggests that the fetus is not contributing to the peripheral
immunoreactive inhibin during pregnancy (Kettel et al, 1991; Tabei et al, 1991).
Activin A has been detected in amniotic fluid of pregnant women (Abe et al, 1989) and
inhibin a-immunoactivity is present in amniotic fluid from 16-20 weeks gestation
(Sinosich et al, 1991) which suggests that the feto-placental unit is a source of inhibin.
The aims of this study were firstly to examine the immunoactivity of inhibin in
amniotic fluid at various stages of pregnancy using three antibodies which recognize
different parts of the inhibin molecule, secondly to examine the in vitro bioactivity of
amniotic fluid inhibin and lastly to verify dimeric inhibin bioactivity by
immunoneutralization using an antibody raised against the human inhibin a-subunit
5.2 Materials & Methods
Amniotic fluids
Amniotic fluids were collected at various stages of gestation: at 7 weeks from
pregnancy terminations, 16-17 weeks from amniocentesis and at term from delivery.
The amniotic fluid was centrifuged at lOOOg, for 15 min at 4°C to remove blood and
amniotic fluid cells and was kept at -20°C until assayed.
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Radioimmunoassays
Inhibin a-subunit radioimmunoassay using the Y29 antibody, inhibin (3A-subunit
radioimmunoassay using the R187 antibody and the heterologous inhibin
radioimmuno-assay using the Monash antibody were performed as described in
Section 2.2 of Chapter 2.
Inhibin in vitro bioassav
A sensitive in vitro bioassay using sheep pituitary cells was carried out as described by
Tsonis et al, 1986 ( see Section 4.2 of Chapter 4).
Sample preparation
Amniotic fluids from the same stages of pregnancy were pooled and concentrated to
one quarter of their original volume using polyethyleneglycol 6000 (BDH). The
concentrated amniotic fluid was charcoal-stripped (lOmg/ml amniotic fluid) to remove
steroid residues (McLachlan et al, 1986b) and filtered using Millex GS filters (0.22
pm, Waters) prior to the assay.
Assay procedure
As previously described for placental extracts, five doses of amniotic fluid were
assayed in quadruplicate ranging from 25-300 pi for 7 weeks or term amniotic fluids
and 12.5-100 pi for 16 weeks concentrated amniotic fluid. The inhibin reference
standard used was a recombinant human inhibin A with an arbitrary potency of 51
IU/ng (NEH rhINH-R-90/1). A charcoal-Sep-Pak-treated ovine follicular fluid (CGT-
1083-oFF) was used as the quality control.
Neutralization of inhibin bioactivity
The in vitro neutralization of amniotic fluid was performed using the same basic
procedure as outlined in Section 2.2 of Chapter 4. Different doses of charcoal-stripped
amniotic fluid from 16 weeks and term were assayed to generate FSH-inhibition
curves. Doses producing inhibition ranging from 40-60% were chosen to study the in
vitro neutralization effect of the Y29 polyclonal antibody. The test materials at the
selected doses (400 pi of 16 week amniotic fluid and 133 pi of term amniotic fluid)
were incubated with different concentrations of antibody at room temperature for 2 h
before being added to the preincubated ovine pituitary cell cultures in triplicate. After
making the final incubation volume up to 600 pi with supplemented DMEM, the
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culture plates were incubated for a further 48 h and the spent media collected and
assayed for FSH.
5.3 Results
Figure 5.1 demonstrates parallelism between the dose-response lines of partially-
purified human follicular fluid inhibin standard and amniotic fluids from 7 weeks and
16 weeks of gestation, and delivery, in the heterologous RIA using the Monash
antibody against 31 kDa bovine inhibin. The parallelism between the dose-response
curves of synthetic human inhibin a-(l-23)-NH2 and amniotic fluids from 7 weeks,
16 weeks and delivery in the RIA using the Y29 antibody is shown in Figure 5.2.
Figure 5.3 also reveals that the dilution curves of synthetic human inhibin (3-(97-l 12)-
NH2 and amniotic fluids from 7 weeks, 16 weeks and delivery are parallel in the RIA
using the R187 antibody.
The immunoactivity of inhibin in amniotic fluid was measured by the Monash, R187
and Y29 antibodies. In Figure 5.4, the immunoactivity with the Monash antibody
increases towards pregnancy from 135.83 ± 25.10 mU/100 pi, n=9, at 6 weeks to
172.49 ± 20.26 mU/100 pi, n=15, at 16 weeks and 221.49 ± 23.21 mU/100 pi,
n=ll, at term (p<0.05). The immunoactivity with the R187 antibody decreases
throughout pregnancy from 450.39 ± 84.36 pg/100 pi, n=9, at 6 weeks to 369.02 ±
30.22 pg/100 pi, n=15, at 16 weeks (p<0.01) and 136.84 ± 10.85 pg/100 pi, n=ll,
at term (p<0.01).The immunoactivity with the Y29 antibody also decreases throughout
pregnancy from 115.82 ± 17.41 pg/100 pi, n=9, at 6 weeks to 88.49 ± 9.98 pg/100
pi p, n=15, at 16 weeks (p<0.01) and 27.52 ± 2.36 pg/100 pi, n=ll, at term
(p<0.01). Values are means ± SEM.
Bioactivity of pooled amniotic fluids (n=5) from 7 weeks, 16 weeks and delivery was
measured using the in vitro sheep pituitary cell bioassay. The results in Figure 5.5
demonstrate parallelism for the dilution curves of amniotic fluids and human
recombinant inhibin A. The bioactivity of inhibin in 7 weeks and term amniotic fluid
are 3.86 IU/100 pi and 3.22 IU/100 pi which are higher than in mid-term (0.81
IU/100 pi).
The data from immunoneutralization of bioactive amniotic inhibin are shown in Figure
5.6. The suppressing activity of bioactive inhibin in amniotic fluids from 16 weeks
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Figure 5.1 Dose-response curves of partially-purified human follicular fluid inhibin
standard ( O ) and amniotic fluids from 7 weeks ( • ), 16 weeks ( ■ ) and delivery
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Figure 5.2 Dose-response curves of synthetic human inhibin a-(l-23)-NH2 (O) and
amniotic fluids from 7 weeks ( • ), 16 weeks ( ■ ) and delivery (A) demonstrating
parallelism in the RIA using the Y29 antibody.
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Figure 5.3 Dose-response curves of synthetic human inhibin |3-(97-112)-NH2 ( 0 )
and amniotic fluids from 7 weeks ( • ), 16 weeks ( ■ ) and delivery ( A )








Figure 5.4 Immunoactivity of inhibin in amniotic fluids during pregnancy measured
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Figure 5.5 Bioactivity of amniotic fluids from 7 weeks ( D ), 16 weeks ( ■ ) and
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pregnancy and term pregnancy on FSH secretion by sheep pituitary cells in vitro was
reversed by immunoneutralization using the Y29 antibody.
5.4 Discussion
These results demonstrate changes in the immunoactivity of inhibin and its related
peptides in amniotic fluid throughout pregnancy. The parallelism of the standard
curves and dose-response curves of amniotic fluids from different stages of pregnancy
in each RIA show the specificity of the antibodies and the assays.
The profile of inhibin immunoactivity in amniotic fluid measured by RLAs using
various antibodies are different. The RIAs with the Y29 and R187 antibodies reveal a
decrease in inhibin concentration towards term which is entirely different from the
results obtained from the RIA using the Monash antibody which shows that
immunoactive inhibin increases towards term.
The level of inhibin bioactivity is different from its immunoactivity level. The lowest
bioactivity was observed in mid-pregnancy amniotic fluid whereas similar higher levels
were measured in 7 weeks and term amniotic fluids.
At present, it is rather difficult to explain the reasons for the different profiles of
bioactivity and immunoactivity of inhibin in amniotic fluids because of its unknown
molecular species. Although the antibodies used in the RIAs seem to be specific as
shown in the previous section, they all recognize different parts of the inhibin
molecule. The Monash and Y29 antibodies recognize the free a-subunit or its protein
precursor (pro-aC) as well as dimeric inhibin (Robertson et al, 1989), but the Monash
antibody recognizes human follicular fluid inhibin, which is mostly dimeric inhibin
(Robertson et al, 1990b), better than the Y29 antibody (see Chapter 2). Thus, it is
possible that there are larger amounts of the free a-subunit or pro-aC secreted into
amniotic fluid in early pregnancy in comparison to the dimeric inhibin, and when the
gestation age increases the dimeric inhibin which is poorly recognized by Y29 is
secreted in larger quantities. This hypothesis is in agreement with the results from
Chapter 4, suggesting that in the early stages of pregnancy placental tissue produces
more free a-subunit or its precursor than in the later stages of pregnancy.
The bioactivity of inhibin pattern is again different from the immunoactivity measured
by the Monash antibody. This might due to the presence of non-bioactive inhibin
species as well as bioactive inhibin are produced during pregnancy as mentioned
earlier. However, the success in immunoneutralization of inhibin bioactivity using Y29
antibody suggests the presence of real dimeric inhibin in amniotic fluid among other
molecular species.
The origin of inhibin in amniotic fluid has not been clearly identified. The human
placenta has been demonstrated as a potential source of inhibin (McLachlan et al,
1986b; 1987b; Tovanabutra et al, 1990) and also decidual tissue (Petraglia et al, 1990).
Maternal blood and fetal cord blood contain immunoactive inhibin (McLachlan et al,
1986b). These are likely to be possible sources of inhibin in amniotic fluid.
The presence of inhibin activity in amniotic fluid at the very beginning of pregnancy
suggests that the fetus may play a role in secreting inhibin at an early stage of life.
However, the level of inhibin in umbilical vein and artery are similar and lower than in
maternal serum (Kettel et al, 1991; Tabei et al, 1991) suggesting that the fetus is not
contributing to the peripheral immunoactive inhibin at least during late pregnancy.
Furthermore, there is indirect evidence to support the possible secretion of inhibin by
the fetus. The most abundant cells in amniotic fluid are the so-called "typical amniotic
cells". These cells arise from fetal membranes and retain some of the properties of the
trophoblast such as the synthesis of hCG (Priest et al 1979; 1980). Whether these cells
also produce inhibin requires further investigation.
In conclusion, the findings in this chapter provide background information which will
be beneficial in the future for further investigations of the role of inhibin in pregnancy.
CHAPTER 6
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Immunolocalization of inhibin a- and (3A-
subunits in human placental tissue at various
stages of pregnancy
6.1 Introduction
The presence of inhibin immunoactivity and bioactivity in placenta during pregnancy
has been clearly demonstrated in previous chapters of this thesis and by McLachlan and
colleagues (McLachlan et al, 1986b). In term placenta, inhibin a-subunit immuno¬
activity has been localized in cytotrophoblast cells and decidual cells°which also contain
inhibin PA- and pB- subunits (Petraglia et al, 1990). These findings suggest that
during pregnancy, both trophoblast and decidual cells are sources of inhibin or inhibin-
related proteins. As described in previous chapters and elsewhere, the concentration of
immunoactive inhibin in the human placenta decreases throughout gestation while the
level of bioactive inhibin does not change (Tovanabutra et al, 1990).
At present the available radioimmunoassay systems not only measure the intact inhibin
molecule but may also measure the free inhibin a-subunit or pro-aC which have no
FSH-suppressing bioactivity in vitro. Furthermore, the presence of inhibin (3-subunit
immunoactivity in human placental tissues at various stages of pregnancy has not been
clearly demonstrated.
Therefore, the following studies were carried out firstly to obtain methods for inhibin
a- and PA-subunit immunolocalization in placenta by modifying the established method
for immunolocalization of the inhibin a-subunit in ovarian tissues and the Western
immunoblotting method for inhibin (3-subunit. Secondly, we hoped to use these
methods to investigate the presence and cellular localization of the inhibin PA-subunit in
human placenta during pregnancy and to relate this to the localization of the inhibin a-
subunit. Moreover, we also wanted to determine whether there are changes in the
intensity of inhibin a- and pA-subunit staining in placental tissue which might suggest
a differential secretion of these subunits and thus production of intact inhibin, free a-
subunit or activin.
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6.2 Modification of the inhibin subunit immunostaining
methods
6.2.1 Inhibin oc-subunit staining
The inhibin a-subunit staining method was established and validated by Smith and co¬
workers (Smith et al, 1991) to localize the cellular inhibin a-subunit proteins in primate
ovaries. This method is an immunoperoxidase technique which uses the highly
sensitive avidin-biotin complex as the detection system. The principle of this method is
shown in Figure 6.1. Following this method, placental tissue from 7 weeks, 16 weeks
and term pregnancy were fixed in 0.1 M sodium cacodylate buffer, pH 7.4 containing
2.5% glutaraldehyde and 4% paraformaldehyde. After conventionally processing to
paraffin, the tissues were cut and mounted on to glass slides and then the sections were
treated with 3% (v/v) hydrogen peroxide in methanol for 30 min to remove endogenous
peroxidase activity. The sections were washed in 0.05 M Tris-HCl buffer (TBS), pH
7.6 containing 0.9% NaCl and 0.5% (v/v) Triton-X-100 for 10 min, distilled water for
5 min and TBS for 5 min. The sections were incubated with blocking solution
containing normal rabbit serum diluted 1:5 in TBS for 30 min to reduce non-specific
background staining. The primary antiserum (Y33), a sheep polyclonal antibody raised
against synthetic human inhibin a-(l-23)-NH2, was diluted 1:2000 in TBS and applied
to the sections and incubated for 30 min. The sections were washed twice in TBS for 5
min and were then incubated for 30 min with the secondary antibody, biotinylated
rabbit anti-sheep immunoglobulin, diluted 1:500 in TBS. After two washes in TBS for
5 min each, peroxidase-conjugated avidin-biotin complex was applied to the tissue
sections and incubated for 30 min. The sections were then washed twice in TBS for 5
min. The sections were visualized using 0.5mg 3,3'-diaminobenzidine
tetrahydrochloride/ml in TBS containing 0.1ml 3% hydrogen peroxide which was
applied to the sections for 3-5 min or until the colour was developed. The sections were
then washed in TBS and counterstained in haematoxylin (BDH), dehydrated and
mounted using Histomount (National Diagnostics) for DAB treated sections.
The results showed considerably high background staining and very weak intensity
staining in trophoblast cells of placental tissues from different stages of pregnancy. The
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Figure 6.1 Avidin-biotin complex (ABC) method
1. The primary antibody dilution
Apart from the concentration of protein or antigen content in tissue, unsuitable dilution
of the primary antibody can cause low intensity staining. To improve the intensity of
staining, the antibody was assayed at dilutions of 1:100, 1:250, 1:500 and 1:1000. The
results showed that the optimum dilution of antibody was 1:500
which gave a compromise between the intensity of specific staining and acceptable
background staining.
2. The fixative
For the optimum fixation of tissues, the ideal fixative should produce good cellular
morphology without destroying the immunoactivity of the antigen. The most popular
fixative for immunocytochemistry is paraformaldehyde which fixes the tissues by
reacting with basic amino acids e.g. lysine and arginine to form cross-linking bridges.
This means that there is relatively low permeability to the antibody molecules and their
structures are not altered. Glutaraldehyde is another fixative that works in the same way
as paraformaldehyde but it reacts more strongly and gives more cross-linkages. The
fixative used for the human ovary contains both paraformaldehyde and glutaraldehyde.
However, in a loose compact tissue like placenta this fixative may give rise to too many
cross-linkages, thus reducing the access of the primary antibody to the antigen
molecules. Inhibin a-subunit immunolocalization was previously demonstrated in term
placenta using ice-cold 4% paraformaldehyde in phosphate-buffered saline (Petraglia et
al, 1987a; Merchenthaler et al, 1987). Under these circumstances, a fixative containing
4% paraformaldehyde in PBS pH 7.4 was used to fix placental tissues and proteolytic
digestion using trypsin was introduced into the staining procedure. The final protocol
for inhibin a-subunit staining of placental tissue is as shown in Section 6.3.1.3.
6.2.2 Inhibin PA-subunit staining
In combination with the system used for Western immunoblotting analysis of inhibin p-
subunit as described in Chapter 2 and the method for localizing the inhibin a-subunit
mentioned above, an inhibin pA-subunit staining method was established. The
peroxidase-anti-peroxidase complex method was employed as the detection system.
The principle of the method is shown in Figure 6.2. To obtain the optimum intensity of
staining the antibody was assayed at dilutions of 1:100, 1:200, 1:500, 1:750 and
1:1000. The dilutions which gave strong staining were 1:100 and 1:200, so a dilution
of 1:200 was chosen. The final protocol is shown in Section 6.3.1.3.
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Figure 6.2 Peroxidase-anti-peroxidase (PAP) method .
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6.3 Immunolocalization of inhibin a- and PA-subunits in
human placental tissue at various stages of pregnancy
The immunocytochemical localization methods obtained above were used to investigate
the presence and cellular localization of inhibin subunit proteins in human placental
tissue.
6.3.1 Materials and Methods
6.3.1.1 Tissue preparation.
Human placentae were obtained from pregnancy termination at 7 weeks, 16 weeks and
at term. Approval of the Local Ethical Committee (Division of Reproductive Medicine,
Lothian Health Board) was obtained. The tissues were processed within 30 min of
removal. The placentae were cut across the basal plate into slices of approximately 1 cm
thickness, and were washed in ice-cold phosphate-buffered saline (PBS, see Appendix
1), pH 7.4 to remove blood. The tissues were fixed in freshly prepared ice-cold 4%
paraformaldehyde in PBS, pH 7.4 (see Appendix 1) at 4°C overnight and then
dehydrated and embedded in paraffin. Sections of 4 Jim thickness were cut, mounted
on glass slides and dried at 37°C overnight.
6.3.1.2 Antibodies
Antibody to the inhibin a-subunit
A polyclonal antibody to synthetic human inhibin a-(l-23)-NH2 (Peninsula
Laboratories, San Carlos, CA) was raised in sheep. The synthetic peptide was
conjugated to porcine thyroglobulin by the carbodi-imide method (McNeilly et al,
1989). The parallelism between the dose-response curves of a term placental extract,
human follicular fluid and the standard curve using human inhibin a-(l-23)-NH2 in the
RIA system is shown in Figure 6.3.
Radioimmunoassay of inhibin in placental extracts from various stages of pregnancy
using the Y33 antibody, raised against the amino acids 1-23 N-terminal sequence of
synthetic human a-inhibin, and iodinated appropriate peptide as the tracer was
performed to check the specific activity of the antibody to inhibin in placental extracts
from 7 weeks, 16 weeks and term. To obtain a rapid assay, the RIA system using Y29
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Figure 6.3 Logit-log dose-respose curves of human 1-23 a-inhibin standard
( ■ ), term placental extract ( O ) and human follicular fluid (A ) demonstrating
parallelism.
antibody as described earlier in Chapter 2 was modified using primary antibody
conjugated to fluorescein thiocyanate (FITC). The antigen-antibody-FITC complexes
were separated from free antigen by a second antibody to FITC conjugated to magnetic
particles. The antigen-antibody-FITC-anti-FITC magnetic particle complexes were
sedimented in a magnetic field. The assay procedure is as follows:
Assay procedure:
The following reagents were added in sequence to the assay tubes:
100 p.1 standard (human inhibin 1-23 a-subunit standards, range 31.25-7,800
pg/100 |il) or diluted sample (placental extracts or human follicular fluid).
100 |il of tracer (125 I-human 1-23 a-inhibin peptide) containing approximately 15,000
cpm.
100 |il of diluted antibody (1:6000 in assay buffer) conjugated to fluorescein
isothiocyanate (FITC), supplied by Serono Laboratories, Woking, Surrey.
Incubation at 37°C for 1 h.
200 |_il of anti-FITC magnetic particles (Serono).
Incubation at room temperature for 5 min.
The assay tubes were placed on a magnetic tray for 2 min and the supernantant was
discarded by tipping.
The assay tubes including the maximum binding (Bo) and non-specific binding (NSB)
tubes were counted and the results were calculated in the same way as the other
radioimunoassays described in Chapter 2.
Antibody to inhibin pA-subunit
A monoclonal antibody against amino acids 84-112 of the human synthetic pA-inhibin
subunit was raised in mouse. The peptide was coupled to tuberculin via the -SH group
using protocols obtained in a kit available from Cambridge Research Biochemicals,
Button End Industrial Estate, Harston, Cambridge, U.K (Groome & Lawrence, 1991).
This antibody has been shown to localize the inhibin P-subunit in human corpus luteum
(Smith et al, 1992)
6.3.1.3 Immunocytochemistry
Paraffin sections were deparaffinised in xylene and rehydrated in graded ethanol. The
tissue sections were incubated with 3% H2O2 (BDH) in methanol (BDH) for 30 min to
block any endogenous peroxidase activity. The sections were washed with two changes
of 0.05 M Tris-HCl buffer, pH 7.6 (TBS). The sections were incubated for 15 min at
37°C in 0.1% trypsin (BDH) and 0.1% CaCl2 (BDH) in water and then washed in 0.5
% Triton X-100 (BDH) in TBS for 10 minutes. Following two 5 min washes in TBS,
the sections were incubated for 30 min with the blocking solution [normal rabbit serum
(Dako Ltd.), diluted 1:5 in TBS containing 5% BSA] to minimize non-specific
background staining.
Inhibin a-subunit staining
The sections were incubated with the primary antibody diluted 1:500 in blocking
solution for 30 min at room temperature. After washing with TBS twice (5 min each),
the sections were incubated for 30 min with second antibody, biotinylated rabbit anti-
sheep immunoglobulin (Vector Laboratories, Bretton, Peterborough) diluted 1:500 in
blocking solution. The sections were washed twice in TBS for 5 min and then
incubated with the avidin-biotin peroxidase complex (DAKOPATTS, Dako Ltd.) for 30
min. The sections were washed again with TBS and the colour reaction developed by
incubating the sections with 0.05M Tris buffer (pH 7.6) containing 0.05% 3, 3'
diaminobenzidine tetrahydrochloride (Sigma) and 0.01% H2O2 (BDH) for 3-5 min.
The sections were washed with water and then counterstained with haematoxylin
(BDH). Finally, the sections were mounted using Histomount (National Diagnostics)
and microscopically examined. Specific binding was evaluated by replacing the primary
antibody with 1) normal sheep serum (Vector Laboratories) at the same dilution of
primary antibody and 2) the appropriate synthetic peptide-preadsorbed antibody.
Inhibin ft-subunit staining
The sections were incubated with the primary antibody diluted 1:200 in blocking
solution at 4°C overnight. After washing twice with TBS (5 min each), the sections
were incubated with rabbit anti-mouse immunoglobulin (Dako Ltd.) diluted 1:50 in
blocking solution for 30 min. The sections were again washed with TBS twice and
incubated with peroxidase-monoclonal mouse-peroxidase complexes (Dako Ltd.)
diluted 1:100 in blocking solution for 30 min. The sections were again washed twice
with TBS and the colour developed as described for a-subunit staining. To check the
specificity of binding, the preadsorbed (3A-subunit antibody with 200 |ig/ml of
synthetic human (3A-(82-l 14) was used in place of the primary antibody. The intensity




As shown in Figures 6.4, 6.6 and 6.8, the trophoblast cells of placental tissues from 7
weeks, 16 weeks and term were positively stained for the inhibin a-subunit. The
specificity of the staining was confirmed by the absence of staining with non-immune
serum. In Figures 6.5 and 6.7 both syncytiotrophoblast and cytotrophoblast cells were
clearly demonstrated in 7 weeks and 16 weeks placentae under high magnification. In
term placenta (Figure 6.9) where it is difficult to distinguish between syncytio¬
trophoblast and cytotrophoblast cells, the trophoblast shell showed positive staining.
Figures 6.10, 6.11, 6.12, 6.13, 6.14 and 6.15 show positive staining of inhibin J3A-
subunit in placentae during pregnancy. Inhibin PA-subunit staining in 7 weeks, 16
weeks and term placental tissues was demonstrated within the same cell types as inhibin
a-subunit staining. Specific staining was absent when the primary antibody was
replaced by the antibody preadsorbed with the appropriate peptide.
Some mesenchymal cells in 16 weeks and term placental tissues showed faint positive
staining with both antibodies. Furthermore, in mid- and term placentae the endothelial
cells lying in fetal blood vessels also showed positive staining with the inhibin a- and
PA-subunit antibodies. The pattern of staining is shown in Figure 6.17. The
extravillous cytotrophoblast in term placenta also showed positive staining with inhibin
a- and PA-subunit antibodies. The staining with PA-antibody is shown in Figure 6.16.
Although positive staining for both inhibin a- and PA-subunits was shown in
trophoblast cells throughout pregnancy, positive staining for these two subunits varied
with the stage of pregnancy, as determined by an arbitrary scoring system (Table 6.1).
Maximum staining of inhibin a-antibody was shown in early pregnancy while the
intensity of inhibin PA-subunit staining increased towards term.
6.3.3 Discussion
This study demonstrates the presence of both inhibin a- and PA-subunit
immunoactivity in trophoblast cells throughout pregnancy. Although inhibin a-subunit
immunoactivity has been localized in human cytotrophoblast cells (Petraglia et al,
1987a; Merchenthaler et al, 1987) our results demonstrate that the inhibin a-subunit is
also localized in syncytiotrophoblast cells. Furthermore, our results indicate for the first
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Figure 6.4 Immunolocalization of inhibin a-subunit in 7 weeks placental tissue.
(A) Low-magnification photomicrograph (x20) showing positive staining in
trophoblast cells with primary antibody and (B) no specific staining in control
section with non-immune sheep serum.
Figure6.5High-magnificationphotomicrograph(x40)showingt elocalizati n




Figure 6.6 Immunolocalization of inhibin a-subunit in 16 weeks placental
tissue. (A) Low-magnification photomicrograph (x20) showing positive staining
in trophoblast cells with primary antibody and (B) no specific staining in control
section with non-immune sheep serum.





Figure 6.8 Immunolocalization of inhibin a-subunit in term placental tissue. (A)
Low-magnification photomicrograph (x20) showing positive staining in
trophoblast cells with primary antibody and (B) no specific staining in control
section with non-immune sheep serum.























Figure 6.10 Immunolocalization of inhibin pA-subunit in 7 weeks placental
tissue. (A) Low-magnification photomicrograph (x20) showing positive staining
in trophoblast cells with primary antibody and (B) no specific staining in control
section with the appropriate synthetic peptide-preadsorbed antibody.
Figure6.11High-magnificationphotomicrograph(x40)sh w ngthelocalizati n
ofinhibinPA-subuniti cytotrophoblast(C)andsyncytiotroph blast(S)cellof 7weeksplacentaltissu .
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Figure 6.12 Immunolocalization of inhibin pA-subunit in 16 weeks placental
tissue. (A) Low-magnification photomicrograph (x20) showing positive staining
in trophoblast cells with primary antibody and (B) no specific staining in control
section with the appropriate synthetic peptide-preadsorbed antibody.







Figure 6.14 Immunolocalization of inhibin pA-subunit in term placental tissue.
(A) Low-magnification photomicrograph (x20) showing positive staining in
trophoblast cells with primary antibody and (B) no specific staining in control
section with the appropriate synthetic peptide-preadsorbed antibody.
Figure6.15High-magnificationphotomicrograph(x40)showingtlocalizati n
ofinhibin(iA-su u ittr phoblastcelfermplace taltiss e.
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Figure 6.16 Localization of inhibin pA-subunit in term placenta. (A)
Extravillous cytotrophoblast cells (C) show intense staining with monoclonal
antibody and (B) no staining with the preadsorbed antibody. Magnification x20.
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Figure 6.17 Immunolocalization of inhibin pA-subunit in term placental tissue.
The endothelial cells (E) lying in fetal blood vessels show very specific intense
staining (A) and the staining is not present in the control section (B).
Magnification x20.
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Table 6.1 The relative positive staining intensities of trophoblast cells in placentae
from various stages of pregnancy to inhibin a- and pA- subunit
antibodies.
Inhibin subunit Age of pregnancy
7 weeks 16 weeks Full term
a +++ + ++
PA + ++ +++
The intensities of staining were graded;
+ positive staining, ++ strong staining and +++ very strong
staining.
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time that inhibin PA-subunit is present in both cytotrophoblast and syncytiotrophoblast
cells and this result is supported by the expression of inhibin PA-subunit mRNA in
human term placenta (Davis et al, 1987). The existence of both inhibin a- and |3A-
subunits in the same cell type provides evidence that the placenta produces biologically
active intact inhibin as well as the free a-subunit.
The fact that the intensity of staining to inhibin pA-subunit antibody in trophoblast cells
increases during pregnancy suggests that the trophoblast cells produce more inhibin
PA-subunit as the gestational age increases. Therefore, these differences in the degree
of staining of both inhibin subunits in placental tissues from various stages of
pregnancy suggest that the human placenta may produce different amounts of various
inhibin-like molecules during pregnancy. The strong staining of inhibin a-subunit and
reduced staining of inhibin PA-subunit in early pregnancy may indicate a greater
production of free a-subunit or pro-aC than intact inhibin at this stage. Meanwhile, the
lower staining of inhibin a-subunit and stronger staining of pA-subunit in mid- and
term placentae suggest that activin may be the major inhibin-related protein in the later
stages of pregnancy. This hypothesis is supported by an earlier finding that inhibin
bioactivity in placental extracts does not change during pregnancy while both inhibin
and free a-subunit immunoactivity decrease (Tovanabutra et al, 1990).
At present, the physiological role of inhibin and inhibin-related peptides in pregnancy
remains unclear. Our results suggest the concept of an autocrine/paracrine role for
inhibin and/or activin within the trophoblast. This concept is consistent with current
evidence that inhibin has a paracrine role in the regulation of placental hCG production
by syncytiotrophoblast cells (Petraglia et al, 1987a). Furthermore, activin enhances the
stimulatory action of GnRH on hCG secretion in human placental cell cultures and this
effect is reversed by inhibin (Petraglia et al, 1989). The presence of both inhibin
subunits in the endothelial cells of fetal blood vessels in mid-term and term pregnancy
suggests a possible role of inhibin or activin in fetus development. This is supported by
the finding that human recombinant activin A inhibits proliferation of human fetal
adrenal cells in vitro and inhibin a-, pA- and PB-subunits have been localized in
human fetal adrenal glands (Spencer et al, 1990). However, the localization of inhibin
a- and PA-subunits in the same cell type and the change in their proportions throughout
pregnancy further suggests that the relative roles or requirements for inhibin and activin
may change during pregnancy.
CHAPTER 7
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Inhibin a- and (3-subunit mRNA expression in
placental tissue from various stages of pregnancy
7.1 Introduction
Northern blot analysis is a useful approach to demonstrate gene expression in many
experimental models. In the last decade, many studies have employed this technique to
demonstrate inhibin a-, PA- and PB- subunit mRNA expression in various
cells/tissues from different species. In the human, inhibin a-subunit cDNA has been
isolated from a placental cDNA library (Mayo et al, 1986). Davis and colleagues
(1987) have shown the expression of inhibin a- and PA- but not PB-subunit mRNAs
in term placenta. However, Reddi and colleagues (1990b) have been able to
demonstrate a- and PB-subunit gene expression in term placenta by Northern blot
analysis. Petraglia et al (1990) have also shown that inhibin a-, PA- and PB-subunit
mRNAs are expressed in decidual tissue throughout pregnancy by Northern blot
analysis. These findings taken together with the results presented in previous chapters
of this thesis suggest that secretion and synthesis of inhibin subunits occurs within the
feto-placental unit
The aims of the current study were firstly to investigate inhibin gene subunit
expression in the human placenta throughout pregnancy and secondly to use Northern
blot analysis to examine the expression of mRNAs for the different inhibin subunits in
placental tissue at various stages of pregnancy.
7.2 Expression of inhibin a- and PB-subunit genes in
placenta during pregnancy
7.2.1 Materials and Methods
Tissue preparation
Human placental tissue was obtained from pregnancy termination at 7 weeks, 16
weeks and term. The tissue was collected in ice-cold PBS and transported at once to
the laboratory. Tissue was cut and weighed, then immediately processed for RNA
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RNA extraction was performed using acid guanidinium thiocyanate-phenol-
chloroform as described by Chomczynski & Sacchi (1987). The preparation was kept
on ice at all times. All glassware, plasticware and reagents were RNAse-free. 1 g of
fresh or frozen tissue was completely homogenized in 10 ml of ice-cold denaturing
solution containing 4 M guanidinium thiocyanate, 25 mM sodium citrate, 0.5%
sarcosyl and 0.1 M 2-mercaptoethanol (see Appendix 2.1) using a Polytron
homogenizer at speed 8. The homogenate was transferred to sterile polypropylene
tubes (Falcon 2059) and 0.1 ml of 2 M sodium acetate, pH 4.0, 10 ml of water-
saturated phenol (see Appendix 2.2) and 0.2 ml of chloroform (Sigma)/isoamyl
alcohol (Sigma) mixed 49:1 were added to each 10 ml of homogenate. The solution
was mixed throughly by inverting after each addition and finally mixed vigorously for
at least 10 sec before being placed on ice for 15 min. The solution was centrifuged at
10,000 g for 20 min at 4°C, then the RNA-containing aqueous phase was transferred
to a new polypropylene tube and 10 ml cold isopropanol (Sigma) added. The solution
was kept at -20°C for lh to precipitate the RNA. The RNA was pelleted by
centrifugation at 10,000 g for 20 min at 4°C. After discarding the supernatant, the
RNA was redissolved in 0.3-1 ml of denaturing solution by vortexing. The RNA
solution was transferred to a 1.5 ml microcentrifuge tube and mixed with an equal
volume of cold isopropanol. The RNA was reprecipitated at -20°C for lh and collected
by centrifugation at 13,000 g for 10 min at 4°C. The supernatant was discarded, and
the RNA washed with 1 ml 75% EtOH (Aristar, BDH) then centrifuged at 13,000 g
for 2 min before careful removal of the supernatant. The RNA pellet was air-dried and
dissolved in 50-100 p.1 of sterile RNase-free water by warming at 65°C for 10 min.
The preparation was stored at -70°C until electrophoresis was performed.
Preparation ofpoly (A)+ RNA
Poly (A)+ RNA was prepared from total RNA by affinity chromatography on an oligo
(dT)-cellulose matrix. 80 p.g oligo (dT) cellulose P-L type 7 (Pharmacia) was
reconstituted in loading buffer (20 mM Tris-HCl, pH 7.5, 1 M NaCl, ImM EDTA and
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0.1% SDS) and packed in a sterile minicolumn (Pharmacia). The column was washed
with 3 bed volumes of 0.1M NaOH with 5mM EDTA and then with at least 10
volumes of sterile water until the pH of the effluent was less than 8.0. The column
was equilibrated with loading buffer. Approximately 1 mg total RNA was dissolved in
500 pi of sterile water by heating at 65°C for 5 min, cooled to room temperature for 2
min and mixed with 500 pi 2x loading buffer. The RNA solution was applied to the
column and washed through with 1 ml of loading buffer and the effluent collected.
The RNA-containing effluent was reheated at 65°C for 5 min and reapplied to the
column. The column was washed with 5 ml of washing buffer containing 10 mM
Tris-HCl pH 7.5, 0.1 M NaCl, ImM EDTA and 0.1% SDS. Poly (A)+ RNA was
eluted from the matrix with 1.5 ml of elution buffer (10 mM Tris-HCl pH 7.5, ImM
EDTA, 0.05 % SDS) and collected as four fractions. The mRNA in each fraction was
mixed with 1/10th volume of 3 M sodium acetate (pH 5.5) and precipitated with 2.5
volumes of cold ethanol at -70°C for 2 h. The RNA was pelleted by centrifugation at
13,000 g for 10 min at 4°C, air-dried, redissolved in 20 pi sterile water and stored at -
70°C until electrophoresis was carried out.
Electrophoresis ofRNA on denaturingformaldehyde!agarose gels
4.4 pi of RNA sample containing 20 pg of total RNA or 5 pg of poly (A)+ RNA (see
Appendix 2.3) was added to 15.6 pi of loading buffer (see Appendices 2.4 and 2.5)
and then denatured at 65°C for 5 min. Prior to loading on to a 1.5% formaldehyde
agarose gel (see Appendices 2.6 and 2.7), 8 pi of dye solution containing 7.5% Ficoll
400 (Sigma), and 0.1% bromophenol blue (Sigma) and 1 pi of lmg/ml ethidium
bromide (Sigma) were added. The gel was electrophoresed at 50 V overnight in
running buffer. The gel was visualized and photographed under a UV-transilluminator
with a ruler to locate the position of ribosomal 28S (5kb) and 18S (2kb) species.
Transfer ofRNA to nitrocellulosefilter
The electrophoresed RNA was transferred immediately from the agarose gel on to a
Hybond-N filter (Amersham) by capillary elution as described by Thomas (1980).
The blotting apparatus was set up as described by Southern (1975). Briefly, the gel
was placed on a Whatman 3MM paper wick (Figure 7.1). A Hybond-N membrane
(Amersham) was prewetted in sterile water and placed over the gel carefully so as to
avoid air bubbles and capillary transfer in 20x SSC (see Appendix 2.8) of RNA onto
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Figure 7.1 Northern blot transfer set up diagram. (1) Placing the Whatman 3MM
paper as a wick over glass plate. (2) Mounting the gel on wick. (3) Schematic diagram
of final layered organization of materials. (Modified from Davis et al, 1986).
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wrapped in plastic film, exposed to UV light (260 nm) for 5 min to permanently fix
the RNA and stored until the hybridization was performed.
Preparation of the radiolabeledprobes
Human inhibin a-cDNA, 1160 bp in length, was provided by Dr. R.G. Forage. The
DNA fragments were released from pBR322 by Pst I and further purified on a
NuSieve gel run in TAE buffer. The purified DNA was retrieved by glass powder
elution using the GENECLEAN II Kit (BIO 101 Inc.). This preparation was done by
Dr. Philippa Saunders and Dr. Kogie Reddi.
Probe labelling
32P-inhibin a-cDNA probe
A labelled cDNA probe was prepared from the DNA obtained above by the "random
primed" DNA labelling method (Feinberg & Vogelstein,1983; 1984) using a random
primed DNA labelling kit (Boehringer Mannheim). Briefly, 9 |il purified cDNA
solution (50 ng) in a 1.5 ml microcentrifuge tube was heated at 95°C for 5 min to
denature the DNA and then immediately placed on ice. The following solutions were
added in order; 2 (il of reaction mixture (containing 100 p.1 of hexanucleotide mixture
in lOx reaction buffer), 1 nl dATP, 1 nl dGTP, 1 ^1 dTTP, 5 |il of 32P-dCTP
(Amersham, 10 |j.Ci/jil) and 1 |ll Klenow polymerase (2 U/fil). The reaction mixture
was incubated at 37°C for 30 min. The synthesized double-stranded DNA probe was
denatured by adding 50 jj.1 of 10 N NaOH and incubating for a further 5 min. The
reaction was stopped by adding 600 p.1 of 1 M Tris-HCl (pH 7.6) and 375 jil of 0.1 N
HC1. The probe was diluted in hybridization buffer and incubated with the membrane
(see below).
32P-inhibin flB-subunit riboprobe
The radioactive probe was synthesized from cDNA by DNA-independent RNA
polymerase transcription using an RNA transcription kit (Stratagene). 8 (il of
linearized plasmid DNA (1 p.g), lp.1 RNAse inhibitor, 1 jil rATP(10 mM), 1 p.1 rCTP
(10 mM), 1 p.1 rGTP (10 mM), 5 |il of 5x transcription buffer, 1 (il 0.75 M
dithiothreitol (DTT, Sigma), 5 |il 32P-UTP (10 (iCi/(ll, Amersham) and 2 fil of T7
RNA polymerase (1 U) were added in order to a 1.5 microcentrifuge tube. The
reaction mixture was incubated at 37°C for lh and made up to 100 (il with 75 [il of TE
buffer (0.1M triethanolamine, pH 8.0). The mixture was extracted twice with an equal
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volume of phenol/chloroform (see Appendices 2.9 and 2.10). The RNA was
precipitated by adding 10 (il of 3 M sodium acetate and 330 |il cold ethanol at -70°C
for 3 h. The RNA was collected by centrifugation at 13,000 g for 15 min at 4°C. The
RNA pellet was washed in 400 (il 75% cold ethanol, air-dried and dissolved in 50 pi
of sterile water. The activity of the probe was determined by counting in a scintillation
counter (1 pi of the probe to 5 ml of scintillation fluid).
Hybridization
Inhibin a-subunit cDNA probe
The membrane was placed in a hybridization bottle (Hybraid) and prehybridized with
50 ml hybridization buffer containing 0.2 M sodium phosphate buffer (pH 7.2), 1 mM
EDTA, 1% BSA (Sigma), 7% SDS and 15% deionised formamide at 65°C overnight
with gentle rotation. The hybridization was performed by adding the prepared probe
into the bottle to obtain a final concentration of 0.5 x 106 cpm/ml and continued at
65°C for a further 16 h. The filter was rinsed three times with prewarmed (65°C)
washing buffer (40 mM sodium phosphate pH 7.2, 1 mM EDTA and 0.1% SDS),
washed thoroughly by rotation (two changes of buffer) at 65°C for 30 min and finally
rinsed in prewarmed buffer. The filter was wrapped in plastic film and exposed to
Kodak Xomat AR-5 film in an X-Ray film holder cassette containing an image
intensification screen (Du Pont Cronex) for 3 days at -70°C. The exposed film was
developed in Kodak developer for 2 min, rinsed in water for 20 sec and then fixed in 1
in 4 diluted Kodak Unifix for 2 min.
Inhibin (3B-subunit riboprobe
The a-inhibin 32P-cDNA probe was stripped from the membrane by washing with
0.2% SDS in sterile water at 90°C for 15 min. The filter was rehybridized with 32P-
(3B-subunit riboprobe as described for the cDNA probe except the hybridization buffer
was replaced with high-stringency formula hybridization buffer (0.2 M sodium
phosphate pH 7.2, 1 mM EDTA, 1% BSA, 7%SDS and 45% deionized formamide)
and the final concentration of the probe was 2x10^ cpm/ml.
The evenness of loading of RNA was assessed by Dr. Kogie Reddi by reprobing the
membrane with a labelled oligonucleotide directed against 18S RNA.
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7.2.2 Results
Expression of inhibin a-subunit m-RNA
Total RNAs from 7 weeks (E), 16 weeks (M) and term (L) placentae had mRNA
which hybridized to an inhibin a-subunit cDNA probe (Figure 7.2). There was some
background hybridization to both ribosomal RNA species. The specificity of the
hybridization signal obtained and the apparent message size was verified by studying
the signal obtained with 5 fig of messenger RNA (A) separated on the same agarose
gel. The results showed expression of inhibin a-subunit mRNA throughout
pregnancy. The message size was approximately 1.6 kb (Figure 7.2 arrowed).
Expression was high in early pregnancy (7 weeks) when compared to other stages of
pregnancy. The signal was especially low in mid-term (16 weeks).
Expression of inhibin pB-subunit m-RNA
Inhibin (3B-subunit riboprobe demonstrated specific hybridization to both total RNA
and mRNA and revealed only one message size of approximately 2.4 kb throughout
pregnancy (Figure 7.3). However, mRNA expression appeared to vary at different
stages of pregnancy. The highest level of expression was observed in the sample
obtained at 16 weeks and slightly less at term while the expression was least in early
(7 weeks) pregnancy.
7.2.3 Discussion
Previous studies have demonstrated expression of inhibin a- and (3-subunit-genes in
human term placenta (Mayo et al, 1986; Davis et al, 1987; Reddi et al, 1990b). The
results obtained from this study confirm the expression of inhibin a- and (3B-subunit
genes in term placenta and the expression of these two inhibin-subunit genes
throughout pregnancy. The message size of these subunits are approximately the same
as previously reported (Davis et al, 1987; Reddi et al, 1990b).
In other species, reproductive tissues such as follicles and corpora lutea have been
shown to demonstrate different expression of inhibin genes during growth and
development (Meunier et al, 1988a; Woodruff et al, 1988; Torney et al, 1989; Schwall
et al, 1990). The results from this study also demonstrate differential expression of
inhibin a-and (3B-subunit mRNAs in human placenta at different stages of pregnancy.
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Figure 7.2 Northern blot analysis of inhibin a-subunit mRNA in placental tissues
from 7 weeks (E), 16 weeks (M) and term (L) pregnancy. 20 pg of total RNA (T) and
5 pg ofmRNA (A) from each stage of pregnancy showed hybridization to the inhibin
a-subunit cDNA probe. The specific hybridization to mRNA demonstrated the
message size of inhibin a-subunit mRNA as 1.6 kb. The signal was highest at 7
weeks and hardly detected at latter stages of pregnancy.
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Figure 7.3 Northern blot analysis of inhibin pB-subunit mRNA in placental tissues
from 7 weeks (E), 16 weeks (M) and term (L) pregnancy. 20 pg of total RNA (T) and
5 pg of mRNA (A) from each stage of pregnancy showed specific hybridization to the
inhibin PB-subunit riboprobe. The specific hybridization to total RNA and mRNA
corresponded to a message size of inhibin PB-subunit mRNA of 2.4 kb. The signal
was highest at mid-term, and least but easily detectable at 7 weeks of pregnancy.
Figure 7.2 illustrates that inhibin a-subunit gene expression is greatest in the early
stage of pregnancy (7 weeks) but very much less in mid-term (16 weeks) and term.
This would suggest that, during pregnancy, the placenta might produce different
amounts of inhibin a-subunit protein throughout gestation. This result agrees with the
finding outlined in Chapter 4; that inhibin immunoactivity in placenta extracts is
abundant in early pregnancy in comparison with mid-term and term.
The expression of inhibin PB-subunit mRNA has been also found to vary during
pregnancy (Figure 7.3). The message is abundant throughout pregnancy but the
expression of this subunit gene in mid-term and term is greater than in early
pregnancy. This finding supports the results from the immunoneutralization of inhibin
bioactivity in Chapter 4 which suggest that the placenta may produce activin in mid¬
term and term pregnancy.
The present study has demonstrated the expression of inhibin a- and p-subunit
mRNAs in placental tissue throughout pregnancy. The results presented elsewhere in
this thesis have shown the localization of inhibin subunit proteins in trophoblast cells
and also the measurement of inhibin in vitro bioactivity in placental extracts throughout
pregnancy. These results taken together provide conclusive evidence that the placenta
is a source of inhibin and activin during pregnancy.
CHAPTER 8
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Cellular localization of inhibin-subunit mRNAs
in human placental tissue from early and term
pregnancy by in situ hybridization
8.1 Introduction
The development of in situ hybridization methods have allowed us to investigate
expression of the inhibin gene in different cell types of gonadal and non-gonadal
tissues in various species. We expect data from this method to aid us in understanding
the physiology of inhibin at the cellular level.
The presence of, and changes in, inhibin a-, PA- and PB-subunit mRNA expression
in rat ovarian cell types during the oestrous cycle have been shown by Meunier et al
(1988a) and Woodruff et al (1988). Inhibin gene expression during the rat oestrous
cycle is modulated by LH and FSH (Rivier et al, 1989). In cow ovaries, inhibin a-
subunit mRNA is expressed in granulosa and thecal cells of antral follicles while only
PA-subunit mRNA is localized in granulosa cells (Torney et al, 1989). In the monkey,
the expression of inhibin subunit mRNA is differentially regulated during the growth
and development of ovarian follicles. The PB-subunit mRNA is the only subunit that
is expressed in granulosa cells of small antral follicles while inhibin a- and PA-subunit
mRNAs are expressed in dominant follicles (Schwall et al, 1990).
In the human placenta, the available data concerning inhibin/activin gene expression
has only been obtained from Northern blot analysis of term placental RNA (Davis et al,
1987; Reddi et al, 1990b). The cellular localization of inhibin subunit proteins in both
cytotrophoblast and syncytiotrophoblast cells by immunohistochemistry has been
reported in Chapter 6. However, gene expression and protein localization may not
necessarily be within the same cell types. Therefore, to further our understanding of
the site of inhibin subunit protein synthesis and gene expression, the study described
in this chapter was carried out to localize inhibin mRNA in human placental tissue by
in situ hybridization.
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8.2 Cellular localization of inhibin a-, (3A- and (3B-subunit
mRNAs in human placenta
In situ hybridization of inhibin-subunit mRNAs was performed using the method
described as follows.
8.2.1 Materials and Methods
8.2.1.1 Tissue preparation
Human placental tissues were obtained from pregnancy termination at 7 weeks and
term. The tissues were fixed using the method outlined in Chapter 6, section 6.3.1.1.
Approval of the Local Ethical Committee (Division of Reproductive Medicine, Lothian
Health Board) was obtained. The placentae were cut across the basal plate about 5 mm-
thick, and washed in PBS to remove blood. The tissues were transferred to freshly
prepared ice-cold 4% paraformaldehyde in PBS, pH 7.4, and fixed at 4°C overnight
and then dehydrated and embedded in paraffin. Sections, 4 |im thick, were cut and
mounted on tespa-coated slides (see Appendix 3.1) then incubated at 60°C overnight
8.2.1.2 Preparation of 35S-labelled RNA probes
Nucleotide sequences of the human a-, (3A- and pB-inhibin subunit cDNAs (Mason et
al, 1986) were studied to find areas of sequences which were not homologous. Oligo
nucleotide primers with restriction sites at their 5' ends were synthesized and used to
amplify the selected sequences of cDNA by Polymerase chain reaction (PCR)
technique from inhibin a, PA- and PB-subunit cDNAs provided by Dr. R. G. Forage
(Forage et al, 1986; Reddi et al, unpublished data). The cDNA obtained for each
subunit was purified and subcloned into precut pBluescript SK(/-) plasmid; plasmids
were transformed into competent XL I blue E. coli, amplified and sequenced to
confirm correct cDNA insertion (Saunders, unpublished data). The details of the
cDNA fragments thus obtained are described as follows:
The a-subunit cDNA was 345 base pairs in length, corresponding to the nucleotides
712-1057, coding part of the mature region of human inhibin a-subunit. The PA-
subunit cDNA length was 447 base pairs, complementary to nucleotides 670 -1118,
corresponding to amino acids in the pro- and mature regions of the PA-subunit protein
precursor. The PB-subunit cDNA was 558 base pairs in length, corresponding to the
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nucleotides 745-1303, coding part of the inhibin fiB-subunit mature region and 3'
untranslated region.
Plasmids were amplified, extracted, and purified prior to use as templates for cRNA
synthesis using the Mini-Prep Kit Plus (Pharmacia) with slight modifications as
follows:
Plasmid amplification, extraction andpurification
To 15 ml of Terrific Broth (Sambrook et al, 1989a; see Appendix 3.2), containing
ampicillin (50 pg/ml, Beecham Research Laboratories, Brentford), a single bacterial
colony was inoculated and incubated overnight at 37°C with shaking. Cells were then
harvested by centrifugation at 2,000 g for 10 min. The supernatant was discarded and
the pellet resuspended by vortexing vigorously in 1 ml of lysis buffer containing
50mM Tris-HCl (pH 8.0), 50 mM glucose, 10 mM EDTA and 0.15% Kathon CG/ICP
(Mini-Prep Kit Plus, Pharmacia). The reaction mixture was incubated on ice for 5 min,
2 ml of 0.2 M NaOH with 1% Triton X-100 was added, mixed by inverting several
times and incubated for a further 5 min on ice. The reaction mixture was neutralized by
adding 1.5 ml of 3M sodium acetate (pH 4.8), mixed by inverting and left on ice for 5
min. The E.coli chromosomal DNA and cell wall debris were precipitated by
centrifugation at 12,000 g at 4°C for 10 min. Four aliquots of 750 pi supernatant were
carefully transferred to 1.5 ml microcentrifuge tubes containing 750 pi of isopropanol
(Sigma). The mixture was mixed by inverting and incubated at room temperature for
10 min and the DNA was precipitated at 12,000 g for 5 min at 4°C. The supernatant
was discarded and the DNA pellet washed with 750 pi of isopropanol without being
disturbed and allowed to air-dry before being dissolved in 50 pi of TE buffer (column
buffer) containing 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA. The extracted DNA
was purified using spun columns (Pharmacia) following the supplier's instructions
(see Appendix 3.3). Briefly, 50 pi of extracted DNA was carefully applied to the
centre of the surface of the compacted gel bed. The column was centrifuged at 400g for
2 min, removed and discarded while approximately 50 pi of the effluent which
contained the purified DNA was collected. The amount of purified DNA in the effluent




The plasmids containing inhibin a- and (3A-subunit cDNAs were linearized with
BamH I and Xho I to obtain the antisense and sense probes respectively while the (3B-
subunit cDNA plasmid was linearized with Hind III and EcoR I for the antisense and
sense probes. Briefly, 10 pi of purified plasmid (approximately 750 ng-1 pg), 2 pi of
lOx restriction buffer, 1 unit of the appropriate restriction enzyme (Boehringer
Mannheim) and 7 pi of sterile water were pipetted in sequence to a microcentrifuge
tube and the reaction mixture incubated at 37°C for 1.5 h. After adding lpl of
proteinase K type XXVIII (Sigma, lOmg/ml in water), the mixture was incubated for
a further 30 min at 37°C. The volume of the mixture was made up to 100 pi with 80 pi
of sterile water and extracted with an equal volume of phenol/chloroform. The
phenol/chloroform layer was discarded and re-extracted with an equal volume of
chloroform (IBI). DNA was precipitated following the addition of 200 pi of cold
ethanol (BDH) and 20 pi of 10.5 M ammonium acetate (Sigma) by incubation at -20°C
for 2 h. DNA was recovered by centrifugation at 13,000 g for 15 min. The pellet was
washed with 400 pi of 75% ethanol, air-dried, resuspended in 10 pi of TE buffer and
stored at -20°C.
To determine the complete linearization and the amount ofDNA in the preparation, 5
pi of a mixture of 1 pi of linearized or uncut DNA, 2 pi of "orange juice" (see
Appendix 3.5) and 7 pi of water was loaded on to a 0.8% agarose gel (see Appendix
3.6) along with known concentrations (10-100 ng/pl) of a standard-size marker
(pBR322 DNA standard, Pharmacia). The gel was run at 100 V for approximately 3 h,
then visualized and photographed under a UV transilluminator.
Probe labelling
35S-inhibin subunit sense and antisense riboprobes were generated by transcription
with the DNA-dependent RNA polymerase labelling method using an RNA
transcription kit (Stratagene). The transcription reaction was performed by adding the
following solutions into a 1.5 ml microcentrifuge tube in order; 6 pi 5x transcription
buffer, 1 pi 10 mM rCTP, 1 pi 10 mM rATP, 1 pi 10 mM rGTP, 1 pi 1M
dithiothreitol (DTT, Sigma), 3 pi sterile water, 12 pi 35S-rUTP (10 pCi/pl,
Amersham), 5 pi of restricted DNA template (0.5-1 pg/5 pi), 1.2 pi of RNase-Block
II (lU/pl) and 0.8 pi of T3 or T7 RNA polymerase (0.8 U). The reaction mixture was
incubated at 37 °C for 25 min. 0.8 pi RNA polymerase was then added and the
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reaction continued at 37°C for a further 25 min. The activity of incorporated
nucleotides was monitored by TCA precipitation of 1 pi of the reaction mixture at this
step (Sambrook et al, 1989b). The reaction was stopped by adding 2 pi tRNA
(lOmg/ml, Sigma) and 1 pi RNase-free DNase I (lmg/ml, Promega) and incubated at
37°C for 10 min. After adding 1 pi of 200 mM EDTA and 67.5 pi of TE buffer
containing 50 mM DTT the mixture was extracted twice with 100 pi of phenol and
once with phenol:chloroform (1:1) and precipitated with 10 jil 3 M sodium acetate and
330 pi cold ethanol at -20°C overnight. The RNA was pelleted by centrifugation at
13,000 g for 15 min. The RNA pellet was washed twice in cold 80% ethanol
containing 50 mM DTT and once in cold ethanol. The pellet was air-dried and
dissolved in 100 pi of DEPC-treated water (see Appendix 3.7) containing 50 mM
DTT.
Probe hydrolysis
To obtain shorter RNA probes approximately 100 bases in length which give higher
hybridization signals, the cRNAs obtained above were subjected to alkaline
hydrolysis. 100 pi of dissolved RNA pellets from the previous step were added to an
equal volume of freshly prepared 0.2 M carbonate buffer containing 80 mM sodium
bicarbonate, 120 mM sodium carbonate and 50 mM DTT. The reaction mixture was
incubated at 60°C for 30 min. The reaction was stopped by the addition of 100 pi of
6M ammonium acetate (pH 5.2) and 1 pi of tRNA (10 mg/ml). The RNA was
precipitated with three volumes of cold ethanol at -20°C overnight. The pellet was
collected by centrifugation at 13,000 g for 20 min. The pellet was washed twice in cold
80% ethanol containing 50 mM DTT and once in cold ethanol. After air-drying, the
pellet was dissolved in 20 pi of DEPC-treated water containing 50 mM DTT and the
activity of the probe was monitored by TCA precipitation of 1 pi of the solution as
outlined above. The probe was kept at -70°C until the hybridization was performed.
8.2.1.3 In situ hybridization procedure
The in situ hybridization procedure was performed as described by Wilkinson et al
(1987a) in combination with the high-stringency washing steps described by
Wilkinson et al (1987b).
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Prehybridization treatment
The sections were deparaffinized twice in xylene (BDH) for 5 min and rehydrated
through a series of alcohols (100, 95, 85, 70, 50 and 30% EtOH) for 2 min each.
After further rehydration for 5min each in normal saline and PBS the sections were
fixed in 4% paraformaldehyde in PBS, pH 7.4, for 20 min and then washed twice in
PBS (5 min each). The sections were treated for 7.5 min with 20 (ig/ml proteinase K
(Sigma) in buffer (pH 7.2) containing 50 mM Tris and 5 mM EDTA to allow
permeability of the probes. After washing for 5 min in PBS the sections were refixed
in 4% paraformaldehyde in PBS for 10 min, then immersed in sterile water and TE
buffer for 10 and 30 sec respectively. To reduce electrostatic binding of the probe the
sections were incubated twice in 0.25% acetic anhydride (Sigma) in TE buffer for 10
min (due to the very short half-life of acetic anhydride in aqueous solution the sections
must be placed in a staining dish containing TE buffer and a magnetic bar and placed
on a magnetic stirrer before acetic anhydride is added). The sections were washed in
PBS and 0.85% NaCl for 5 min each, then dehydrated through graded EtOH (30, 50,
70, 85, 95%) for 1 min each. After dehydration twice in 100% EtOH for 5 min the
sections were air-dried and the hybridization performed.
Hybridization
The 35S-riboprobes were diluted in hybridization mixture (see Appendix 3.8) to obtain
lxlO5 dpm/jil. The diluted probes were heated at 80°C for 2 min and cooled on ice
before applying to the sections (10 |il/section). After overlaying with tespa-coated
cover slips the sections were hybridized overnight in a humidified chamber (saturated
with 5x SSC and 50% formamide) at 55°C.
Posthybridization treatment
The sections were washed with 5x SSC containing 10 mM DTT for 30 min at 55°C
and then with 2x SSC, 50% formamide and 0.1 M DTT for 20 min at 65°C. The
sections were washed three times in buffer (pH 7.5) containing 0.5 M NaCl, 10 mM
Tris and 5 mM EDTA (NTE) for 10 min at 37°C and were then treated with RNase (40
jig/ml) in NTE for 30 min at 37°C and washed in NTE for 15 min at the same
temperature. The washing step with 2x SSC, 50% formamide and 0.1 M DTT for 20
min at 65°C was repeated, then the sections were washed in 2x SSC three times (10
min each) and finally washed thrice in O.lx SSC (10 min each) at room temperature.
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The sections were dehydrated in graded EtOH (30, 50, 70, 90%) containing 0.3 M
ammonium acetate for 1 min each and then in 100% EtOH twice for 5 min before air-
drying.
Autoradiograph dipping
This step was performed in a dark room with a safety light The slides were dipped in
a mixture of Dford K5 emulsion in water (1:1, diluted immediately before use) at 40-
42°C twice and left to drain. The slides were then placed in a light-tight box and left to
dry for 3 h or overnight before being left to autoexpose in a light-tight box, containing
silica gel, wrapped in aluminum foil for 2-4 weeks at 4°C.
Autoradiograph developing
This step was also carried out in a dark room. The slides were placed in developer D
19 (Kodak) for 4 min and then rinsed in distilled water before being placed in fixative
(Kodafix:distilled water, 1:3) for 4 min and washed twice in distilled water for 10 min.
The slides were counterstained in 1 % Methyl Green in water (Sigma) for 2 min and
mounted in DPX (Sigma) before visualizing under the light microscope.
8.2.2 Results
The a-subunit riboprobe was hybridized to sections of 7 week and term placentae
(Figures 8.1, 8.2, 8.3 and 8.4). In the area of the chorionic villi, inhibin a-subunit
messenger RNA expression was localized only within trophoblast cells. High
magnification photomicrographs (Figures 8.2 and 8.4) clearly showed that both
syncytiotrophoblast and cytotrophoblast cells expressed messenger RNA (silver
grains). The amount of inhibin a-subunit mRNA expression in 7 week placental tissue
was higher than in term placenta. The |3A-subunit riboprobe also hybridized to 7 week
and term placental tissue and the expression of mRNA was confined to trophoblast
cells (Figures 8.5, 8.6, 8.7 and 8.8). In 7 week placenta, the high magnification
photomicrograph (Figure 8.6) shows hybridization of the f3A-subunit riboprobe
occurred on syncytiotrophoblast and cytotrophoblast cells, and the expression of this
inhibin subunit mRNA appeared stronger in trophoblast cells of term placental tissue
(Figure 8.8). None of the placental tissues from 7 weeks and term pregnancy
demonstrated hybridization to sense inhibin a- and PA-subunit riboprobes. The
inhibin (3B-subunit riboprobe hybridized to trophoblast cells of 7 week placental tissue
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Figure 8.1 Hybridization of 7 weeks placental tissue with inhibin a-subunit riboprobe.
Low-magnification (x20) bright field photomicrograph (A) and dark field
photomicrograph (B) of the same area showing expression of inhibin a-mRNA (silver
grains) which appears to be within trophoblast cells.
Figure8.2High-magnificationphotomicrograph(x40)dem nstratinghybrid zationf theinhibina-subunitprobeinsyncytiotrophoblasta dcytot hoblastelf7week placentaltissue.
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Figure 8.3 Hybridization of term placental tissue with inhibin a-subunit riboprobe.
Low-magnification (x20) bright field photomicrograph (A) and dark field
photomicrograph (B) of the same area showing expression of inhibin a-mRNA within
trophoblast cells.
Figure8.4High-magnificationphotomicrograph(x 0)de ns atinghybrid z i nf theinhibina-subunitprobentropho lastcelftermlace talt ss .
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Figure 8.5 Hybridization of 7 weeks placental tissue with inhibin |3A-subunit
riboprobe. Low-magnification (x20) bright field photomicrograph (A) and dark field
photomicrograph (B) of the same area showing expression of inhibin f}A-mRNA
within trophoblast cells.
i
Figure8.6High-magnificationphotomi rograph(x40)dem nstratingybrid zationf theinhibinPA-su u itriboprobensyncyti trophoblastandcytotro blastllf7 weekplacentaltissue.
1
Figure 8.7 Hybridization of term placental tissue with inhibin pA-subunit riboprobe.
Low-magnification (x20) bright field photomicrograph (A) and dark field
photomicrograph (B) of the same area showing expression of inhibin PA-mRNA
within trophoblast cells.
Figure8.8High-magnificationphotomicrograph(x40)dem nstr tinghybridizationof theinhibin( A-su u itriboprobesyncytiotropho lastandcytotro hoblastellsof termplacentalissue.
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but the expression of this subunit mRNA (Figures 8.9 and 8.10) appeared low and a
high background of non-specific signal was present. The same degree of hybridization
was also demonstrated in term placenta and again the hybridization appeared in the area
of the trophoblast cells (Figures 8.11 and 8.12). Comparing the hybridization of PB-
antisense and pB-sense probes to 7 week and term placentae (Figures 8.13 and 8.14),
the antisense probe clearly showed more specific hybridization signal.
8.3.2 Discussion
The data presented above demonstrate that inhibin a- and pA-subunit mRNAs are
expressed in syncytiotrophoblast and cytotrophoblast cells of human chorionic villi
throughout pregnancy. This finding, supported by the original observation of
immunolocalization of inhibin a- and pA-subunit proteins in the same cell types
(Tovanabutra et al, 1990; Petraglia et al, 1987a; Merchenthaler et al, 1987), has
identified syncytiotrophoblast and cytotrophoblast cells as the site of inhibin
production in the human placenta.
The amount of inhibin-subunit mRNAs detected in placental tissue sections varies
during pregnancy. More inhibin a-subunit mRNA was present in early pregnancy
than in late pregnancy and this confirms the earlier finding (Chapter 7) that inhibin a-
subunit mRNA expression is decreased with age of gestation. Furthermore, high level
of inhibin immunoactivity in placental extracts and strong intensity of a-inhibin
subunit staining in early pregnancy are also consistent with this differential expression
of the inhibin a-subunit gene.
Expression of inhibin PA-subunit mRNA occurs in early and term placentae but
hybridization of the inhibin pB-subunit riboprobe did not show as strong a signal as
the inhibin PA-subunit riboprobe. Although there is evidence of transient expression of
inhibin PA- and PB-subunit genes in rat follicles during the oestrous cycle (Meunier et
al, 1988a) and monkey follicles during growth and development (Schwall et al, 1990)
this is unlikely to be the case in the human placenta. The pattern of increase in inhibin
pA-subunit mRNA expression by trophoblast cells towards term is similar to the
pattern of inhibin PB-subunit mRNA demonstrated by Northern blot analysis. This
leads to the conclusion that inhibin PA- and PB-subunit genes are both expressed
throughout pregnancy but the failure to demonstrate convincing expression of inhibin
PB-subunit inhibin gene expression using the in situ hybridization technique may be
due to the lack of a suitable riboprobe. This requires further investigation.
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Figure 8.9 Hybridization of 7 week placental tissue with the inhibin (3B-subunit
riboprobe. Low-magnification (x20) bright field photomicrograph (A) and dark field
photomicrograph (B) of the same area showing expression of inhibin (3B-mRNA in the
trophoblast layer.
Figure8.10High-magnificationphotomic ograph(x4 )showinghybridizatioft e inhibinpB-su u itriboprobensyncytiotrophoblastandc totrophoblastellsf7 weekplacentaltissue.
CO
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Figure 8.11 Hybridization of term placental tissue with the inhibin (3B-subunit
riboprobe. Low-magnification (x20) bright field photomicrograph (A) and dark field
photomicrograph (B) of the same area showing slight expression of inhibin PB-mRNA
in chorionic villi.
Figure8.12High-magnificationphotomic ograph(x40)showi ghybridizat not e inhibinPB-su u itriboprobentermplacentaliss e.
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Figure 8.13 Photomicrograph showing no hybridization of sense inhibin PB-riboprobe
to 7 weeks placenta.
i
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Figure 8.14 Photomicrograph showing no hybridization of sense inhibin PB-riboprobe
to term placenta.
There have been previous reports on the preferential production of inhibin fiA-subunit
dimers by the human leukaemia cell line THP-1 (Eto et al, 1987) as well as in bone
marrow where the expression of inhibin {JA-subunit mRNA is the predominant form
(Meunier et al, 1988b). In addition, Mason (1988) has demonstrated that in a
mammalian cell line transfected with inhibin cDNAs, inhibin heterodimers are only
produced in the presence of an excess of inhibin a-subunit gene whereas inhibin {3-
monodimers are preferentially formed when there are equimolar ratios of a- and |3-
subunit proteins.
This current study suggests that in placentae the expression of the inhibin a-subunit
gene decreases while the expression of the inhibin (3A-subunit gene increases with the
age of gestation. This provides further evidence for the hypothesis that production of
activin by trophoblast cells is favoured in late pregnancy. This has been confirmed by
our previous findings showing the in vitro stimulatory effect of activin-like substance
in mid-term and term placental extracts.
In conclusion, the results from this study clearly show that cytotrophoblast and
syncytiotrophoblast cells are the sites of inhibin a- and (3-subunit protein production in
the human placenta and the amount and species of secreted proteins vary during
pregnancy. Moreover, this finding also supports the concept proposed in Chapter 6 on





Among the various tissues and organs in the human body, the human placenta was
reported to possess bioactive and immunoactive inhibin (Bandivdekar et al, 1981;
McLachlan et al, 1986b). The presence of inhibin in a totipotential tissue such as
placenta, which has an important role and complex functions in supporting the growth
and development of the fetus throughout pregnancy, raises questions about the
function of inhibin. In the past five years, there has been much information obtained
by different investigators on the synthesis and role of inhibin present in human term
placentae. Nevertheless, many more studies are required to understand the role of
inhibin in pregnancy. The studies described in this thesis provide further information
on the molecular species of inhibin and its related peptides produced by the human
placenta, the potential sources of peripheral inhibin during pregnancy, the cellular
localization of inhibin subunit proteins including the expression of mRNA and the
presence of inhibin in amniotic fluid.
The molecular species of inhibin produced by the placenta and the relative amounts
during gestation were examined in Chapter 2. Placental extracts from various stages of
pregnancy showed parallel displacement with hFF in the radioimmunoassay with the
Monash and Y29 antibodies whereas the results from Chapter 4 also demonstrated
parallelism between dose-response lines of placental extracts and hFF during the
measurement of bioactive inhibin using the sheep pituitary cell monolayer culture.
These findings suggest that the same species of immunoactive and bioactive inhibin is
secreted by the ovary and placenta during pregnancy.
The level of inhibin immunoactivity in human placenta is highest in the early weeks of
gestation (7 weeks) and declines significantly towards term whereas the bioactivity
remains constant throughout pregnancy. Further investigations in Chapter 4 on inhibin
bioactivity in placental extracts by in vitro immunoneutralization using anti-inhibin a-
subunit antibody (Y29) confirms that the inhibin-like bioactivity in placental extract is
due to dimeric inhibin produced by the placenta. The results from the same experiment
also provide the indirect evidence for the presence of activin-like activity in the human
placenta from the late stages of pregnancy. When inhibin bioactivity in mid- and term
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placental extracts was completely immunoneutralized by antibody (Y29), the release of
FSH was stimulated above the level found in control pituitary cell cultures. In
addition, the observed FSH stimulatory effect of placental extracts is similar to that
shown by recombinant activin A in Chapter 4. This suggests that activin is produced
by the placenta in the second and third trimesters. However, the RIA with the Monash
antibody has been shown to measure pro-aC which is found in abundance in hFF and
has no bioactivity whatsoever. Thus, changes in the ratio of immunoactivity to
bioactivity might be due to different molecular species of inhibin being produced
during pregnancy.
It was previously reported that the placenta was the only source of inhibin in
pregnancy due to the finding that inhibin levels increased within a few days of
implantation in pregnant women who had undergone a superovulation induction and
follicular aspiration for the purpose of in vitro fertilization (McLachlan et al, 1987c)
and in agonadal women who became pregnant following embryo donation (McLachlan
et al, 1987b). In Chapter 3, the pattern of peripheral inhibin levels in pregnancy along
with progesterone and hCG from day 0 of pregnancy (day of the LH peak) until day
65 provide strong evidence that in the early stages of pregnancy the corpus luteum is
the main source of inhibin. The significant correlation between hCG and inhibin levels
including their pattern of secretion during early pregnancy, suggests a relationship
between hCG and inhibin production by the corpus luteum and it is clearly shown that
hCG at concentrations similar to those seen in early pregnancy can stimulate inhibin
secretion by the corpus luteum in normal women (Illingworth et al, 1990).
An increase in inhibin levels was observed within a few days after implantation
(McLachlan et al, 1987c), but the pattern of inhibin secretion in that study might be
unusual because of the result from superovulation induction. However, the presence
of inhibin immunoactivity in placental extracts provides strong evidence that from 7
weeks of pregnancy until term, the placenta is another source of inhibin. The pattern of
inhibin immunoactivity in plasma differs from that shown in placental extracts. The
rise in peripheral inhibin levels throughout pregnancy as shown in Chapter 3 and also
by Abe et al (1990) and Tabei et al (1991) is in contrast to the decline in the
concentration of inhibin in placentae towards term (Chapter 3). This is presumably due
to an increase in placental weight and blood flow. This presumption also applies to the
different patterns of bioactive inhibin in the circulation and in placenta extracts. The
concentration of bioactive inhibin in peripheral plasma measured using the sheep
pituitary cell bioassay rises progressively (Qu et al, 1991) whereas in the placenta it
remains the same throughout pregnancy (Tovanabutra et al, 1990). Interestingly, the
patterns of inhibin and oestradiol are very similar. The incompatibility between the
pattern of peripheral immunoactive and bioactive inhibin may be explained by different
inhibin species being produced at various stages of pregnancy. It should be
remembered that steroids e.g. oestradiol and progesterone also have an FSH-
suppressing effect in sheep pituitary cell cultures. Thus it is important to ensure that all
residual steroids are removed from the sample before a reliable assessment of inhibin
bioactivity can be obtained using the sheep pituitary cell bioassay.
Inhibin (a-, (3A- and (3B-) subunit mRNA is expressed in human term placenta (Mayo
et al, 1986; Davis et al, 1987; Reddi et al, 1990b) as demonstrated by Northern blot
analysis. These findings provide conclusive evidence that inhibin subunits are
synthesized within term placental tissues. The expression of inhibin a- and P-subunit
mRNAs in placental tissue from 7 weeks, 16 weeks and term, further demonstrate the
synthesis of inhibin subunits within the placenta throughout pregnancy (Chapter 7).
The expression of these subunits varies during gestation. The high degree of
expression of a-subunit mRNA at 7 weeks of pregnancy suggests preferential
production of the free a-subunit of inhibin and the higher expression of P-subunit
mRNA in second trimester and term suggests the production of activin which is
compatible with the activin-like activity in mid- and term placental extracts
demonstrated in Chapter 4.
It is known that cytotrophoblast cells contain the inhibin a-subunit (Petraglia et al,
1987a; Merchenthaler et al, 1987). The studies in Chapter 3 show that both inhibin a-
and PA-subunits are localized in cytotrophoblast and syncytiotrophoblast cells
throughout pregnancy. This result is in agreement with the presence of bioactive
inhibin in placental extracts. The difference in intensity of staining at various stages of
pregnancy seems to suggest a differential production of inhibin subunits. The high
intensity of a-subunit staining in 7 weeks placental tissues and an increase in intensity
of inhibin PA-subunit staining again suggest the preferential production of the free a-
subunit or pro a-C when compared to dimeric inhibin, and the production of activin in
later stages of pregnancy. It can be stated that there are many factors which could
influence the intensity of staining apart from the amount of immunoactive proteins.
However, with the evidence from other studies (e.g. gene expression, immunoactivity
and immunoneutralization) it is tempting to conclude that under these circumstances the
intensity of staining is proportional to the amount of inhibin subunit proteins.
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The last finding of this thesis is the localization of inhibin a- and PA-subunit mRNAs
in trophoblast cells using in situ hybridization. The degree of expression of inhibin a-
and PA-subunit mRNAs in 7 weeks and term placental tissues are different but are in
keeping with the results from the immunolocalization study which shows that, in the
early stages of pregnancy, trophoblast cells produce more a-subunit than at term and
more P-subunit is produced as the pregnancy progresses. This is very conclusive
evidence which reveals that most inhibin and/or activin secreted by the placenta is
synthesized by trophoblast cells.
The presence of inhibin subunits in decidual tissue has recently been demonstrated by
immunohistochemistry using affinity-purified polyclonal rabbit antibodies raised
against N-terminal synthetic porcine peptides of inhibin a-, PA- and PB-subunits
(Petraglia et al, 1990). These authors also demonstrated different degrees of gene
expression of these subunits at various stages of pregnancy by Northern blot analysis.
However, there is a discrepancy between the small amounts of inhibin PA-subunit
protein detected by immunocytochemistry and its high degree of gene expression
detected by Northern blot analysis in term decidual tissue. Taken together with the fact
that the decidua contains migratory cells of trophoblast origin and our observation that
the cultured medium from decidua parietalis contains very little immunoactive inhibin
whereas medium from decidua capsularis contains a considerably greater amount, it is
not entirely clear whether maternally-derived decidual cells can produce inhibin, and
this needs further investigation.
There is evidence for the presence of inhibin in mid-term amniotic fluid (Sinosich et
al, 1991) and activin A in amniotic fluid (Abe et al, 1989). The study in Chapter 5
demonstrates both inhibin immunoactivity and bioactivity in amniotic fluid throughout
pregnancy. The source of inhibin in amniotic fluid remains unclear. It is likely that
trophoblast and decidual tissues and possibly the fetus are potential sources of inhibin
and activin in amniotic fluid. The circulating inhibin in umbilical cord is shown to be
lower than in maternal blood vessels and there is no difference between umbilical vein
and artery levels (McLachlan et al, 1986b; Tabei et al 1991; Kettel et al, 1991)
indicating that the fetus is not contributing to the peripheral immunoactive inhibin.
However, the results in Chapter 5 demonstrate the presence of inhibin bioactivity and
immunoactivity in 7 week amniotic fluid, suggesting the production of inhibin by the
fetus or trophoblast.
The physiological function of inhibin and activin in pregnancy remains unknown. In a
normal woman, the endocrine function of inhibin is likely to be a synergistic effect
with oestradiol on suppressing FSH secretion. The concentration of immunoactive
FSH in the circulation is very low during pregnancy (Jaffe et al, 1969) which suggests
a combined suppressive effect of inhibin and oestradiol on the secretion of pituitary
FSH and this hypothesis is supported by the evidence that throughout pregnancy the
development of antral follicles continues although they never achieve the final stages of
maturation beyond 10 mm (Govan, 1968). Several studies have reported relatively
high levels of bioactive FSH in serum samples in early pregnancy (Padmanabhan et al,
1989). It may be that this bioactivity represents an intrinsic property of hCG which has
both LH and FSH activity.
A paracrine function of inhibin and activin in pregnancy with other hormones was
proposed by Petraglia et al, (1987a; 1989). In placental cell cultures, activin has no
effect on hCG secretion but it can augment the stimulation by GnRH of hCG release as
well as stimulate progesterone secretion. These effects of activin can be reversed by
inhibin (Petraglia et al, 1989). Inhibin also suppresses the stimulatory effects of GnRH
on hCG secretion (Petraglia et al, 1987a). Interestingly, in placental explant tissue
culture inhibin suppresses hCG secretion by term placenta but not by first trimester
placenta (Mersol-Barg et al, 1990). This suggests a transient interaction of inhibin and
hCG during pregnancy. However, our finding in Chapter 6 that inhibin a- and (3A-
subunits are present in the same cell type strongly suggests an autocrine function
between inhibin, activin and hCG.
Structural analysis of inhibin shows homology between inhibin and other growth
factors e.g TGF-(3, MIS, activin, the VG1 gene in Xenopus and decapentaplegic
peptides in Drosophila, all of which are growth factors needed for embryogenesis in
different species (see de Kretser & Robertson, 1989). Taken together with the results
in Chapter 3 that in early pregnancy the corpus luteum secreted large amounts of
inhibin, it is likely that inhibin has a potential role in the early development of the
embryo or in the establishment of pregnancy.
Since inhibin is produced by trophoblast cells, it may be a potential marker of
trophoblastic disease in women. A single study suggests that, apart from hCG, inhibin
may be another circulating marker of hydatidiform mole and even better than hCG as
an early indicator of persistent trophoblastic disease (Yohkaichiya et al, 1989).
Hydatidiform mole is due to cystic degeneration of the chorionic villi; the trophoblast
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cells persist and invade while the mesodermal core undergoes myxomatous change and
blood vessels disappear. The incidence of hydatidiform mole is 1 in 200 in Asian and
African countries - which is 10 times higher than in Western countries. About 10% of
hydatidiform moles become malignant and give rise to choriocarcinoma. This disease
is now curable with chemotherapy if the treatment is started early enough and this
means that an effective diagnostic marker is needed.
It would be worthwhile to conduct a study to investigate the relationship between
inhibin and other reproductive hormones and some growth factors in normal
pregnancy and trophoblastic diseases using the placental explant culture as an
experimental model. This would enable us to understand more about the physiological





1.1 Phosphate-buffered saline (PBS)
Dissolve 1 tablet of phosphate-buffered saline (Oxoid, Unpath Ltd, Basingstoke,
Hampshire, England, Code BR 14a) in 100 ml distilled water and autoclave at 115°C
for 10 min and adjust to pH 7.4 with 5 N NaOH.
12 4% paraformaldehyde in PBS, pH 7.4
Dissolve 4 g of paraformaldehyde (Aldrich Chemical Company Ltd., Gillingham,
Dorset) in 100 ml of PBS at 60°C. Add a few drops of 5 N NaOH to completely




A stock solution was prepared by dissolving 250 g of guanidinium thiocyanate (Fluka)
in the manufacturer's bottle with 293 ml sterile water. Add 17.6 ml of 0.75 M sodium
citrate, pH 7.0 and 26.4 ml of 10% sarcosyl (N-laurylsarcosine, Sigma). Incubate at
65°C until the solution is clear. The shelf-life of this solution is 3 months at room
temperature.
Prepare the final denaturing solution by adding 0.36 ml of 2-mercaptoethanol (Sigma)
to 50 ml of the stock solution.
22 Water- saturatedphenol.
100 g phenol (Gibco-BRL) was melted at 68°C. Sterile water was added up to the
neck of the bottle and the mixture was left to separate at 4°C overnight. Most of the
water was removed and the solution stored at 4°C for up to 1 month.
2.3 Determination of the amount andpurity ofRNA
To estimate the amount and purity of RNA, 4 pi of RNA obtained from the extraction
step was made up to 1 ml with sterile water. The solution is spectrophotometrically
read at 260 nm and 280 nm respectively. An optical density (OD) reading of 1 at 260
nm corresponds to approximately 40 pg/ml of RNA which allows an estimation of the
total concentration of RNA in the preparation after correcting for dilution. The ratio
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between the readings at 260 nm and 280 nm provides an estimation as to the purity of
the RNA. Pure preparations give an OD260/OD280 value between 1.8-2.0.
2.4 Loading buffer
Mix 200 pi lOx running buffer, 1ml deionized formamide and 356 pi formaldehyde
(37% solution, Sigma).
2.5 Deionizedformamide
Mix 5 g of a mixed-bed resin (Amberlite MB-1, Sigma) with 50 ml of formamide
(Sigma). Stir gently at 4°C overnight and filter through Whatman No.l filter paper.
Store at -20°C.
2.6 10% formaldehyde agarose gel running buffer.
Dissolve 8.36 g of 3-(N-morpholino) propanesulfonic acid (MOPS, Sigma), 0.744 g
EDTA and 0.82 g of sodium acetate in 150 ml of sterile water. Adjust the pH of the
solution to 7.0 with RNAse-free 5 M NaOH and bring the final volume to 200 ml with
sterile water.
2.7 Casting of0.8% agarose gel
Dissolve 1.5 g of SeaKem ME agarose gel (ICN) in 72.1 ml of sterile water.
Heat the solution in a microwave oven at 100% heat for 3 min or until the agarose
dissolves.
Cool the solution to 60° C and add 17.9 ml of formaldehyde (37% solution, Sigma)
with gentle swirling.
Pour the gel on to a prepared mold (20x15 cm) with a 15 well comb and let the gel set
at room temperature (20-30 min). Remove the comb and mount the gel in the
electrophoresis tank containing 1.5 litre of lx running buffer.
2.8 20X SSC
Dissolve 175.3 g NaCl and 88.2 g sodium citrate in 800 ml DEPC-treated water.
Adjust the pH of the solution to 7.0 with 10 N NaOH and bring the volume up to 1
litre with DEPC-treated water.
2.9 Buffer-saturated phenol
Add 8-hydroxyquinone (Sigma) to water-saturated phenol at a final concentration of
0.1%. Add an equal volume of 1.0 M Tris buffer (pH 8.0). Stir on a magnetic stirrer
for 15 min and discard the buffer layer. Repeat the extractions with an equal volume of
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0.1M Tris buffer (pH 8.0) until the pH of the phenol phase is less than 7.8 and then
store under the same buffer for up to 1 month.
2.10 Phenol:Chloroform (1:1)
An equal volume of buffer-saturated phenol and chloroform was mixed well.
Appendix 3
3.1 Preparation of tespa-coated slides.
Dip the pre-washed and pre-baked new glass slides in the following solutions in order:
10% HC1 in 70% EtOH (10 sec).
Sterile water (10 sec).
95% EtOH (10 sec).
Dry the slides at 150°C for 5 min and allow to cool.
2% tespa (3-aminopropyltriethoxy-silane, Sigma) in acetone (BDH) for 10 sec.
100% acetone twice (10 sec each).
Sterile water (10 sec).
Dry the slides at 42°C overnight
32 Preparation ofTerrific Broth
In a microwave oven, dissolve 12 g bactotryptone (Gibco), 24 g yeast extract (Gibco)
and 4 ml glycerol (Sigma) in 900 ml of sterile water and then autoclave to sterilize.
Allow the solution to cool and then add 5 ml of sterile phosphate buffer solution
containing 0.17 M KH2P04 (BDH) and 0.72 M K2HP04 (BDH) to 45 ml of the
solution.
33 Plasmidpurification
Prepare a spun column as follows:
Invert the column several times to suspend the Sephacryl S-400 gel.
Set the column upright in a rack and allow the gel to settle into a continuous bed.
Remove the top cap and then the bottom closure. Allow the column to drain by gravity
but do not let it dry. Wash the column with 2 ml of 0.1 M triethanolamine, pH 8.0 (TE
buffer) twice.
Place the column in a 15 ml polypropylene, round-bottomed tube (Falcon) and spin at
400g for 2 min. The gel will appear compacted and, at the top, will have retracted
slightly from the inside wall of the column.
Remove the column from the tube and discard the eluate.
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Place a microcentrifuge tube in the bottom of the polypropylene tube and place the
column in the same tube. The tip of the column must be inside the microcentrifuge
tube. The column is now ready for the application of the sample.
3.4 DNA estimation
A rapid way to estimate the amount of DNA in the effluent from the spun column is to
utilize the UV- induced fluorescence emitted by ethidium bromide molecules
intercalated into the DNA. Because the amount of fluorescence is proportional to the
total mass ofDNA, when the fluorescent yield of the unknown is compared to that of a
series of standards (0.5-20 |ig/ml or ng/p.1) small amounts of DNA can be detected.
Procedure:
Cut a piece of 3" x 4" parafilm and place on a small plastic tray.
Spot 0.5 pi of DNA sample on to the parafilm sheet and add 4.5 pi of sterile water to
the DNA spot.
Spot 5 pi of standards by arranging them in series.
Add 5 pi of ethidium bromide solution (2 pg/ml of ethidium bromide in TE buffer, 10
mM Tris-HCl and 1 mM EDTA, pH 8.0) and mix well by pipetting.
Photograph the spots under UV light. Estimate the concentration of DNA by
comparing the intensity of fluorescence in the sample with the standard
5_5 lOx "Orange Juice" (gel loading bufferforDNA)
0.25% Orange G (Sigma O 7252)
15% Ficoll (Type 400, Pharmacia)
0.5 M EDTA
Make the solution up in lOx Tris-borate buffer (TBE, 0.089 M Tris-borate, 0.089 M
boric acid and 0.002 M EDTA) and store at -20°C
3.6 Casting of0.8% agarose gel
Add 0.4 g of SeaKem agarose gel (ICN) to 50 ml TBE in a conical flask.
Heat the solution in a microwave oven at 50% heat for 3 min or until the agarose
dissolves.
Cool the solution to 50° C and add 2.5 pi of ethidium bromide (10 mg/ml) to give a
final concentration of 0.5 p.g/ml.
Pour the gel on to a prepared mold. Immediately place the comb and let the gel set at
room temperature (20-30 min). Remove the comb and mount the gel in the
electrophoresis tank with 200 ml of TBE buffer as the running buffer.
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3.7 DEPC-treated water
Make the stock DEPC by diluting 5 ml of diethylpyrocarbonate (DEPC; Sigma) in 45
ml EtOH. Dispense 500 p.1 of stock solution into a prebaked bottle, dry down EtOH
under N2 and add 500 ml distilled water. Leave the solution (0.01% DEPC) to stand
overnight and then autoclave.
3.8 Hybridization mix
Make up a solution containing the following:
50% deionized formamide (Sigma)
10% Dextran sulphate (Sigma)
lx Denhardt's solution (Sigma)
20 mM Tris, pH 8.0
0.3 M NaCl
5 mM EDTA
10 mM sodium phosphate
0.5 mg/ml yeast RNA (Sigma)
50 mM dithiothreitol (add immediately before use)
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